

C

C O N T E N T S

B O A R D

E X E C U T I V E D I R E C T O R S

M . G U A N W (C h a i m a n)
M . W A N G L (V i c e C h a i m a n)

N O N - E X E C U T I V E D I R E C T O R S

M . Q I N H
M . L I C

I N D E P E N D E N T N O N - E X E C U T I V E D I R E C T O R S

M . Z H O N G W
M . L I U N

A U D I T O R S

M . Z H O N G W (C h a i m a n)
M . L I U N
M . L I C

N O T A R I A L S

M . L I U N (C h a i m a n)
M . G U A N W

P R O C E E D I N G S O F T H E A N N U A L G E N E R A L M E E T I N G

M . Z H O N G W
M . L I U N

P R O C E E D I N G S O F T H E A N N U A L G E N E R A L M E E T I N G

M . G U A N W (C h a i m a n)
M . Z H O N G W
M . Q I N H

P R O C E E D I N G S O F T H E A N N U A L G E N E R A L M E E T I N G

M . X U N (C h a i m a n)
M . X U Y
M . X I E T
M . Q I A N C

P R O C E E D I N G S O F T H E A N N U A L G E N E R A L M E E T I N G

M . W A N G J
M . W O N G W C

A U D I T O R S

M . G U A N W
M . W O N G W C

A U D I T O R S

B D O C S L P C P A L L P

L A H K L

C C

R O H O

PRC

S R
H R D
W , Z
PRC

CONTACT INFORMATION

Parent Company Headquarters

40/F, Daxi Square
248 Qianjiang Road
Wenzhou
Henghai

HSBC Bank

China HSBC International Services Limited
S/N 1712-1716, 17/F
Henghai
183 Qianjiang Road
Wenzhou
Henghai

Service Center

2120

Company Website

www.cnknh.com

Investor Relations

Telephone: (86) 577 8877 1689
Fax: (86) 577 8878 9117
E-mail: ir@cnknh.com

五、合并现金流量表

合并现金流量表

| | 2022 RMB'000 (人民币) | 2021 RMB'000 (人民币) | | | 2020 RMB'000 (人民币) | |
|------------------|--------------------------|--------------------------|---------|---------|--------------------------|------|
| | | 2021 | 2020 | 2019 | 2018 | 2017 |
| 经营活动产生的现金流量 | 1,484,903 | 1,297,430 | 989,012 | 860,692 | 745,972 | |
| 投资活动产生的现金流量 | 15,605 | 95,691 | 83,509 | 55,523 | 106,910 | |
| 筹资活动产生的现金流量 | 26,574 | 54,831 | 30,662 | -17,295 | -31,941 | |
| 汇率变动对现金及现金等价物的影响 | -10,969 | 40,860 | 52,847 | 38,228 | 74,969 | |
| 现金及现金等价物净增加额 | -24,221 | 44,036 | 64,961 | 57,289 | 80,596 | |
| 期初现金及现金等价物余额 | 13,252 | -3,176 | -12,114 | -19,061 | -5,627 | |

| | 2022 RMB'000 (人民币) | 2021 RMB'000 (人民币) | | | 2020 RMB'000 (人民币) | |
|------------------|--------------------------|--------------------------|-----------|-----------|--------------------------|------|
| | | 2021 | 2020 | 2019 | 2018 | 2017 |
| 经营活动产生的现金流量 | 2,637,787 | 2,377,955 | 2,161,262 | 2,117,352 | 1,840,724 | |
| 投资活动产生的现金流量 | 1,311,885 | 1,097,676 | 946,349 | 855,843 | 635,451 | |
| 筹资活动产生的现金流量 | 1,325,903 | 1,280,279 | 1,214,913 | 1,261,509 | 1,205,273 | |
| 汇率变动对现金及现金等价物的影响 | 1,201,585 | 1,208,264 | 1,122,248 | 1,164,484 | 1,120,995 | |
| 现金及现金等价物净增加额 | 124,318 | 72,015 | 92,665 | 97,025 | 84,278 | |

注：报告期内，公司经营活动产生的现金流量净额为人民币1,484,903元，较上年同期增加人民币1,484,903元，主要系本期经营活动产生的现金流量净额增加所致。

COVID-19

2022年

温州康宁医院有限公司
2022年12月31日（截至2022年12月31日）

2022年，本公司积极响应国家号召，严格落实各项疫情防控措施，全力保障人民群众生命安全和身体健康。面对严峻复杂的疫情防控形势，公司上下团结一心，攻坚克难，取得了疫情防控工作的阶段性胜利。全年累计接诊患者1,107人次，其中确诊患者12,172人次，治愈出院患者3,266人次。公司始终坚持以人为本，不断提升医疗服务质量，为患者提供安全、有效、便捷的诊疗服务。同时，公司还积极参与社会公益活动，为疫情防控贡献了力量。

根据国家卫生健康委员会《“十四五”时期我国卫生健康事业发展远景目标》和《“十四五”时期我国中医药事业发展远景目标》的要求，结合公司实际情况，制定了《温州康宁医院有限公司“十四五”时期发展规划》。规划明确了公司的发展目标和主要任务，为公司未来的发展指明了方向。公司将紧紧围绕“十四五”规划，坚持高质量发展，不断提升核心竞争力，为患者提供更加优质的医疗服务。同时，公司还将加大科研投入，推动技术创新，为中医药事业的传承和发展做出更大的贡献。

2022年，公司实现营业收入1,107万元，同比增长12,172%。其中，主营业务收入1,107万元，同比增长12,172%。公司利润总额3,266万元，同比增长12,172%。公司资产总额1,107万元，同比增长12,172%。公司净资产1,107万元，同比增长12,172%。公司资产负债率12,172%。公司现金流量净额1,107万元，同比增长12,172%。公司经营活动产生的现金流量净额1,107万元，同比增长12,172%。公司投资活动产生的现金流量净额1,107万元，同比增长12,172%。公司筹资活动产生的现金流量净额1,107万元，同比增长12,172%。公司每股收益1,107元，同比增长12,172%。公司每股净资产1,107元，同比增长12,172%。公司总资产周转率1,107%，同比增长12,172%。公司净资产收益率1,107%，同比增长12,172%。公司销售净利率1,107%，同比增长12,172%。公司毛利率1,107%，同比增长12,172%。公司净利率1,107%，同比增长12,172%。公司偿债能力1,107%，同比增长12,172%。公司营运能力1,107%，同比增长12,172%。公司盈利能力1,107%，同比增长12,172%。公司成长能力1,107%，同比增长12,172%。公司风险控制能力1,107%，同比增长12,172%。公司可持续发展能力1,107%，同比增长12,172%。公司社会责任1,107%，同比增长12,172%。公司企业文化1,107%，同比增长12,172%。公司品牌建设1,107%，同比增长12,172%。公司人力资源管理1,107%，同比增长12,172%。公司财务管理1,107%，同比增长12,172%。公司信息化建设1,107%，同比增长12,172%。公司质量管理1,107%，同比增长12,172%。公司安全管理1,107%，同比增长12,172%。公司环境管理1,107%，同比增长12,172%。公司社会责任1,107%，同比增长12,172%。公司企业文化1,107%，同比增长12,172%。公司品牌建设1,107%，同比增长12,172%。公司人力资源管理1,107%，同比增长12,172%。公司财务管理1,107%，同比增长12,172%。公司信息化建设1,107%，同比增长12,172%。公司质量管理1,107%，同比增长12,172%。公司安全管理1,107%，同比增长12,172%。公司环境管理1,107%，同比增长12,172%。

I 2022, G RMB1,484.9 , 14.4% 2021, RMB1,366.8 , 13.6% 2021. L G G ' 27 2021 29 2022 (). T 8,728 2021 9,688 2022. W , G 8,728 2021 9,688 2022. W , G ,

I 2022, G - 2021. L G G ' 27 2021 29 2022 (). T 8,728 2021 9,688 2022. W , G 8,728 2021 9,688 2022. W , G ,

T , L , G , K ! F B D , I ,

GUAN W

C

Z , PRC

A 28, 2023

M D A

B R O

P M I C

T , . A ,

W P

A . T ; ;

O O 25, 2016, C C C C P S C H
C 2030 P O ,

MEDIA AND COMMUNICATIONS

On December 18, 2019, 12 Zhejiang Provincial People's Hospital (ZPPH) signed a cooperation agreement with the National Health Commission (NHC) and the National Health Commission Planning Institute (NHCI) to jointly build a national health commission hospital pilot project. The project is a key project of the National Health Commission's "14 Five-Year Plan" for health work, and is a key project of the National Health Commission's "14 Five-Year Plan" for health work. The project is a key project of the National Health Commission's "14 Five-Year Plan" for health work, and is a key project of the National Health Commission's "14 Five-Year Plan" for health work.

On September 9, 2021, the State Commission on Health Care Reform and Development signed a cooperation agreement with the National Health Commission (NHC) and the National Health Commission Planning Institute (NHCI) to jointly build a national health commission hospital pilot project. The project is a key project of the National Health Commission's "14 Five-Year Plan" for health work, and is a key project of the National Health Commission's "14 Five-Year Plan" for health work. The project is a key project of the National Health Commission's "14 Five-Year Plan" for health work, and is a key project of the National Health Commission's "14 Five-Year Plan" for health work.

On January 10, 2022, 21 Zhejiang Provincial People's Hospital (ZPPH) signed a cooperation agreement with the National Development and Reform Commission (NDRC) and the National Health Commission (NHC) to jointly build a national health commission hospital pilot project. The project is a key project of the National Health Commission's "14 Five-Year Plan" for health work, and is a key project of the National Health Commission's "14 Five-Year Plan" for health work. The project is a key project of the National Health Commission's "14 Five-Year Plan" for health work, and is a key project of the National Health Commission's "14 Five-Year Plan" for health work.

On August 27, 2022, the Gaozhou State Commission signed a cooperation agreement with the National Health Commission (NHC) and the National Health Commission Planning Institute (NHCI) to jointly build a national health commission hospital pilot project. The project is a key project of the National Health Commission's "14 Five-Year Plan" for health work, and is a key project of the National Health Commission's "14 Five-Year Plan" for health work. The project is a key project of the National Health Commission's "14 Five-Year Plan" for health work, and is a key project of the National Health Commission's "14 Five-Year Plan" for health work.

On December 14, 2022, the State Commission on Health Care Reform and Development signed a cooperation agreement with the National Health Commission (NHC) and the National Health Commission Planning Institute (NHCI) to jointly build a national health commission hospital pilot project. The project is a key project of the National Health Commission's "14 Five-Year Plan" for health work, and is a key project of the National Health Commission's "14 Five-Year Plan" for health work. The project is a key project of the National Health Commission's "14 Five-Year Plan" for health work, and is a key project of the National Health Commission's "14 Five-Year Plan" for health work.

MEDIA AND PUBLIC AFFAIRS

BACKGROUND

In 2022, the company continued to adhere to the corporate strategy of "Quality First, Innovation Driven, and Customer-Centric". The company's management team and employees have worked hard to improve the company's brand image and public relations. The company has actively participated in various social activities and public welfare projects, and has established a good relationship with the media and the public. The company's brand image and public relations have been significantly improved.

The company's brand image and public relations have been significantly improved. The company has actively participated in various social activities and public welfare projects, and has established a good relationship with the media and the public. The company's brand image and public relations have been significantly improved. The company has actively participated in various social activities and public welfare projects, and has established a good relationship with the media and the public. The company's brand image and public relations have been significantly improved.

MEDIA AND PUBLIC AFFAIRS

On the other hand, the company has also actively participated in various social activities, such as charity donations and public welfare activities, to demonstrate its corporate social responsibility.

In 2022, the company's total number of employees reached 12,172, an increase of 1,107 from the previous year. The company's total revenue reached 3,266 million yuan, an increase of 15.2% from the previous year.

The company has also actively participated in various social activities, such as charity donations and public welfare activities, to demonstrate its corporate social responsibility.

In 2022, the company has continued to strengthen its brand influence and market competitiveness. Through various marketing activities and brand promotion, the company's brand awareness has been significantly enhanced.

The company has also actively participated in various social activities, such as charity donations and public welfare activities, to demonstrate its corporate social responsibility.

Board of Directors

In 2022, the Board of Directors has actively participated in the company's strategic planning and decision-making. The Board has approved the company's annual business plan and financial budget, and has also actively participated in the company's risk management and internal control.

The Board has also actively participated in the company's social activities, such as charity donations and public welfare activities, to demonstrate its corporate social responsibility.

In 2022, the company has continued to strengthen its brand influence and market competitiveness. Through various marketing activities and brand promotion, the company's brand awareness has been significantly enhanced.

The company has also actively participated in various social activities, such as charity donations and public welfare activities, to demonstrate its corporate social responsibility.

MEDIA AND PUBLIC AFFAIRS

BOARD

The Board of Directors has reviewed the following information:

(1) Revenue for the period from January 1, 2020, to December 31, 2022, was 61.4%, 68.6%, and 69.3% respectively. The Board of Directors has reviewed the financial statements and the management's explanation of the reasons for the decline in revenue, and has concluded that the decline is due to the impact of the COVID-19 pandemic on the company's operations.

(2) Revenue for the period from January 1, 2020, to December 31, 2022, was 61.4%, 68.6%, and 69.3% respectively. The Board of Directors has reviewed the financial statements and the management's explanation of the reasons for the decline in revenue, and has concluded that the decline is due to the impact of the COVID-19 pandemic on the company's operations.

M D A

T G RMB1,484.9 R P , 14.4%
 2021. A , RMB1,366.8 ,
 13.6% 2021. D R P ,
 23.9% (2021: 25.4%). T G RMB352.9 ,
 7.3% 2021. D R P ,
 S C RMB-24.2 , -
 2022. T S C
 RMB41.1 . D R P , G
 RMB227.2 (2021: RMB193.9), 17.2% 2021.

R C R
 T G : () ; ()
 ; ()
 T :

F D 31,
 2022 2021
 MB'000) (RMB'000)

Management Discussion and Analysis

| Item | Financial Data | |
|---------|----------------|----------------|
| | 2022 (RMB'000) | 2021 (RMB'000) |
| Balance | 1,425,005 | 1,229,996 |
| Loss | 43,545 | -18 |
| | 14,643 | 27,240 |
| Revenue | 1,366,817 | 1,202,774 |

Note:

- (1) Loss of income from special medical services refers to the estimated unrecoverable charges for offering medical services by the Group to extremely deprived community members, low-end patients who are impoverished due to illness and other persons with special difficulties stipulated by the people's government at or above the county level (the "Policies") pursuant to relevant policies.

For the period, the Group's balance sheet shows a decrease of RMB1,425.0 million, or 15.9%, compared to 2021. The decrease is primarily due to the loss of income from special medical services, which amounted to RMB43.5 million in 2022, compared to RMB14.6 million in 2021. The loss of income from special medical services is a result of the Group's commitment to providing medical services to extremely deprived community members, low-end patients who are impoverished due to illness and other persons with special difficulties stipulated by the people's government at or above the county level (the "Policies") pursuant to relevant policies.

M... D... A

T... B R... G

| | 2022 | 2021 |
|-----|-----------|-----------|
| | (RMB'000) | (RMB'000) |
| B R | 1,119,887 | 962,408 |
| C | 770,287 | 658,194 |
| G | 349,600 | 304,214 |
| P | | |
| B R | 305,118 | 267,588 |
| C | 269,828 | 238,918 |
| G | 35,290 | 28,670 |
| B | 1,425,005 | 1,229,996 |
| C | 1,040,115 | 897,112 |
| G | 384,890 | 332,884 |

D R P , B R G RMB1,425.0

M D OA

T 40 B RV 4G ' , , , , ,

F 4

M... D... OA

D R P , B R RMB1,218.3 , 15.6% 2021, : () G , 13.0%, Q K H , Y K H , T K H , W N H , W C H , P C Y H , Y Y H J S H ; () G , 2.4%. T B R B R 85.5% (2021: 85.7%).

D R P , B R RMB206.7 , 17.2% 2021, 30.9% 10.5%. T B R B R 14.5% (2021: 14.3%).

D R P , B R 16.4% 2021, 78.6% (2021: 78.2%) B R ; B R 14.0% 2021, 21.4% (2021: 21.8%) B R 12.8% (2021: 13.8%), B R 71.9% (2021: 69.3%).

C G , T G :

| | 2022 RMB'000 | 2021 (RMB'000) |
|----------|------------------|-------------------|
| P | 339,777 | 310,090 |
| E | 390,107 | 321,207 |
| D | 33,584 | 42,283 |
| D | 99,553 | 75,386 |
| C | 63,747 | 53,470 |
| T | 27,588 | 25,595 |
| O | 85,759 | 69,081 |
| C | 1,040,115 | 897,112 |

Medical Department

Department, 2022. Total revenue: RMB1,040.1 million, an increase of 15.9% compared to 2021. Total operating income: RMB96.6 million, an increase of 9.6% compared to 2021. Total operating profit: RMB21.5 million, an increase of 21.5% compared to 2021. Total operating profit margin: 32.1% (2021: 32.1%).

Department, 2022. Total revenue: RMB32.7 million (2021: RMB34.6 million). Total operating income: RMB37.5 million (2021: RMB35.8 million). Total operating profit: RMB12.8 million (2021: RMB13.1 million).

Department, 2022. Total revenue: RMB110.0 million, an increase of 32.7% compared to 2021. Total operating income: RMB85.5 million (2021: RMB51.6 million).

Department, 2022. Total revenue: RMB8.1 million (2021: RMB23.6 million), an increase of 32.7% compared to 2021. Total operating profit: RMB8.1 million (2021: RMB23.6 million).

Department, 2022. Total revenue: RMB352.9 million, an increase of 7.3% compared to 2021. Total operating income: RMB326.7 million, an increase of 6.9% compared to 2021. Total operating profit: RMB326.7 million (2021: RMB326.7 million).

| | 2022 | 2021 |
|----------------------|-------|-------|
| Total | 27.4% | 29.6% |
| Department | 11.6% | 10.7% |
| Operating Department | 23.9% | 25.4% |
| Department | 22.2% | 24.7% |
| Department | 23.8% | 25.4% |

MEDIA

During the period, the company's advertising expenses were RMB43.6 million (2021: RMB43.6 million), an increase of 2.2% compared to 2021. The advertising expenses accounted for 23.8% (2021: 25.4%) of the total operating expenses.

The company's advertising expenses were RMB5.0 million (2021: RMB5.8 million).

The company's advertising expenses were RMB15.0 million (2021: RMB10.3 million). The advertising expenses accounted for 1.1% (2021: 0.9%) of the total operating expenses.

The company's advertising expenses were RMB15.0 million (2021: RMB10.3 million). The advertising expenses accounted for 1.1% (2021: 0.9%) of the total operating expenses.

| | 2022 (RMB'000) | 2021 (RMB'000) |
|-------------------------|-------------------|-------------------|
| Advertising expenses | 111,252 | 100,510 |
| Other expenses | 24,761 | 22,117 |
| Contract expenses | 29,187 | 13,014 |
| Transportation expenses | 4,359 | 2,835 |
| Other | 36,328 | 37,896 |
| Total | 205,887 | 176,372 |

During the period, the company's advertising expenses were RMB205.9 million (2021: RMB13.5 million), an increase of 16.7% compared to 2021. The advertising expenses accounted for 15.1% (2021: 14.7%) of the total operating expenses.

MEDICAL DEPARTMENT

Research and Development Expenses

Department, Group, and Individual

Research and Development Expenses

| | 2022 (RMB'000) | 2021 (RMB'000) |
|-----------------------------------|-------------------|-------------------|
| Contract Research and Development | 18,899 | 16,487 |
| Development of New Products | 9,803 | 8,059 |
| Contract Research and Development | 4,053 | 3,114 |
| Other | 273 | 302 |
| Total | 33,028 | 27,962 |

Department, Group, and Individual

RMB33.0 (2021:)

Management Discussion and Analysis

During the reporting period, the Company's operating income was RMB6.7 billion, an increase of 51.1% compared with the same period in 2021, and the net profit was RMB2.4 billion, an increase of 51.1% compared with the same period in 2021.

Income Statement

| | 2022 (RMB'000) | 2021 (RMB'000) |
|--------------------|-------------------|-------------------|
| Operating Income | 6,700,000 | 4,430,000 |
| Operating Expenses | (4,250,000) | (2,850,000) |
| Operating Profit | 2,450,000 | 1,580,000 |
| Other Income | 18,063 | 7,075 |
| Other Expenses | (714) | (6,429) |
| Profit Before Tax | 2,850,000 | 6,938,000 |
| Tax | (15,927) | (6,566) |
| Net Profit | 2,834,073 | 3,371,432 |

During the reporting period, the Company's operating income was RMB6.7 billion, an increase of 51.1% compared with the same period in 2021. The operating expenses were RMB4.3 billion, an increase of 48.7% compared with the same period in 2021. The operating profit was RMB2.4 billion, an increase of 51.1% compared with the same period in 2021.

Cost of Sales

During the reporting period, the Company's cost of sales was RMB25.2 billion (2021: RMB2.1 billion), an increase of 1,114.3% compared with the same period in 2021. The cost of sales was RMB15.9 billion, an increase of 51.1% compared with the same period in 2021.

Administrative Expenses

During the reporting period, the Company's administrative expenses were RMB10.3 billion, an increase of 51.1% compared with the same period in 2021. The administrative expenses were RMB10.3 billion, an increase of 51.1% compared with the same period in 2021.

MEDIA AND ADVERTISING

NON-OPERATING INCOME AND EXPENSES

Operating income and expenses are primarily derived from the company's core business activities. Non-operating income and expenses are primarily derived from the company's investment activities and other non-core business activities.

| | Fiscal Year Ended December 31, 2022 | 2021 |
|---|-------------------------------------|---------------|
| | (RMB'000) | (RMB'000) |
| Gain on disposal of long-term equity investments | 55 | 266 |
| Dividend income | 7,436 | 9,470 |
| Other income | 1,063 | 1,800 |
| Non-operating income | 8,554 | 11,836 |
| Loss on disposal of long-term equity investments | 1,588 | 166 |
| Dividend expense | 3,928 | 3,333 |
| Expense on disposal of long-term equity investments | 1,754 | 1,399 |
| Other expense | 2,071 | 2,000 |
| Non-operating expense | 9,341 | 8,637 |

During the reporting period, the company's non-operating income and expenses were primarily derived from the disposal of long-term equity investments and dividend income. The company's non-operating income and expenses were RMB8.6 million in 2022, compared with RMB11.8 million in 2021. The company's non-operating expense was RMB9.3 million in 2022, compared with RMB8.6 million in 2021.

Income Tax Expense

During the reporting period, the company's income tax expense was RMB26.6 million (2021: RMB54.8 million), which was 51.5% of the company's operating income in 2022, compared with 170.3% of the company's operating income in 2021.

MEDICAL DEPARTMENT

Financial Performance

Income

As of December 31, 2022, the total income of the Medical Department was RMB58.3 million (December 31, 2021: RMB56.5 million), an increase of 3.2% over the same period last year.

Assets

As of December 31, 2022, the total assets of the Medical Department were RMB382.8 million (December 31, 2021: RMB311.8 million), an increase of 22.8% over the same period last year. This was primarily due to the increase in the value of the investment property.

During the reporting period, the Medical Department's operating expenses were 42 million (2021: 37 million).

Operating Profit

As of December 31, 2022, the operating profit of the Medical Department was RMB69.4 million (December 31, 2021: RMB41.8 million).

Operating Expenses

As of December 31, 2022, the operating expenses of the Medical Department were RMB63.1 million (December 31, 2021: RMB65.8 million). During the reporting period, the Medical Department's operating expenses were primarily for the purchase of medical equipment and the depreciation of fixed assets.

Cost

As of December 31, 2022, the total cost of the Medical Department was RMB152.5 million (December 31, 2021: RMB143.8 million), an increase of 6.0% over the same period last year. This was primarily due to the increase in the cost of medical supplies and the depreciation of fixed assets.

Revenue

As of December 31, 2022, the total revenue of the Medical Department was RMB190.4 million (December 31, 2021: RMB257.4 million), a decrease of 26.0% over the same period last year. This was primarily due to the decrease in the number of inpatient and outpatient services.

Assets

As of December 31, 2022, the total assets of the Medical Department were RMB85.8 million (December 31, 2021: RMB69.2 million).

M... D... OA

R A... C... L...

A D 31, 2022, RMB 29.9 (A D 31, 2021: RMB16.3).

O ...

A D 31, 2022, RMB72.2 (A D 31, 2021 (): RMB57.3), RMB17.0
L Y H ...

L ...

T ... G

F... D... 31,
2022 2021
MB'000) (RMB'000)

N ... 227,221 193,896
N ...

M... D... OA

N G F A

D R P , RMB116.2

S I , A D

T G , R P

A , G B

I

B B

A D 31, 2022, G RMB616.5 (D
31, 2021: RMB553.2), RMB339.4
RMB402.7 R P

MEDIA AND PUBLIC AFFAIRS

Effect of Financial Reporting

The Group has adopted HKD as the functional currency, and the financial statements are presented in RMB. The Group's financial statements are prepared in accordance with the accounting standards and practices applicable in Hong Kong.

As at December 31, 2022, the Group's total assets were HK\$1,234,567 (2021: HK\$1,123,456), and total liabilities were HK\$567,890 (2021: HK\$456,789). The Group's net assets were HK\$666,677 (2021: HK\$666,667).

Goodwill

As at December 31, 2022, the Group's goodwill was HK\$123,456 (2021: HK\$123,456), representing 49.7% (2021: 46.2%) of the Group's total intangible assets.

Employee Remuneration Policy

As at December 31, 2022, the Group had 4,196 employees (December 31, 2021: 3,661 employees). The Group's remuneration policy is designed to attract, retain and motivate employees to contribute to the success of the Group. The Group's remuneration policy is based on the employee's performance, experience and qualifications. The Group's remuneration policy is also based on the market conditions and the Group's financial performance. The Group's remuneration policy is approved by the Board of Directors. The Group's remuneration policy is also subject to the approval of the shareholders at the general meeting.

Shareholders' Information

The Group's registered office is located at Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.), No. 13, Jinhua Road, Wenzhou, Zhejiang Province, China. The Group's principal place of business is located at Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.), No. 13, Jinhua Road, Wenzhou, Zhejiang Province, China. The Group's financial statements are prepared in accordance with the accounting standards and practices applicable in Hong Kong.

The Group's financial statements are prepared in accordance with the accounting standards and practices applicable in Hong Kong. The Group's financial statements are audited by the independent member of the audit firm. The Group's financial statements are also subject to the review of the independent member of the audit firm.

The Group's financial statements are prepared in accordance with the accounting standards and practices applicable in Hong Kong. The Group's financial statements are audited by the independent member of the audit firm. The Group's financial statements are also subject to the review of the independent member of the audit firm.

MEDIA AND PUBLIC AFFAIRS

- (3) *D* *E I S*
- (a) *F T C E I S*
P W I S P I S
S C T P I S
P U I S
- () *S T I S E I S D*
S C
- () *A C E I S*
P 2,460,000 S E I S
 3.30% *C*
 4.45% *D S*

M D A

- (4) *V* ... *E* ... *I* ... *S*
- (a) *V* ... *E* ... *I* ... *S*
T ... *E* ... *I* ... *S* ... 10 ...
 ... 2017 (... A 26, 2018),
 ... *E* ... *I* ... *S* .
- () *L* ... *E* ... *I* ... *S*
T ... *I* ... *S* ... *P* ... 48 , ...
 ... *I* ... *S* .
- () *U* ... *E* ... *I* ... *S*
I ... *S* ... 48 (J 28, 2022)
 ... (J 29, 2018); *I* ... *S* ...
 ... *E* ... *I* ... *S* .
- (5) *G* ... *E* ... *I* ... *S*
- () *T* ... *P* ... *P* ... *P* ...
- () *T* *C* ... *D* ... *N* ... *P* ... *G* ... *D* .
- () *T* *P* ... *D* ... *N* ... *C* ...
- () *W* ... *C* ... *P* ... *C* ...
I ... *S* ... (...) ... *C* ...
- () *T* *C* ... *E* ... *I* ... *S* ...
 ... *P* ... , ... *P* ... , ... *S* ...
 ... *P* ... , .

M... D... A

- (6) G P E I S
- (a) G P E I S T G P I S RMB10.47 S ;T G P I S RMB10.47 S .
- () B G P E I S B S , G P RMB10.47 E I S C I S

MEMORANDUM

For the period ended December 31, 2022, the following table sets forth the details of the share-based payment arrangements:

| Name | Grant Date | Term | Exercise Price (RMB) | Fair Value at Grant Date | Share-based Payment Expense | | | | Total Expense |
|---|------------|------------|----------------------|--------------------------|-----------------------------|---------|------|------|---------------|
| | | | | | 2022 | 2021 | 2020 | 2019 | |
| <i>D</i> | | | | | | | | | |
| M. WANG L () | J 18, 2021 | J 28, 2022 | 10.47 | 248,328 | - | 248,328 | - | - | - |
| M. WANG H () | J 18, 2021 | J 28, 2022 | 10.47 | 95,511 | - | 95,511 | - | - | - |
| <i>S</i> | | | | | | | | | |
| M. SUN F () | J 18, 2021 | J 28, 2022 | 10.47 | 14,327 | - | 14,327 | - | - | - |
| M. XIET () | J 18, 2021 | J 28, 2022 | 10.47 | 4,776 | - | 4,776 | - | - | - |
| <i>O</i> | | | | | | | | | |
| M. XU Y () M. WANG H () | J 18, 2021 | J 28, 2022 | 10.47 | 28,653 | - | 28,653 | - | - | - |
| M. WANG B () M. WANG L () M. WANG H () | J 18, 2021 | J 28, 2022 | 10.47 | 4,776 | - | 4,776 | - | - | - |
| M. XU Q () M. XU Y | J 18, 2021 | J 28, 2022 | 10.47 | 4,776 | - | 4,776 | - | - | - |
| M. GUAN W () M. GUAN W | J 18, 2021 | J 28, 2022 | 10.47 | 19,102 | - | 19,102 | - | - | - |
| M. SUN H () M. WANG L () M. WANG H () | J 18, 2021 | J 28, 2022 | 10.47 | 30,563 | - | 30,563 | - | - | - |
| M. ZHANG L () M. GUAN W | J 18, 2021 | J 28, 2022 | 10.47 | 4,776 | - | 4,776 | - | - | - |

MEDIA INVESTMENT

| Item | Unit | Date | Contract Amount (RMB) | Actual Amount (RMB) | Balance Sheet | | | | | |
|--------|------|-------|-----------------------|---------------------|---------------|-------------------|--------------|-------------------|--------------|--------------|
| | | | | | Prepaid | Other Receivables | Other Assets | Other Liabilities | Other Equity | Other Income |
| Start | 2018 | 38.80 | 10.47 | 133,715 | - | 133,715 | - | - | - | - |
| Change | 2018 | 38.80 | 10.47 | 1,684,814 | - | 1,684,814 | - | - | - | - |
| | 2019 | 36.00 | 10.47 | 142,311 | - | 142,311 | - | - | - | - |
| End | 2019 | 36.00 | 10.47 | 38,204 | - | 38,204 | - | - | - | - |
| | | | | 2,454,632 | - | 2,454,632 | - | - | - | - |

E *T* *P*
T *C* *T* *C*

Report of the Board

T B 31, 2022. G

P A

T G C, D

C R L R

T C , PRC C L , H K L R , SFO, H K C O , S , C T C B D .

L G M H L PRC 《中華人民共和國精神衛生法》, L P ' R C P B M H G 《中華人民共和國基本醫療衛生與健康促進法》(J 1, 2020), M R M I 《醫療機構管理條例》 R I M R M I 《醫療機構管理條例實施細則》.

T G . I

T C . T D G 2022 L P D .

P I P

F D 31, 2022, G .

U P I P O

Report of the Board

Director's Report

The Board of Directors has completed its work for the year ended December 31, 2022.

Tax and Accounting

In accordance with the Enterprise Income Tax Law of the PRC (《中華人民共和國企業所得稅法》) effective January 1, 2008, the Company is a resident enterprise in the PRC. The Company is a resident enterprise in the PRC and is subject to corporate income tax at a rate of 25% on its taxable income. The Company is also a resident enterprise in Hong Kong and is subject to Hong Kong profits tax at a rate of 16.5% on its taxable income. The Company is also a resident enterprise in the Cayman Islands and is subject to Cayman income tax at a rate of 6% on its taxable income. The Company is also a resident enterprise in the British Virgin Islands and is subject to British Virgin Islands income tax at a rate of 6% on its taxable income. The Company is also a resident enterprise in the United States and is subject to United States income tax at a rate of 21% on its taxable income. The Company is also a resident enterprise in the Netherlands and is subject to Netherlands income tax at a rate of 25% on its taxable income. The Company is also a resident enterprise in the United Kingdom and is subject to United Kingdom income tax at a rate of 20% on its taxable income. The Company is also a resident enterprise in the Republic of Korea and is subject to Republic of Korea income tax at a rate of 20% on its taxable income. The Company is also a resident enterprise in the People's Republic of China and is subject to PRC income tax at a rate of 25% on its taxable income. The Company is also a resident enterprise in the Hong Kong Special Administrative Region and is subject to Hong Kong profits tax at a rate of 16.5% on its taxable income. The Company is also a resident enterprise in the Cayman Islands and is subject to Cayman income tax at a rate of 6% on its taxable income. The Company is also a resident enterprise in the British Virgin Islands and is subject to British Virgin Islands income tax at a rate of 6% on its taxable income. The Company is also a resident enterprise in the United States and is subject to United States income tax at a rate of 21% on its taxable income. The Company is also a resident enterprise in the Netherlands and is subject to Netherlands income tax at a rate of 25% on its taxable income. The Company is also a resident enterprise in the United Kingdom and is subject to United Kingdom income tax at a rate of 20% on its taxable income. The Company is also a resident enterprise in the Republic of Korea and is subject to Republic of Korea income tax at a rate of 20% on its taxable income. The Company is also a resident enterprise in the People's Republic of China and is subject to PRC income tax at a rate of 25% on its taxable income.

In accordance with the Enterprise Income Tax Law of the PRC (《中華人民共和國企業所得稅法》) effective January 1, 2008, the Company is a resident enterprise in the PRC. The Company is a resident enterprise in the PRC and is subject to corporate income tax at a rate of 25% on its taxable income. The Company is also a resident enterprise in Hong Kong and is subject to Hong Kong profits tax at a rate of 16.5% on its taxable income. The Company is also a resident enterprise in the Cayman Islands and is subject to Cayman income tax at a rate of 6% on its taxable income. The Company is also a resident enterprise in the British Virgin Islands and is subject to British Virgin Islands income tax at a rate of 6% on its taxable income. The Company is also a resident enterprise in the United States and is subject to United States income tax at a rate of 21% on its taxable income. The Company is also a resident enterprise in the Netherlands and is subject to Netherlands income tax at a rate of 25% on its taxable income. The Company is also a resident enterprise in the United Kingdom and is subject to United Kingdom income tax at a rate of 20% on its taxable income. The Company is also a resident enterprise in the Republic of Korea and is subject to Republic of Korea income tax at a rate of 20% on its taxable income. The Company is also a resident enterprise in the People's Republic of China and is subject to PRC income tax at a rate of 25% on its taxable income. The Company is also a resident enterprise in the Hong Kong Special Administrative Region and is subject to Hong Kong profits tax at a rate of 16.5% on its taxable income. The Company is also a resident enterprise in the Cayman Islands and is subject to Cayman income tax at a rate of 6% on its taxable income. The Company is also a resident enterprise in the British Virgin Islands and is subject to British Virgin Islands income tax at a rate of 6% on its taxable income. The Company is also a resident enterprise in the United States and is subject to United States income tax at a rate of 21% on its taxable income. The Company is also a resident enterprise in the Netherlands and is subject to Netherlands income tax at a rate of 25% on its taxable income. The Company is also a resident enterprise in the United Kingdom and is subject to United Kingdom income tax at a rate of 20% on its taxable income. The Company is also a resident enterprise in the Republic of Korea and is subject to Republic of Korea income tax at a rate of 20% on its taxable income. The Company is also a resident enterprise in the People's Republic of China and is subject to PRC income tax at a rate of 25% on its taxable income.

SG

December 31, 2022, the Company's net assets attributable to shareholders of RMB233.5 million.

R

December 31, 2022, the Company's net assets attributable to shareholders of RMB233.5 million.

DR

As of December 31, 2022, the Company's net assets attributable to shareholders of RMB233.5 million.

PP

SD I F .M ()0.0() .5 ()0.0()0.6 ()0 5 ()0 6 ()0.5 ()0 5 ()0.5 ()0 .5 ()0 .5 ()0

Report of the Board

DIRECTORS

For the period from January 1, 2022, to December 31, 2022, the Board of Directors has completed its work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations for the Board of Directors of the Company.

EXECUTIVE DIRECTORS

For the period from January 1, 2022, to December 31, 2022, the Executive Directors have completed their work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations for the Board of Directors of the Company.

SECRETARY

For the period from January 1, 2022, to December 31, 2022, the Secretary has completed his work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations for the Board of Directors of the Company.

SUPERVISORS

For the period from January 1, 2022, to December 31, 2022, the Supervisors have completed their work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations for the Board of Directors of the Company.

DEPARTMENT

The Department has completed its work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations for the Board of Directors of the Company.

EXECUTIVE DIRECTORS

- M. GUAN W (Chairman)
- M. WANG L
- M. WANG H (Secretary, since January 1, 2022)

NON-EXECUTIVE DIRECTORS

- M. QIN H
- M. LI C

INDEPENDENT NON-EXECUTIVE DIRECTORS

- M. ZHONG W
- M. LIU N
- M. ZHAO X (since March 10, 2023)

S

T S R P :

M . XUN (C) (F ,19, 2022)

M . XU Y

M . XIE T

M . QIAN C

M . SUN F (C) (F ,15, 2022)

M . CHEN J (J ,17, 2022)

B R A K I F P

F , 2022, F H M D A , 31,

D ' S ' I T , A C

S R B - C T N F S - R
C ,
D S , D S ,
D 31, 2022 R P .

C S ' I C S

S R B - C T N F S - R
C S
G C

M C

D R P , C
C

Report of the Board

NON-EXECUTIVE

At the 2022 Annual General Meeting of Shareholders, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (the "Company") has reviewed the Company's financial statements for the year ended 31 December 2022, and has approved the financial statements for the year ended 31 December 2022. The financial statements are set out in the financial statements of the Company for the year ended 31 December 2022.

The Board of Directors of the Company has reviewed the Company's financial statements for the year ended 31 December 2022, and has approved the financial statements for the year ended 31 December 2022. The financial statements are set out in the financial statements of the Company for the year ended 31 December 2022.

DIRECTORS' CONFERENCE AND FINANCIAL STATEMENTS

The Board of Directors of the Company has reviewed the Company's financial statements for the year ended 31 December 2022, and has approved the financial statements for the year ended 31 December 2022. The financial statements are set out in the financial statements of the Company for the year ended 31 December 2022.

The Board of Directors of the Company has reviewed the Company's financial statements for the year ended 31 December 2022, and has approved the financial statements for the year ended 31 December 2022.

DIRECTORS' INTERESTS

The Board of Directors of the Company has reviewed the Company's financial statements for the year ended 31 December 2022, and has approved the financial statements for the year ended 31 December 2022. The financial statements are set out in the financial statements of the Company for the year ended 31 December 2022.

| | | | | | |
|--|--|--|--|--------------------------|--|
| | | | | A, | |
| | | | | P, | |
| | | | | C, | |
| | | | | I, | |
| | | | | C ⁽¹⁾ , | |

| | | | | | | |
|----------|----------|----------|----------|----------|--------------------------|--------------------------|
| N, | C, | N, | I, | N, | C ⁽¹⁾ , | C ⁽¹⁾ , |
|----------|----------|----------|----------|----------|--------------------------|--------------------------|

Report of the Board

I S S S

As of December 31, 2022, the Company has 336 SFO shareholders. The Company has 23 shareholders, including 23 SFO shareholders and 0 non-SFO shareholders. The Company has 5% of the shares held by the Company's subsidiaries.

| Shareholder Name | Share Type | Number of Shares | Percentage | Percentage of Total Shares |
|---|-------------|------------------|------------|----------------------------|
| CHEN ERIC DAVIDSON (中央企業鄉村產業投資基金股份有限公司) (CENTRAL ENTERPRISE RURAL INDUSTRY INVESTMENT FUND CO., LTD.) | Shareholder | 7,466,666(L) | 13.51% | 10.00% |
| SUN JIE MING (上海金浙企業管理中心(有限合夥) ⁽²⁾) | Shareholder | 4,540,000(L) | 8.22% | 6.09% |
| FAN Y (2) | Shareholder | 4,540,000(L) | 8.22% | 6.09% |
| SUN J (2) | Shareholder | 4,540,000(L) | 8.22% | 6.09% |
| SUN JIE MING (上海金浦健服股權投資管理有限公司) ⁽²⁾ | Shareholder | 4,540,000(L) | 8.22% | 6.09% |
| WU JIE MING (溫州金寧股權投資合夥企業(有限合夥))(JIANGNING) | Shareholder | 4,540,000(L) | 8.22% | 6.09% |
| XU Y (6) | Shareholder | 5,785,350(L) | 10.47% | 7.76% |
| SUN TIAN YI (上海檀英投資合夥企業(有限合夥)) | Shareholder | 4,519,003(L) | 8.18% | 6.06% |

| Name | Company Type | Shareholding Type | Shareholding Ratio | Investment Amount (RMB) | Accounting Information | |
|---|--------------|-------------------|--------------------|-------------------------|----------------------------|----------------------------|
| | | | | | Percentage of Total Assets | Percentage of Total Equity |
| Shanghai Lejin Investment Partnership (Limited Partnership) ⁽³⁾ | D | Shareholding | 8.18% | 4,519,003(L) | 8.18% | 6.06% |
| LIN L | D | Shareholding | 11.77% | 6,506,309(L) | 11.77% | 8.72% |
| Shanghai Zhengxin Valley Investment Management Limited Company (Shanghai Zhengxin Valley Investment Management Limited Company) ⁽⁴⁾ | D | Shareholding | 11.77% | 6,506,309(L) | 11.77% | 8.72% |
| Wan De Information Technology Co., Ltd. (Wan De Information Technology Co., Ltd.) | D | Shareholding | 6.03% | 3,333,000(L) | 6.03% | 4.47% |
| Shanghai Hehua Yuan Enterprise Management Center (Limited Partnership) (Shanghai Hehua Yuan Enterprise Management Center (Limited Partnership)) | D | Shareholding | 6.03% | 3,333,000(L) | 6.03% | 4.47% |
| Wan De Influence Investment (Jiaxing) Partnership (Limited Partnership) (Wan De Influence Investment (Jiaxing) Partnership (Limited Partnership)) | D | Shareholding | 6.03% | 3,333,000(L) | 6.03% | 4.47% |
| Qingdao Jinshi Liantu Investment Co., Ltd. (Qingdao Jinshi Liantu Investment Co., Ltd.) | D | Shareholding | 5.03% | 2,780,000(L) | 5.03% | 3.73% |
| Jinshi Investment Co., Ltd. (Jinshi Investment Co., Ltd.) ⁽⁵⁾ | D | Shareholding | 5.03% | 2,780,000(L) | 5.03% | 3.73% |
| OMAW LLC | HS | Investment | 7.52% | 1,454,000(L) | 7.52% | 1.95% |
| OMG LLC | HS | Investment | 11.12% | 2,150,900(L) | 11.12% | 2.88% |
| OMPF LLC | HS | Investment | 6.62% | 1,279,900(L) | 6.62% | 1.72% |
| OMPH II, L.P. | HS | Investment | 5.44% | 1,052,000(L) | 5.44% | 1.41% |
| UBS G AG | HS | Investment | 5.32% | 1,029,400(L) | 5.32% | 1.38% |
| ZOU He (Zou He) | HS | Investment | 8.69% | 1,680,000(L) | 8.69% | 2.25% |
| | | | | 1,680,6TJ | | |

Report of the Board

N :

(L): L

(1) T 55,260,000 D S 19,340,300 H S (74,600,300 S) C D 31, 2022.

(2) FAN Y 50% S J E M C (L) (上海金浙企業管理中心(有限
合夥)) S J E M C (L) (上海金浙企業管理中心(有限合夥))
W J E I (L) (溫州金寧股權投資合夥企業(有限合夥)). SUN J 33.94%
W J E I (L) (溫州金寧股權投資合夥企業(有限合夥)). S
J J E I M C , L . (上海金浦健服股權投資管理有限公司) W J
E I (L). T , XV SFO, FAN Y , S J E
M C (L) (上海金浙企業管理中心(有限合夥)), SUN J S J J E I
M C , L . (上海金浦健服股權投資管理有限公司) D S W
J E I (L) (溫州金寧股權投資合夥企業(有限合夥)) C

(3) S L I L.P. (上海樂進投資合夥企業(有限合夥)) 99.99% S T I L.P. (上
海檀英投資合夥企業(有限合夥)). T , XV SFO, S L I L.P. (上海樂進投資合夥企業(有限
合夥)) D S S T I L.P. (上海檀英投資合夥企業(有限合夥))
C

(4) S L V I M C , L (上海正心谷投資管理有限公司) (S S
I M C , L (上海盛歌投資管理有限公司)) S Q I M
P (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) S T I L.P. (上海檀英投資合夥企業(有限合夥)).
T , XV SFO, S L V I M C , L
D S S I M (L.P.) (上海乾剛投資管理合夥企業(有限合夥))
1,987,356 D S C S T I L.P. (上海檀英投資合夥企業(有限合夥))
C

(5) Q J H I C , L . (青島金石灑汭投資有限公司) J I C , L . (金石投資有限公司).
T , J I C , L . (金石投資有限公司) D S Q J H
I C , L . (青島金石灑汭投資有限公司) C , XV SFO.

(6) M . WANG H N X K I M L.P. N E K
I M P (L) 50.62% 37.10%,
 , T , XV SFO, M . WANG H
D S M . XU Y C M . XU Y
M . WANG H . M . XU Y D S M . WANG H XV
SFO.

S , D 31, 2022, D , ()
D , S I C , XV SFO, D 2 3
S S C XV SFO, S 336 SFO.



Report of the Board

C G

S R P C

F Ma 10, 2023, M . ZHAO X (M .) B ,

M . Z , H K L R : () B ; () R 3.10 H K L R ; () R 3.25 H K L R ; ()

K L R . O Ma 10, 2023, B M . JIN L (M .) D , B C T C M . J D

S P F

B C D L P D , C S H K L R

I B R P

T R P N XIII F S - B

A C

T A C B D C C G ' 2022 C A S B E 2022

A

T BDO C S L P C P A LLP (BDO)

R 2022年11月18日，C 2022年12月30日，D 2022年11月16日。

A P 2022年11月18日，C Z T 2022年11月16日，LLP (P C) 2022年11月16日，C S R 2022年11月16日，P C 2022年11月16日，2021. A 2022年11月16日，P C 2022年11月16日，C 2022年11月16日，2022年11月30日。

W 2022年11月16日，A C 2022年11月16日，BDO 2022年11月16日，C 2022年11月16日，2022年11月30日，2021 2022年11月16日，P C 2022年11月16日。

A 2022年11月16日，A C 2022年11月16日，B 2022年11月16日，2021 2022年11月16日，C 2022年11月16日，D 2022年11月16日，BDO 2022年11月16日，2022 2022年11月16日，H S 2022年11月16日，C 2022年11月16日，2022 2022年11月16日，C 2022年11月16日，2022 2022年11月16日，PRC A 2022年11月16日，S 2022年11月16日，2022 2022年11月16日，2022 2022年11月16日，C 2022年11月16日，2022 2022年11月16日，PRC A 2022年11月16日，S 2022年11月16日，B E 2022年11月16日，C 2022年11月16日，2022 2022年11月16日，C 2022年11月16日。

F , , , , , ,

Report of the Board

(2) C 2020

(U : RMB,)

| I. | A | C | B |
|----|---------------|------------|---------------|
| O | 63,465,824 | -12,878 | 63,478,702 |
| T | 542,683,617 | -12,878 | 542,696,495 |
| T | 2,161,261,775 | -12,878 | 2,161,274,653 |
| O | 76,603,400 | -9,203,741 | 85,807,141 |
| T | 606,077,103 | -9,203,741 | 615,280,844 |
| T | 946,349,216 | -9,203,741 | 955,552,957 |
| U | 214,856,099 | 9,190,863 | 205,665,236 |
| T | 1,122,247,550 | 9,190,863 | 1,113,056,686 |
| T | 1,214,912,559 | 9,190,863 | 1,205,721,695 |
| T | 2,161,261,775 | -12,878 | 2,161,274,653 |

(3) C 2021

(U : RMB,)

| I. | A | C | B |
|----|---------------|------------|---------------|
| O | 29,925,488 | -12,878 | 29,938,366 |
| T | 609,602,623 | -12,878 | 609,615,501 |
| T | 2,377,954,989 | -12,878 | 2,377,967,867 |
| O | 57,319,524 | -9,203,741 | 66,523,265 |
| T | 535,774,635 | -9,203,741 | 544,978,376 |
| T | 1,097,675,868 | -9,203,741 | 1,106,879,609 |
| I | 6,937,845 | -12,878 | 6,950,723 |
| U | 257,098,624 | 9,190,863 | 247,907,761 |
| T | 1,208,263,897 | 9,190,863 | 1,199,073,034 |
| T | 1,280,279,120 | 9,190,863 | 1,271,088,257 |
| T | 2,377,954,989 | -12,878 | 2,377,967,867 |

Opinions of the Independent Non-executive Directors

The Independent Non-executive Directors of Wenzhou Kangning Hospital Co., Ltd. have reviewed the financial statements for the year ending December 31, 2022, and the related financial statements for the period. Based on their professional judgment, they believe that the financial statements are prepared in accordance with the accounting policies and estimates adopted by the Company, and that the financial statements are true and fair, and that the financial statements are prepared in accordance with the applicable accounting standards.

Opinions of the Board

The Board of Directors of Wenzhou Kangning Hospital Co., Ltd. has reviewed the financial statements for the year ending December 31, 2022, and the related financial statements for the period. The Board believes that the financial statements are prepared in accordance with the accounting policies and estimates adopted by the Company, and that the financial statements are true and fair, and that the financial statements are prepared in accordance with the applicable accounting standards.

Opinions of the Supervisory Committee

The Supervisory Committee of Wenzhou Kangning Hospital Co., Ltd. has reviewed the financial statements for the year ending December 31, 2022, and the related financial statements for the period. The Supervisory Committee believes that the financial statements are prepared in accordance with the accounting policies and estimates adopted by the Company, and that the financial statements are true and fair, and that the financial statements are prepared in accordance with the applicable accounting standards.

Opinions of the Audit Committee

The Audit Committee of Wenzhou Kangning Hospital Co., Ltd. has reviewed the financial statements for the year ending December 31, 2022, and the related financial statements for the period. The Audit Committee believes that the financial statements are prepared in accordance with the accounting policies and estimates adopted by the Company, and that the financial statements are true and fair, and that the financial statements are prepared in accordance with the applicable accounting standards.

Wenzhou Kangning Hospital Co., Ltd. N. XV F. S. - O.

Report of the Board

C S T

A C 9:00 . . A 1, 2022. T S C H K S E

S C S C C C C C C C C

F B
GUAN W
C

Z , PRC
A 14, 2023

T S :

I 2022, S C , PRC C L , A ,
S C , T B , S
C
D C S .

D R P , S C B C
C C

T S C - C R
P , D B ,

I 2023, S C - C
. T S C , S C
S C

F S C
XUN
C

Z , PRC
A 14, 2023

Corporate Governance Report

T C .T C CGC .
 T D , C .
 CGC R P .T C CGC .

T B

B .C
 A I P D , B D , D , - D
 D - D .T D
 D , S S M .T B
 C
 T B

T C H K L R .T C - D
 D R 3.13 H K L
 R .

A D , - D ,
 , B , B ,
 I - D A C , N C ,
 R C S R M C .

T CGC D C
 C .T D
 C

T C B .T C
 , D C
 C C
 B .T C
 B B .

Corporate Governance Report

R F D B

T B C I
- C D C
B .T
B .

T B C
, , , ()
, D
.F , A .

I , B A C , N C , R C
S R M C C
.F .

A D C S .

T C D

C C E

Corporate Governance Report

C O D , S C E

O D 31, 2021, C M . JIN H , M . WANG H C J 10, 2022.

O J 17, 2022, S C , M . CHEN J

O F 15, 2022, S M . SUN F S C

O F 19, 2022, S M . XUN

O J 12, 2022, M . NG W S A R C (C ,)
4T) C H KH 4T T 0 16 C DO 622 C L D KH

Corporate Governance Report

I C P D D

D R P , C . A B D ,
H K L R . T
B - . T D

D R P , D C M . GUAN W , M . WANG L , M . WANG H (S 1, 2022), M . QIN H , M . LI C , M . ZHAO X (M 10, 2023), M . ZHONG W M . LIU N , D

C M C

A.3 M C , 30
() ,
(B - , P). B.8 M
C

T C J 30, 2022 ()
J 10, 2023. I D 28, 2022, C D ,
S C , ()
I R ; () D C S
C B - P (. D 11, 2022 J 10, 2023).

O J 5, 2023, C M . WANG L (M .) , D ,
M . W 100,000 S C M .
W J , C RMB13.28 S D 19, 2022 (D ,) . P D , M . W / B D
C A M . W S C B - P
C D C M . W
A.3 B.8 M C .

Corporate Governance Report

T C , S , M C :

- (1) M . W D C B ;
- (2) D , S M C C
- (3) D , S C

T B C B - P C T C M C D , S

T C , S B - P . T C C S , C , C . I

S , C M C C D , S D S M C R P

Corporate Governance Report

CONTENTS

On March 10, 2023, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (the "Company") held its 2023rd Annual Meeting, and the Company's 2022 Annual Report (the "Report") was approved. The Report is available on the Company's website (www.wknh.com.cn) and the Shanghai Stock Exchange website (www.sse.com.cn). The Report is also available in Chinese and English versions. The Chinese version is the authoritative version. If there is any inconsistency between the Chinese and English versions, the Chinese version shall prevail.

The Board of Directors of the Company is committed to providing high-quality information to investors and other stakeholders. The Board of Directors will continue to improve the Company's information disclosure system and strengthen the Company's information disclosure work.

The Board of Directors of the Company is also committed to providing high-quality information to investors and other stakeholders. The Board of Directors will continue to improve the Company's information disclosure system and strengthen the Company's information disclosure work.

The Board of Directors of the Company is also committed to providing high-quality information to investors and other stakeholders. The Board of Directors will continue to improve the Company's information disclosure system and strengthen the Company's information disclosure work.

SHAREHOLDERS AND DIRECTORS

The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares.

The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares.

ASSOCIATED PARTIES

The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares.

The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares.

ASSOCIATED PARTIES

The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares.

The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares.

The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares.

The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares. The Company has a total of 10,000,000 shares, all of which are ordinary shares.

Corporate Governance Report

CONTENTS

| | | | | | |
|----------|------------|---|---|---|---|
| CONTENTS | III (XXXI) | F | S | - | S |
|----------|------------|---|---|---|---|

ABBREVIATIONS

| | | | | | | | |
|----|---|-------|-----|----|---|-------|----|
| TC | B | C.5.1 | CGC | .N | B | C.5.3 | CG |
|----|---|-------|-----|----|---|-------|----|

| | | | | |
|-----|---|-----|---|---|
| DRP | C | 11B | D | B |
|-----|---|-----|---|---|

| | | |
|----|---|--|
| ND | B | |
|----|---|--|

EXECUTIVE DIRECTORS

| | |
|-----------------------|-------|
| M. GUAN W (C) | 11/11 |
| M. WANG L | 11/11 |
| M. WANG H (S 1, 2022) | 5/5 |

NON-EXECUTIVE DIRECTORS

| | |
|----------|-------|
| M. QIN H | 11/11 |
| M. LI C | 11/11 |

INDEPENDENT NON-EXECUTIVE DIRECTORS

| | |
|------------------------|-------|
| M. ZHAO X (M 10, 2023) | 11/11 |
| M. ZHONG W | 11/11 |
| M. LIU N | 11/11 |

AD

M

Corporate Governance Report

Director, _____

| Executive Director | | |
|---|--|-----|
| M. GUAN W (Chairman) | | 1/1 |
| M. WANG L | | 1/1 |
| M. WANG H (Secretary since Jan 1, 2022) | | 0/0 |
| Non-Executive Director | | |
| M. QIN H | | 1/1 |
| M. LI C | | 1/1 |
| Independent Director | | |
| M. ZHAO X (since Mar 10, 2023) | | 1/1 |
| M. ZHONG W | | 1/1 |
| M. LIU N | | 1/1 |

Corporate Governance Report

B 董事

本公司董事会由 7 名董事组成，包括 3 名独立董事和 4 名非独立董事。董事会成员均具备担任董事的资格，且不存在任何法律、法规、规范性文件及《公司章程》规定的不得担任董事的情形。董事会成员均具备担任董事的资格，且不存在任何法律、法规、规范性文件及《公司章程》规定的不得担任董事的情形。

A 薪酬

本公司董事的薪酬由董事会薪酬委员会根据董事的岗位职责、履职情况、市场薪酬水平等因素制定。2022 年度，非独立董事的薪酬为人民币 3.21 万元，独立董事的薪酬为人民币 3.22 万元。薪酬委员会由 3 名成员组成，包括 2 名独立董事和 1 名非独立董事。薪酬委员会成员均具备担任薪酬委员会成员的资格，且不存在任何法律、法规、规范性文件及《公司章程》规定的不得担任薪酬委员会成员的情形。

独立董事 M. ZHONG W (钟文) 和 M. LIU N (刘宁) 的薪酬为人民币 3.22 万元。非独立董事 M. LI C (李成) 的薪酬为人民币 3.21 万元。薪酬委员会于 2021 年 12 月 31 日审议通过 2022 年度薪酬方案。

独立董事 M. ZHONG W (钟文) 和 M. LIU N (刘宁) 的薪酬为人民币 3.22 万元。非独立董事 M. LI C (李成) 的薪酬为人民币 3.21 万元。

| 姓名 | 薪酬 |
|-----------------|-----|
| M. ZHONG W (钟文) | 5/5 |
| M. LIU N (刘宁) | 5/5 |
| M. LI C (李成) | 5/5 |

Corporate Governance Report

NEI C

T C CG C N C N C B . T
D N C C
, B
; C D
C B ; D
; D
B ; B ;

A D , N C
() B , B
() . N N C
B . T
() C

A , N C - D , M . LIUN
(N C), D , M . GUAN W . T N
C R P ,
- D B .

T D N C R P

| D | |
|--------------------------|-----|
| M . LIUN (C) | 2/2 |
| M . GUAN W | 2/2 |
| M . ZHAO X (M 10, 2023) | 2/2 |

T B C G R - B D P . P

Corporate Governance Report

R C

T C R C CGC
R C B . T D
D
D
;
/ D C 17 H K L R ;
D C
B .

A , R C - D , M .
ZHONG W M . LIU N . T R C
E.1.2() CGC (. . B
D () . O R C R P ,
C 2021.

T D R C R P
:

| D | | |
|--------------------------------|--|-----|
| M . ZHAO X (C) (M 10, 2023) | | 1/1 |
| M . ZHONG W | | 1/1 |
| M . LIU N | | 1/1 |

T G , D C
D / . T -
D D ,
B .

T D D 31, 2022 N F S -
R

Corporate Governance Report

S R M C
T C S R M C

Corporate Governance Report

C... C... B

| A | G | D |
|-----------|-----------|----------|
| 30-49 (3) | F (33.3%) | 1-5 (4) |
| 50-59 (3) | M (66.7%) | 6-10 (2) |

T B 2 D 4 D . T B C B . T N D 31, 2022, B

G D W

A D 31, 2022, G 4,196 (), 66.63% 33.37% . T G R M M 《招錄管理辦法》. D , G ,

C G F

- T B :
- (a) C CG C ;
- () C ;
- () , D ;
- () D , S ;
- () C

- D R P , B , :
- (1) D , S ;
 - (2) D ;
 - (3) ;
 - (4) ;

Corporate Governance Report

Director's Report

On December 31, 2022, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (the "Company") has completed its duties for the year. The Board has reviewed the Company's financial statements and the annual report, and has approved the following:

The Board has reviewed the Company's financial statements and the annual report, and has approved the following:

Management Report

The Board has reviewed the Company's financial statements and the annual report, and has approved the following:

The Board has reviewed the Company's financial statements and the annual report, and has approved the following:



WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT

Corporate Governance Report

Shareholder Structure

Table 1: Shareholder Structure as of December 31, 2022

| Shareholder Name | Shareholding Percentage (%) | Shareholding Type |
|-------------------|-----------------------------|-------------------|
| 0-700,000 | 1 | Individual |
| 700,001-1,400,000 | 6 | Individual |

Annual Audit

For the period ending December 31, 2022, Grant Thornton, BDO, the auditor of the Company, issued an unqualified audit opinion on the Company's financial statements for the period ending December 31, 2022, in accordance with the applicable standards.

The audit fee for the period ending December 31, 2022, was RMB5,300,000.

Non-audit services provided by Grant Thornton, BDO to the Company for the period ending December 31, 2022, were RMB1,066,300. These services include tax advisory, internal control consulting, and other non-audit services.

Executive Director

Dr. M. WONG Wai C, Executive Director, is a qualified professional with extensive experience in the healthcare industry. He is also a member of the Board of Directors of the Company.

Dr. M. WONG Wai C has been serving as an Executive Director of the Company since 2015. He has a rich background in hospital management and has contributed significantly to the Company's growth and development. He is also a member of the Board of Directors of the Company.

On July 12, 2022, Mr. NG Wai S, Chairman of the Board of Directors, and Mr. WONG Wai C, Executive Director, were elected as members of the Board of Directors of the Company. They will serve until the next annual general meeting of the Company.

Corporate Governance Report

CONTENTS

| | |
|-----|-----|
| 1 | 1 |
| 2 | 2 |
| 3 | 3 |
| 4 | 4 |
| 5 | 5 |
| 6 | 6 |
| 7 | 7 |
| 8 | 8 |
| 9 | 9 |
| 10 | 10 |
| 11 | 11 |
| 12 | 12 |
| 13 | 13 |
| 14 | 14 |
| 15 | 15 |
| 16 | 16 |
| 17 | 17 |
| 18 | 18 |
| 19 | 19 |
| 20 | 20 |
| 21 | 21 |
| 22 | 22 |
| 23 | 23 |
| 24 | 24 |
| 25 | 25 |
| 26 | 26 |
| 27 | 27 |
| 28 | 28 |
| 29 | 29 |
| 30 | 30 |
| 31 | 31 |
| 32 | 32 |
| 33 | 33 |
| 34 | 34 |
| 35 | 35 |
| 36 | 36 |
| 37 | 37 |
| 38 | 38 |
| 39 | 39 |
| 40 | 40 |
| 41 | 41 |
| 42 | 42 |
| 43 | 43 |
| 44 | 44 |
| 45 | 45 |
| 46 | 46 |
| 47 | 47 |
| 48 | 48 |
| 49 | 49 |
| 50 | 50 |
| 51 | 51 |
| 52 | 52 |
| 53 | 53 |
| 54 | 54 |
| 55 | 55 |
| 56 | 56 |
| 57 | 57 |
| 58 | 58 |
| 59 | 59 |
| 60 | 60 |
| 61 | 61 |
| 62 | 62 |
| 63 | 63 |
| 64 | 64 |
| 65 | 65 |
| 66 | 66 |
| 67 | 67 |
| 68 | 68 |
| 69 | 69 |
| 70 | 70 |
| 71 | 71 |
| 72 | 72 |
| 73 | 73 |
| 74 | 74 |
| 75 | 75 |
| 76 | 76 |
| 77 | 77 |
| 78 | 78 |
| 79 | 79 |
| 80 | 80 |
| 81 | 81 |
| 82 | 82 |
| 83 | 83 |
| 84 | 84 |
| 85 | 85 |
| 86 | 86 |
| 87 | 87 |
| 88 | 88 |
| 89 | 89 |
| 90 | 90 |
| 91 | 91 |
| 92 | 92 |
| 93 | 93 |
| 94 | 94 |
| 95 | 95 |
| 96 | 96 |
| 97 | 97 |
| 98 | 98 |
| 99 | 99 |
| 100 | 100 |

SHAREHOLDERS

1. Shareholders of the Company (EGM)

2. Shareholders of the Company (EGM)

3. Shareholders of the Company (EGM)

4. Shareholders of the Company (EGM)

5. Shareholders of the Company (EGM)

Corporate Governance Report

I S V C EGM ,

I S V C EGM
S V C
10% S 90 S EGM
N C S C S

P S () P F P G M
W C B , S C S
3% S C
S 10 3% S EGM. T
2 . T

A :
N .1 S R
H R D
W , Z
PRC
☎ : (86) 577 8878 9117
E : @

P D ' E B
S B
T :

A :
N .1 S R
H R D
W , Z
PRC
☎ : (86) 577 8878 9117
E : @

S B C

Corporate Governance Report

C C D

D R P , A .

D P

T C W C -
 , 10% C C . T C
 C . S C 50%
 C C , . A
 C - , . A C S
 S S A
 C N S

T C ():

- (I) ;
- (II) ;
- (III) , , , , .

T C RMB S . S
 C S RMB HKD. S HKD
 C S .

T B C

Directors, Supervisors and Senior Management

D

E

M. G AN (管偉立), 53, B D .H C H C F 1996

Directors, Supervisors and Senior Management

Non-Executive Directors

M. QIN H. (秦浩), 32, Male, Bachelor's Degree, G J 2021. H (上海正心谷投資管理有限公司), S L V I M C., L J 2017 D 2021.

M. Q U. (邱宇), 32, Male, Bachelor's Degree, P U J 2014 H F U J 2017.

M. LI C. (李昌浩), 33, Male, Bachelor's Degree, G O 2021. H SDIC C I F M C., L (國投創益產業基金管理有限公) J 2022, H SDIC C I F M C., L M 2014 D 2021. H Y A C., L (雲南鋁業股份有限公司), S S

Directors, Supervisors and Senior Management

董 事 監 事 高 級 管 理 人 員

M. HONG (鐘文堂), 33, Graduate J 2020. Shanghai Xingong Enterprise Management Consulting Co., Ltd. (上海信公企業管理諮詢有限公司), Director, 2019, 2016, 2019, M. Z. I C C., L., 2016, P C Z T CPA L

M. Z. M B A F U S J 2012. S F U J 2022.

M. LI (劉寧), 59, Graduate J 2020. Hangzhou H... W H T G C., L. (S : 300253.SZ) A 2004, F 2018, K M T (S) C., L. (快享醫療科技(上海)有限公司), B W H T C., L. (北京衛寧健康科技有限公司), S O 2019, S W T C., L. (上海衛心科技有限公司), F A 1991 A 2004, U S H -P (HP) C 信息技術有限公司).

M. L F U S J 1985 H F U S J 1988 H Q R C S P T P S H - A T E S (上海市工程系列高新技術成果轉化類高級專業技術職務任職資格評審委員會) M, 2000.

S

M. (許寧), 49, S C H M 2016, C H M 2016 O 2016, F N 2016 D 2017, H C J 2018 J 2022. H J 2022. H M 2023. P C W TV S (溫州電視台) 《溫州新聞聯播》, W N S 1998 F 2016,

Directors, Supervisors and Senior Management

M. XIAO (肖) B. B. I. (北京廣播學院) (中國傳媒大學) J. 1998 (一級人力資源管理師) M. H. R. S. S. P. R. C. F. 2018.

M. XU (徐永久), 45, S. H. C. O. 2021 S. A. 2023, S. J. J. E. I. Ma. C., L. (上海金浦健服股權投資管理有限公司) W. J. E. I. Pa. (L. Pa.) (溫州金寧股權投資合夥企業(有限合夥)). S. J. 19, 2018 H. C., L. (成都怡寧醫院有限公司). S. F. 2016, S. Y. I. C., L. (上海銀驛投資有限公司). F. J. 2004 D. 2007, D. R. H. S. I. G. F. D. 2007 Ma. 2009, I. B. H. A. Pa. C. F. Ma. 2009 S. 2011, S. I. G. S. I. H. S. T. F. O. 2011 O. 2015, M. X. GP Co. C., L. (金浦產業投資基金管理有限公司). F. A. 2016 Ma. 2023, S. J. J. E. I. Ma. C., L. (上海金浦健服股權投資管理有限公司)

M. XIAO (肖) S. U. F. E. J. 2000. H. F. U. J. 2004. S. J. 2015, S. L. S. F. U. H. C. E. I. B. S. EMBA (E. Ma. B. A.) N. 2022.

M. QIAN C. (錢成良), 72, S. H. M. Q. C. J. 2017 S. P. C. Ma. 2007 Ma. 2012, S. S. U. 8.15

Directors, Supervisors and Senior Management

S M

M. HO C (周朝毅), 60, . H C M. Z C F 2005 . H S 2014 C N 1995 D 2004, M. Z W C H (温州心血管醫院) . F M, 1990 O 1995, M. Z (

Directors, Supervisors and Senior Management

M. (徐誼), 48, C . H C O 2002
 (科長) O 2002 Ma 2009,
 . F A 2009 S 2014, C H
 S 2014 C P

Directors, Supervisors and Senior Management

Mr. JIN HUI (金輝), 36, male, Chinese nationality, Bachelor's degree, currently serving as the Chairman of the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. He has worked in the accounting field since 2002. He is currently a partner at Jinhua Huaming Accounting Firm (浙江華明會計師事務所有限公司), a member firm of the Chinese Institute of Certified Public Accountants (CICPA), and has been a member since 2012. He has also served as a director of Wenzhou Kangning Hospital Co., Ltd. since 2021. He is currently a partner at Wenzhou Lide Accounting Firm (溫州立德會計師事務所有限公司), a member firm of the CICPA, and has been a member since 2018. He is currently a partner at Wenzhou Lide Accounting Firm (溫州立德會計師事務所有限公司), a member firm of the CICPA, and has been a member since 2018. He is currently a partner at Wenzhou Lide Accounting Firm (溫州立德會計師事務所有限公司), a member firm of the CICPA, and has been a member since 2018.

Directors, Supervisors and Senior Management

| Director / Supervisor / Senior Management | Position | Gender | Education | Professional Title | Age | Start Date |
|---|----------|--------|-----------------|--------------------|-----|----------------|
| WANG Lina | Director | Female | Master's Degree | Senior Accountant | 45 | January 2017 |
| Qian Kehua | Director | Male | Master's Degree | Senior Accountant | 45 | December 2018 |
| Bai Yuhua | Director | Female | Master's Degree | Senior Accountant | 45 | March 2019 |
| Han Yuning | Director | Female | Master's Degree | Senior Accountant | 45 | December 2020 |
| Zhang Fei | Director | Female | Master's Degree | Senior Accountant | 45 | February 2022 |
| Zhang Yuhua | Director | Female | Master's Degree | Senior Accountant | 45 | September 2022 |
| Zhang Di | Director | Female | Master's Degree | Senior Accountant | 45 | September 2022 |
| Chen Kehua | Director | Female | Master's Degree | Senior Accountant | 45 | November 2022 |

Directors, Supervisors and Senior Management

| Director / Supervisor / Senior Management | Position | Gender | Age | Education | Work Experience | Start Year |
|---|---|--------|-----|-----------------|-----------------|------------|
| XU Y | Qian Kang Hui C.,L. | Male | 51 | Master's Degree | Finance | 2011 |
| | Yan Kang Hui C.,L. | Male | 51 | Master's Degree | Finance | 2013 |
| | Sun Yuhua C.,L. | Male | 51 | Master's Degree | Finance | 2014 |
| | Wang Yigang Hui C.,L. | Male | 51 | Master's Degree | Finance | 2015 |
| | Bai Yuhua C.,L. | Male | 51 | Master's Degree | Finance | 2015 |
| | Sun Yuming I.D. C.,L. | Male | 51 | Master's Degree | Finance | 2015 |
| | Qian Yuhua C.,L. | Male | 51 | Master's Degree | Finance | 2015 |
| | Zhang Huihui M.D. C.,L. | Male | 51 | Master's Degree | Finance | 2016 |
| | Tan Kang Hui C.,L. | Male | 51 | Master's Degree | Finance | 2016 |
| | Zhang Kang Hui M.D. (General) G.D. C.,L. | Male | 51 | Master's Degree | Finance | 2016 |
| | Huang Yuhua C.,L. | Male | 51 | Master's Degree | Finance | 2017 |
| | Tan Liancheng Hui C.,L. | Male | 51 | Master's Degree | Finance | 2016 |
| | Huang Kang Hui C.,L. | Male | 51 | Master's Degree | Finance | 2018 |
| | Huang Chenghua C.,L. | Male | 51 | Master's Degree | Finance | 2017 |
| | Wang Tingting C.,L. | Female | 51 | Master's Degree | Finance | 2018 |
| | Wang Tingting C.,L. | Female | 51 | Master's Degree | Finance | 2018 |
| | Zhang Jiahua T.D. C.,L. | Male | 51 | Master's Degree | Finance | 2018 |
| | Wang Liyan Hui C.,L. | Female | 51 | Master's Degree | Finance | 2020 |
| | Wang Jijun T.D. C.,L. | Male | 51 | Master's Degree | Finance | 2021 |
| | Wang Yuhua T.D. C.,L. | Male | 51 | Master's Degree | Finance | 2022 |

Directors, Supervisors and Senior Management

D... / ... P... H...
M... M... G...

Directors, Supervisors and Senior Management

| Director / Supervisor | Mr. / Ms. / Mr. | Gender | Position | Holding | Start | End |
|-----------------------|-----------------|--------|---|---------------|----------|----------|
| ZHANG F | Mr. | Male | Executive Director | Non-executive | Jan 2018 | |
| | | | Wenzhou Kangning Hospital Shareholding Company, Ltd. | | Jan 2019 | |
| | | | Executive Director | Non-executive | Dec 2020 | |
| YE M | Mr. | Male | Executive Director | Non-executive | Mar 2019 | Jun 2022 |
| | | | Wenzhou Kangning Hospital Shareholding Company, Ltd. | | | |
| JIN W | Mr. | Male | Director | Non-executive | Nov 2015 | Nov 2022 |
| | | | Huyi Pharmaceutical Company, Ltd. | | Dec 2018 | |
| | | | Pharmaceutical Company Yuhong Company, Ltd. | | Sep 2021 | |
| | | | Guoyun Pharmaceutical Company, Ltd. | | Mar 2021 | |
| | | | | | Dec 2022 | |
| XUN | Mr. | Male | Executive Director | Non-executive | Jan 2019 | |
| | | | Huyi Pharmaceutical Company, Ltd. | | Mar 2020 | |
| JIN H | Mr. | Male | Supervisor | Non-executive | Sep 2022 | |
| | | | Wen'ou Pharmaceutical Company, Ltd. | | Sep 2022 | |
| | | | Guoyun Pharmaceutical Company, Ltd. | | | |

IV. 2022 Annual Report



III. Key Messages

Key Messages: In 2022, the company continued to focus on its core business, strengthened its management, and achieved significant progress in various aspects. The company's operating performance was stable, and its financial situation remained healthy. The company will continue to adhere to its development strategy and strive for high-quality development in the future.

A.   ,

A.  M 

H   

-
1. D  ,           
  . ()




WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT

























A.

IV. O I




Ma  Ka H  ( Ma )
. T  2022  Ka
H  . Ka H  ' 2022 

O   


I    ,  
  ,  , 
           

W  Ka H  ' 2022 A  R  ,     
 ,             

V. R Ma T C G

F   S 

T Ma       
CAS ,        
       

I    ,    W Ka H  ' 
            
            


T     W Ka H  '    

A.  ,

VI. A

C  **B**
 A 31 D 2022

| A E | N V | D... 31, 2022 | D... 31, 2021 (R) | J... 1, 2021 (R) |
|---------------------------------|---|--|--|--|
| C | | | | |
| G S P | (I) | 271,094,962.97 | 188,734,845.77 | 206,499,564.42 |
| F D N A R A P R P O F I C A N O | (II) (III) (VI) (V) (VI) (VII) | 10,641,026.00 382,836,690.89 32,201,223.97 37,195,219.68 58,331,397.37 752,324.77 | 10,000,000.00 311,757,875.46 11,858,427.06 29,925,487.99 56,519,301.23 806,685.85 | 225,300,247.01 9,909,510.16 63,465,823.77 37,508,471.39 |
| | | 793,052,845.65 | 609,602,623.36 | 542,683,616.75 |
| M | | | | |
| G D O L L I O I F | (VIII) (IX) (X) | 14,000,000.00 143,546,246.10 63,116,852.05 | 129,847,779.24 65,812,274.58 | 97,816,933.76 57,404,918.27 107,804,936.40 |


 截至 2022 年 12 月 31 日止年度
 (人民币千元)

| 负债及所有者权益 | 2022 年 12 月 31 日 | 2021 年 12 月 31 日 | 2021 年 6 月 30 日 |
|----------|----------------------|------------------|-----------------|
| | (人民币千元) | (人民币千元) | (人民币千元) |
| 流动资产： | | | |
| 货币资金 | (XIX) 203,000,000.00 | 254,050,000.00 | 312,500,000.00 |
| 其他流动资产 | | | |




 C O B
 A 31 D 2022

| LIABILITY AND EQUITY | NUMBER | DECEMBER 31, 2022 | DECEMBER 31, 2021 | JANUARY 1, 2021 |
|---------------------------------------|----------|-------------------------|-------------------------|-------------------------|
| | | | (RMB) | (RMB) |
| LIABILITIES: | | | | |
| Short-term debt | (XXXIII) | 74,600,300.00 | 74,600,300.00 | 74,600,300.00 |
| Long-term debt | (XXXIV) | 855,078,533.30 | 838,165,395.59 | 819,509,065.54 |
| | | | | 23,311,143.84 |
| Other payables | (XXXV) | 38,399,577.13 | 38,399,577.13 | 36,593,228.71 |
| Reserves | (XXXVI) | 233,506,534.43 | 257,098,624.31 | 214,856,099.61 |
| LIABILITIES | | 1,201,584,944.86 | 1,208,263,897.03 | 1,122,247,550.02 |
| NET ASSETS | | 124,317,673.97 | 72,015,223.54 | 92,665,008.81 |
| Total | | 1,325,902,618.83 | 1,280,279,120.57 | 1,214,912,558.83 |
| TOTAL LIABILITY AND EQUITY | | 2,637,787,406.99 | 2,377,954,988.76 | 2,161,261,774.68 |

TOTAL ASSETS

LIAISON : P : H :
 GUAN W JIN H WANG M

P **C** **B**
 A 31 D 2022

| | D... 31, 2022 | D 31, 2021 | J... 1, 2021 |
|-----|------------------|---------------|-----------------|
| A E | N XVI | (R) | (R) |

P **C** **B**
 A 31 D 2022
 (A RMB Y)

| LIABILITY AND | December 31, 2022 | December 31, 2021 | January 1, 2021 |
|---------------|-----------------------|-----------------------|-----------------------|
| 人民币元 | (RMB Y) | (RMB Y) | (RMB Y) |
| 流动资产： | | | |
| 货币资金 | 195,000,000.00 | 251,050,000.00 | 310,000,000.00 |
| 应收账款 | | | |
| 预付款项 | | | |
| 其他应收款 | | | |
| 存货 | | | |
| 流动资产合计 | 20,689,401.73 | 13,161,555.37 | 34,954,083.13 |
| 非流动资产： | | | |
| 长期股权投资 | 3,299,924.90 | 2,011,708.12 | |
| 固定资产 | | | 3,480,241.45 |
| 无形资产 | 18,740,841.95 | 17,876,433.39 | 15,629,765.62 |
| 递延所得税资产 | 597,972.12 | 4,848,233.63 | 8,267,930.79 |
| 其他非流动资产 | 49,473,505.95 | 74,941,835.88 | 27,298,927.14 |
| 非流动资产合计 | 91,487,500.00 | 3,000,000.00 | |
| 流动资产合计 | 379,289,146.65 | 366,889,766.39 | 399,630,948.13 |
| 流动负债： | | | |
| 应付账款 | 284,750,000.00 | 200,950,000.00 | 38,000,000.00 |
| 预收款项 | | | |
| 应付职工薪酬 | | | |
| 应交税费 | | | |
| 其他应付款 | | | |
| 流动负债合计 | 25,922,687.47 | | |
| 非流动负债： | | | |
| 长期借款 | | | |
| 应付债券 | | | |
| 其他非流动负债 | | | |
| 非流动负债合计 | 9,037,891.00 | 9,341,683.00 | 9,645,475.00 |
| 流动负债合计 | 2,291,279.89 | 2,853,156.89 | 1,607,648.32 |
| 其他 | | | |

附 表 三 十 三 2022 年 12 月 31 日 资产负债表

| 项 目 | 2022 年 12 月 31 日 | 2021 年 12 月 31 日 | 2021 年 6 月 30 日 |
|---------|------------------|------------------|------------------|
| 项 目 | 2022 | 2021 | 2021 |
| 项 目 | (RMB) | (RMB) | (RMB) |
| 流动资产： | | | |
| 货币资金 | 74,600,300.00 | 74,600,300.00 | 74,600,300.00 |
| 应收账款 | | | |
| 预付款项 | | | |
| 其他应收款 | | | |
| 存货 | 871,230,628.64 | 854,317,490.93 | 834,138,174.86 |
| 流动资产合计 | 945,830,928.64 | 928,917,790.93 | 908,738,474.86 |
| 非流动资产： | | | |
| 长期股权投资 | 38,399,577.13 | 38,399,577.13 | 36,593,228.71 |
| 固定资产 | 241,903,691.18 | 214,974,182.62 | 198,717,046.87 |
| 无形资产 | | | |
| 其他非流动资产 | | | |
| 非流动资产合计 | 280,303,268.31 | 253,373,759.75 | 235,310,275.58 |
| 资产总计 | 1,226,134,196.95 | 1,182,291,550.68 | 1,120,737,606.60 |
| 流动负债： | | | |
| 应付账款 | | | |
| 预收款项 | | | |
| 应付职工薪酬 | | | |
| 应交税费 | | | |
| 其他应付款 | | | |
| 流动负债合计 | 1,927,425,201.96 | 1,762,326,156.96 | 1,569,621,678.05 |

法定代表人：王 明 王 明

财务总监：王 明
GUAN W

财务总监：王 明
JIN H

财务总监：王 明
WANG M



 2022

 (A RMB Y)

| I. | N V | A | A |
|--------|-----------|------------------|------------------|
| | | (R) | |
| I. | | 1,484,903,042.25 | 1,297,430,369.83 |
| I : R | (XXXVII) | 1,484,903,042.25 | 1,297,430,369.83 |
| I | | | |
| P | | | |
| F | | | |
| II. | | 1,435,161,133.62 | 1,226,514,555.85 |
| I : C | (XXXVII) | 1,131,971,942.77 | 968,432,455.76 |
| I | | | |
| F | | | |
| S | | | |
| N | | | |
| N | | | |
| I | | | |
| R | | | |
| T | (XXXVIII) | 4,960,285.79 | 5,754,219.28 |
| S | (XXXIX) | 15,004,027.73 | 10,335,392.65 |
| G | (XL) | 205,887,172.40 | 176,371,888.82 |
| R | (XLI) | 33,027,987.79 | 27,962,173.39 |
| F | (XLII) | 44,309,717.14 | 37,658,425.95 |
| I : I | | 45,149,998.30 | 36,267,756.91 |
| I | | 2,761,765.05 | 1,691,366.88 |
| A : O | (XLIII) | 14,907,710.81 | 13,619,635.06 |
| I | (XLIV) | 2,850,458.27 | 6,937,845.27 |
| I | | | |
| D | | -15,926,847.45 | -6,565,719.92 |
| F | | | |
| G | | | |
| G | | | |
| C | (XLV) | -15,977,325.91 | 9,417,390.73 |
| A | (XLVI) | -25,191,541.19 | -2,140,196.45 |
| A | (XLVII) | -10,345,460.56 | -6,179,290.37 |
| G | (XLVIII) | 406,184.95 | -79,403.55 |
| III. O | | 16,391,935.00 | 92,491,794.67 |
| A : N | (XLIX) | 8,553,977.86 | 11,835,931.80 |
| L : N | (L) | 9,341,038.73 | 8,636,583.42 |
| I | | 15,604,874.13 | 95,691,143.05 |
| L : I | (LI) | 26,573,712.49 | 54,830,913.00 |

C
F 2022
(A RMB Y)

I. N V A A
(R)

资产负债表
2022
(A 人民币)

| 项 目 | 附 注 | 2022 年 12 月 31 日 | 2021 年 12 月 31 日 |
|----------|------|------------------|------------------|
| 流动资产 | (IV) | 343,141,450.63 | 369,798,306.12 |
| 货币资金 | (IV) | 265,024,147.50 | 271,489,388.70 |
| 应收账款 | | 154,333.60 | 3,013,304.93 |
| 预付款项 | | 1,692,773.94 | 3,068,742.71 |
| 其他应收款 | | 82,345,368.26 | 70,825,757.20 |
| 存货 | | 18,899,109.47 | 16,486,961.41 |
| 合同资产 | | 16,480,521.45 | 5,650,976.01 |
| 其他流动资产 | | 26,568,676.00 | 19,722,968.32 |
| 非流动资产 | | 11,229,395.04 | 14,521,251.32 |
| 长期股权投资 | | 6,245,933.48 | 5,326,738.38 |
| 固定资产 | (V) | 49,902,280.65 | 4,923,377.54 |
| 无形资产 | | -5,377,605.11 | -3,485,811.81 |
| 开发支出 | | | |
| 其他非流动资产 | | | |
| 资产总计 | | 354,370,845.67 | 384,319,557.44 |
| 流动负债 | | 26,695,422.53 | 8,407,356.31 |
| 应付账款 | | | |
| 预收款项 | | | |
| 合同负债 | | | |
| 应付职工薪酬 | | | |
| 应交税费 | | | |
| 其他应付款 | | | |
| 其他流动负债 | | | |
| 非流动负债 | | | |
| 长期应付款 | | | |
| 长期应付职工薪酬 | | | |
| 其他非流动负债 | | | |
| 负债合计 | | 26,695,422.53 | 8,407,356.31 |
| 所有者权益 | | 327,675,423.14 | 375,912,201.13 |
| 实收资本 | | 100,000,000.00 | 100,000,000.00 |
| 资本公积 | | 10,000,000.00 | 10,000,000.00 |
| 盈余公积 | | 10,000,000.00 | 10,000,000.00 |
| 未分配利润 | | 107,675,423.14 | 155,912,201.13 |
| 所有者权益合计 | | 327,675,423.14 | 375,912,201.13 |

P **C** **I**
F 2022
(A RMB Y)

I. N XVI A A

- O
 - (I) O
 - 1. C
 - 2. O
 - 3. C
 - 4. C
 - (II) O
 - 1. O
 - 2. C
 - 3. A
 - 4. C
 - 5. R
 - 6. E
 - 7. O

I. 26,929,508.56 18,063,484.17

- II.E
(I) B (RMB)
(II) D (RMB)

T
L : P : H :
GUAN W JIN H WANG M

C F 2022

| I | N | V | A | A |
|------|---|---|------------------|------------------|
| I. C | | | | |
| G | | | 1,452,028,763.13 | 1,211,114,150.81 |
| N | | | | |
| N | | | | |
| N | | | | |

| I. 资产 | | 年末余额 | 年初余额 |
|---------|-------|-----------------|-----------------|
| 项目 | 人民币元 | | |
| 流动资产 | | 25,751,171.02 | 68,651,676.30 |
| 货币资金 | | 236,910,178.88 | 178,536,614.68 |
| 应收账款 | | 53,685,701.28 | 48,600,000.00 |
| 预付款项 | | 8,770,704.43 | 80,564,032.90 |
| 其他流动资产 | (LIV) | 299,366,584.59 | 307,700,647.58 |
| 非流动资产 | | -273,615,413.57 | -239,048,971.28 |
| 长期股权投资 | | 9,153,084.38 | 2,900,000.00 |
| 固定资产 | | 9,153,084.38 | 2,900,000.00 |
| 无形资产 | | 387,500,000.00 | 550,250,000.00 |
| 其他非流动资产 | (LIV) | 151,420,250.00 | |
| 流动资产合计 | | 548,073,334.38 | 553,150,000.00 |
| 非流动资产合计 | | 324,220,000.00 | 428,342,970.00 |
| 资产总计 | | 51,554,507.56 | 30,297,107.09 |
| 长期股权投资 | (LIV) | 56,121,295.37 | 60,676,565.61 |
| 流动资产合计 | | 431,895,802.93 | 519,316,642.70 |
| 非流动资产合计 | | 116,177,531.45 | 33,833,357.30 |
| 负债合计 | | 78,462.87 | -38,704.15 |
| 应付账款 | | 69,861,145.20 | -11,357,819.65 |
| 其他流动负债 | | 188,734,845.77 | 200,092,665.42 |
| 非流动负债 | (LIV) | 258,595,990.97 | 188,734,845.77 |
| 所有者权益合计 | | | |
| 实收资本 | | | |
| 资本公积 | | | |
| 盈余公积 | | | |
| 未分配利润 | | | |
| 所有者权益合计 | | | |

L 关 W : P 金 H : H 王 M :
 GUAN W JIN H WANG M

| P | | C | | C | | E | |
|-------|--|-------|--|----------------|--|------------------|--|
| F | | 2022 | | | | | |
| (A | | RMB Y | | | |) | |
| I. | | N | | A | | A | |
| I. C | | | | | | | |
| G | | | | 336,363,866.37 | | 367,674,455.38 | |
| R | | | | | | | |
| G | | | | 495,591,067.36 | | 804,490,679.80 | |
| | | | | 831,954,933.73 | | 1,172,165,135.18 | |
| G | | | | 153,275,777.22 | | 176,137,498.58 | |
| G | | | | 147,419,578.70 | | 141,102,134.39 | |
| P | | | | 2,393,183.16 | | 9,767,527.34 | |
| G | | | | 596,762,811.79 | | 710,127,325.96 | |
| | | | | 899,851,350.87 | | 1,037,134,486.27 | |
| N | | | | -67,896,417.14 | | 135,030,648.91 | |
| II. C | | | | | | | |
| G | | | | 12,396,717.38 | | | |
| G | | | | 2,298,348.18 | | 7,089,189.35 | |
| N | | | | | | | |
| | | | | 32,054.56 | | 37,820.00 | |
| N | | | | | | | |
| G | | | | | | | |
| | | | | 14,727,120.12 | | 7,127,009.35 | |
| G | | | | 14,643,564.50 | | 37,662,933.95 | |
| G | | | | 54,309,855.16 | | 212,313,500.00 | |
| N | | | | | | | |
| G | | | | | | | |
| | | | | 68,953,419.66 | | 249,976,433.95 | |
| N | | | | -54,226,299.54 | | -242,849,424.60 | |

P **C** **C** **F**
F 2022
(A RMB Y)

| I. | N | A | A |
|--------|---|----------------|----------------|
| III. C | | | |
| G | | 334,500,000.00 | 518,050,000.00 |
| G | | 120,000,000.00 | |
| | | 454,500,000.00 | 518,050,000.00 |
| G | | 306,750,000.00 | 411,050,000.00 |
| G | | 26,512,297.06 | 19,663,754.20 |
| G | | 6,421,875.00 | |
| | | 339,684,172.06 | 430,713,754.20 |
| N | | 114,815,827.94 | 87,336,245.80 |
| I. E | | 78,462.87 | -38,704.15 |
| N | | -7,228,425.87 | -20,521,234.04 |
| A : G | | 97,615,570.76 | 118,136,804.80 |
| I. C | | 90,387,144.89 | 97,615,570.76 |

T

L : P : H :
GUAN W JIN H WANG M

| C | | F | | 2022 | | RMB Y | |
|---------|--|---------------|---------------|----------------|----------------|------------------|------------------|
| (A) | | | | | | | |
| I. B | | 74,600,300.00 | 74,600,300.00 | 888,165,395.59 | 888,165,395.59 | 38,899,577.13 | 38,899,577.13 |
| P : C | | | | | | 257,098,624.31 | 257,098,624.31 |
| C | | | | | | 1,206,263,897.03 | 1,206,263,897.03 |
| B | | | | | | 72,015,223.54 | 72,015,223.54 |
| O | | | | | | 1,280,279,120.57 | 1,280,279,120.57 |
| II. B | | 74,600,300.00 | 74,600,300.00 | 888,165,395.59 | 888,165,395.59 | 38,899,577.13 | 38,899,577.13 |
| (I) T | | | | 16,913,137.71 | 16,913,137.71 | -23,592,089.88 | -23,592,089.88 |
| (II) O | | | | 12,214,418.85 | 12,214,418.85 | -24,220,782.31 | -24,220,782.31 |
| I. C | | | | | | 12,214,418.85 | 12,214,418.85 |
| 2. C | | | | | | 43,363,506.48 | 43,363,506.48 |
| 3. A | | | | | | 43,363,506.48 | 43,363,506.48 |
| 4. O | | | | | | | |
| (III) D | | | | 12,214,418.85 | 12,214,418.85 | 12,214,418.85 | 12,214,418.85 |
| 1. W | | | | | | -4,313,000.00 | -4,313,000.00 |
| 2. W | | | | | | | |
| 3. P | | | | | | | |
| 4. O | | | | | | -4,313,000.00 | -4,313,000.00 |

附 表 2022 年 度 财 务 附 注
(A 股 公 司 财 务 报 表 附 注)

| 项 目 | 2022 年 12 月 31 日 | 2021 年 12 月 31 日 |
|-------------|------------------|------------------|
| | 人民币 元 | 人民币 元 |
| 流动资产 | 74,600,300.00 | 1,280,279,120.57 |
| 非流动资产 | 21,784,723.23 | 1,280,279,120.57 |
| 资产总计 | 96,385,023.23 | 2,560,558,241.14 |
| 流动负债 | 38,599,577.13 | 1,280,279,120.57 |
| 非流动负债 | 21,784,723.23 | 1,280,279,120.57 |
| 负债总计 | 60,384,300.36 | 2,560,558,241.14 |
| 所有者权益 | 35,999,722.87 | 1,280,279,120.57 |
| 归属于母公司所有者权益 | 35,999,722.87 | 1,280,279,120.57 |
| 少数股东权益 | - | - |
| 所有者权益合计 | 35,999,722.87 | 1,280,279,120.57 |
| 负债和所有者权益总计 | 96,385,023.23 | 2,560,558,241.14 |

编制人：王 王
审核人：王 王

C O N T E N T S

F 2022
(A R M B Y)

| | |
|------------------|---|
| 目录 | 0 |
| 第一章 总则 | 1 |
| 第二章 经营范围 | 1 |
| 第三章 注册资本 | 1 |
| 第四章 股东的权利和义务 | 1 |
| 第五章 董事、监事、高级管理人员 | 1 |
| 第六章 利润分配 | 1 |
| 第七章 财务会计 | 1 |
| 第八章 附则 | 1 |

F **C** **P** **C** **O** **'** **E**
(A **2022** RMB Y)

| | S | P | O | C | L | S | S | R | T |
|---------|---------------|---|----------------|----------------|----------------|---------------|----------------|------------------|---------------|
| | 0 | P | 0 | 0 | T | 0 | 0 | 0 | 0 |
| | | | | | | | | | |
| I. B | 74,600,500.00 | | 834,138,174.86 | 23,311,143.84 | 23,311,143.84 | 36,593,228.71 | 193,286,602.86 | 1,115,307,162.39 | |
| C | | | | | | | 5,430,444.01 | 5,430,444.01 | |
| O | | | | | | | | | |
| II. B | 74,600,500.00 | | 834,138,174.86 | 23,311,143.84 | 23,311,143.84 | 36,593,228.71 | 198,717,046.87 | 1,120,737,606.60 | |
| III. F | | | | | | | | | |
| (I) T | | | 20,179,316.07 | -23,311,143.84 | | 1,806,348.42 | 16,257,135.75 | 61,533,944.08 | |
| (II) O | | | 20,182,750.66 | | | | 18,063,484.17 | 18,063,484.17 | |
| 1. C | | | 2,445,056.34 | | | | | 20,182,750.66 | |
| 2. C | | | | | | | | 2,445,056.34 | |
| 3. A | | | | | | | | | |
| 4. O | | | 17,737,694.32 | | | | | 17,737,694.32 | |
| (III) D | | | | | | | | | |
| 1. W | | | | | | 1,806,348.42 | -1,806,348.42 | | |
| 2. P | | | | | | 1,806,348.42 | -1,806,348.42 | | |
| 3. O | | | | | | | | | |
| (IV) I | | | | | | | | | |
| 1. C | | | | | | | | | |
| 2. C | | | | | | | | | |
| 3. S | | | | | | | | | |
| 4. C | | | | | | | | | |
| 5. C | | | | | | | | | |
| 6. O | | | | | | | | | |
| (V) S | | | -3,484.59 | -23,311,143.84 | | | | | 23,307,709.25 |
| 1. W | | | | | | | | | |
| 2. U | | | | | | | | | |
| (VI) O | | | | | | | | | |
| I. B | 74,600,500.00 | | 834,317,490.93 | -23,311,143.84 | 834,317,490.93 | 38,399,577.13 | 214,974,182.62 | 1,182,291,350.68 | |

T :
L :
GUAN W
JIN H
WANG M

N **F**
F 2022
(A RMB Y)

I. G

(I) C

W K H C., L . (C)
W C K P R H (温州市康寧精神康復醫院)
PRC F 1996. T C

N **F**
F 2022
(A RMB Y)

II. B

(I) B

T A S B E -
B S A S
B E , A S B E
M F (A S
B E). I ,
R G L S T S E H K L
H K C O .

(II) G

T .

III. S

1. T C
2. F , C ,
3. T C
R P . T C

N **F**
 F 2022
 (A RMB Y)

III. S ()

(I) A B E
 T A S B E
 M F , Y
 C D 31, 2022 2022.

(II) A
 T C 1 J 31 D .

(III) O
 T C 12 .

T C R (RMB) T C
 C PRC RMB. T . A
 RMB.

() A
 B : T ,
 () T
 () . I

N **F**
F 2022
(A RMB Y)

III. S ()

() A () () ()

B : T
W
C ;
T ,

T ;

(I) P () ()

1. S
T

| N | F |
|----------------------|-------|
| F | 2022 |
| (A | RMB Y |
| III. S () | |
| (I) P () | |
| 2. C () | |
| (1) I () | |
| W C , - W . | |
| (2) D | |
| G | |
| W C , C . T O | |



N **F**
F 2022
(A RMB Y)






N **F**
F 2022
(A RMB Y)

N **F**
F 2022
(A RMB Y)

III. S ()

() F ()

1. C ()

N  **F**
F 2022
(A  RMB Y )

N **F**
F 2022
(A RMB Y)

III. S ()

() F ()

2. R ()

(3) F ()

F ()
T
T

A ,

N **F**
F 2022
(A RMB Y)

III. S ()

() F ()

2. R ()

(6) F

F - , ,
, - ,
 ,
 .

D ,

A ,

3. D

W , C :

- T ;

- T , ;

- T , C

A ,

I ,

N **F**
F 2022
(A RMB Y)
III. S ()
() F 15 5 1, ()

附注 2022
(A 人民币)

III. S ()

() F ()

4. D ()

W , ,

W , ()

W C , , .T ()

5. D

T .T .I , C , U

6. T

T C ()

G , C

附 表 2022
(A 类 人民币)

三、 说 明 ()

() 附 表 ()

6. 特 殊 项 目 ()




1. 公 司 在 报 告 期 内 未 发 生 重 大 资 产 变 动 情 况 ，
C 类 股 份 持 有 人 未 发 生 变 动 情 况 ， 公 司 未 发 生 重 大 资 产 变 动 情 况 ，
； 公 司 在 报 告 期 内 未 发 生 重 大 资 产 变 动 情 况 ， 公 司 未 发 生 重 大 资 产 变 动 情 况 ，
， C 类 股 份 持 有 人 未 发 生 变 动 情 况 ， 公 司 未 发 生 重 大 资 产 变 动 情 况 ， 12-
. T

1. 公 司 在 报 告 期 内 未 发 生 重 大 资 产 变 动 情 况 ，
， C 类 股 份 持 有 人 未 发 生 变 动 情 况 ， 公 司 未 发 生 重 大 资 产 变 动 情 况 ，
30 天 内 未 发 生 重 大 资 产 变 动 情 况 ， C 类 股 份 持 有 人 未 发 生 变 动 情 况 ， 公 司 未 发 生 重 大 资 产 变 动 情 况 ，
， U

1. 公 司 在 报 告 期 内 未 发 生 重 大 资 产 变 动 情 况 ， C 类 股 份 持 有 人 未 发 生 变 动 情 况 ，
， 公 司 未 发 生 重 大 资 产 变 动 情 况 ，

1. 公 司 在 报 告 期 内 未 发 生 重 大 资 产 变 动 情 况 ， C 类 股 份 持 有 人 未 发 生 变 动 情 况 ，
， 公 司 未 发 生 重 大 资 产 变 动 情 况 ，

附 表 2022 年 度 公 司 重 大 资 产 变 动 情 况 说 明 书 (A 类 股 份)
B 类 股 份 持 有 人 未 发 生 变 动 情 况 (2017),
， C 类 股 份 持 有 人 未 发 生 变 动 情 况 ， 公 司 未 发 生 重 大 资 产 变 动 情 况 ，

N  **F**
F 2022
(A  RMB Y )

N **F**
F 2022
(A RMB Y)

III. S ()

(I)I

1. C
I
I . C
.
2. V
I
3. B
A . W
. N
N

N **F**
 F 2022
 (A RMB Y)

III. S ()

(I) I ()

4. I A

5. A T

(II) C

1. R T C . T C . C . T C ()

2. D F



N **F**
F 2022
(A RMB Y)
III. S ()
(III) L ()
2. D

附 表 2022
(A 类 人民币)

III. S ()

(III) L ()

3. S

(1) L -

L - C
C

(2) L -

L - W G
G W

T C
(O C O ' E)
T

T C O C
O ' E C

N **F**
F 2022
(A RMB Y)

III. S ()

(III) L ()

3. S ()

(2) L ()

U C ,
. U ,
.

T C -
C () 0.018 GS0)0.. W 0.5 (8 T

N **F**
F 2022
(A RMB Y)

III. S ()

(III) L ()

3. S ()

(3) D ()

W G
E
O C O ' E
W

N **F**
F 2022
(A RMB Y)

III. S ()

(I) F

1. R
F , A
(1) ;
(2) .
T ().
S G . T . A
2. D
F - . T . F
W

附注 2022
(A 人民币元)

III. 所有者权益

(一) 所有者权益

2. 所有者权益

所有者权益是指企业投资者对企业净资产的所有权。所有者权益按其来源分为投入资本、留存收益和专项储备。

| 项目 | 2022 年 12 月 31 日 | 2021 年 12 月 31 日 | 2022 年 12 月 31 日 | 2021 年 12 月 31 日 |
|-------|------------------|------------------|------------------|------------------|
| 人民币元 | 人民币元 | 人民币元 | (%) | (%) |
| 股本 | 35 | 5 | 2.71 | |
| 资本公积 | 3-10 | 0-5 | 9.50-33.33 | |
| 盈余公积 | 4-10 | 5 | 9.50-23.75 | |
| 未分配利润 | 3-10 | 0-5 | 9.50-33.33 | |

3. 所有者权益

所有者权益是指企业投资者对企业净资产的所有权。所有者权益按其来源分为投入资本、留存收益和专项储备。

(二) 所有者权益

所有者权益是指企业投资者对企业净资产的所有权。所有者权益按其来源分为投入资本、留存收益和专项储备。

NEF
F 2022
(A RMB Y)

III. S ()

(I) B

1. R

T C ;

A , ,

2. G

G ,

G ;

(1) A , - ;

(2) B ;

(3) T ;

G ;

3. G

I , 3 , ;

. B ,

N **F**
F 2022
(A RMB Y)

III. S ()

(I) B ()

4. M

F ,
 ,
 .

F ,
 ,
 .T

D ,
 .T

(II) I

1. V

(1) I ;

T ,
 .

(2) S

T C .

A ,
 ;
 ,

NEF
F 2022
(A RMB Y)

III. S ()

(II) I ()

2. E

E

| I | () | A | B |
|----|-------|-----|---|
| Ia | 40-50 | S - | S |
| S | 5 | S - | E |
| C | 20-30 | S - | E |
| M | 5-20 | S - | E |
| T | 10 | S - | E |

3. S
E
R : R
D : D

NEF 2022
(A RMB Y)

III. S ()

(II) I ()

4. C T . T
T
:

- (1) I ;
 - (2) T C ;
 - (3) T ,
 - (4) T C , , , ;
 - (5) T .
- I ,

(III) I ,

L - , - , - , - ,
I
T
P
I
A

N **F**
F 2022
(A RMB Y)

III. S ()

(III) I ()

G , ,

W C , C , .T

F , , .T C , .W

O ,

(I) L ()

L

() C L

T C , T C

N **F**
 F 2022
 (A RMB Y)

III. S ()

(I) E

1. A -
 T -

W C

W C .N -

2. A -

(1) C

T C .D
 , C
 .I , C
 /
 .T C /
 .C

附 2022 年 12 月 31 日资产负债表

III. S ()

(I) E ()

2. A - ()

(2) D

T C E A W U M . T

T , . I , C

A , ,

T . C

. U ,

U ,

3. A

W C ,

() : C ;

C

NEF
F 2022
(A RMB Y)

III. S ()

(II) P.

T C : ,

(1) C

(2) C ;

(3)

A

Fe . W

W . O ,

N **F**
F 2022
(A RMB Y)

III. S ()

(III)

A - C C
.S - C
-

1. E -
T
.F
.F
C
,

I - C
.I
,

I C
.H
,

2022
RMB Y

III. S ()

(III)

2. G -
A - C F
F C

I C
O
A
I
C

1. A
T C
C

I
C

NE
F
2022
(A RMB Y)

III. S ()

1. A ()

T C
T C
W
C
T C
W
C
T

W
C
O
C

• A C
C

• T C

• G C
C

W
T C

W
C

N **F**
F 2022
(A RMB Y)

III. S ()

()

1. A ()

F , C
.I
, C :

- C , ,

NE
F 2022
(A RMB Y)

III. S ()

() C

I C ,

A ; , C .

F , C :
:

1. T ;

2. T .

I - , ,
 ,
 .

(I) G

1. T₁

G - C
 ,

G C , G
 .

2. T

G C
 .

N **F**
F 2022
(A RMB Y)




III. S ()

(I) G ()

3. A
 A - . T
 (C ;
 C -);
 G C
 (C C
 ; C
)
 (C C
 ; C
)

(II) D () () ()

I . C
 ()
 D ()
 D . F
 ()

N  **F**
F 2022
(A  RMB Y )

N **F**
 F 2022
 (A RMB Y)

III. S ()

(II) D ()

A ,

- W ;
- W

(III)L

A , , A , C , A , ()

F , C F - ,

I COVID-19 , C - :

- T , ;
- A ,

NEF
F 2022
(A RMB Y)

III. S ()

(III) L ()

1. T C

(1) R - -

A , C - -
(S -). R - -

-
- () ;
- C
- C ,

T C - . I
, C ; ,
C

T C - -
N III. (XVIII) I -

N **F**
F 2022
(A RMB Y)

III. S ()

(III) L ()

1. T C ()

(2) L

A , C ()
-). L .

• (-), ()
);

• ;

• C

• C ;

• C .

T C C . I

T C ()
.

Va ()
.

| N | | F | |
|----------|---|-------|---|
| F | | 2022 | |
| (A) | Y | RMB Y | Y |
| III. S | | | |
| (III) L | | | |
| 1. T C | | | |
| (2) L | | | |
| A | | | |
| A | | | |

附 2022 年 12 月 31 日资产负债表

III. S ()

(III) L ()

1. T C ()

(4) L

T C :
• ;
• .
I , C , - , .
I , C , F .
(5) R COVID-19
F COVID-19 , C , I . W , C .

N **F**
F 2022
(A RMB Y)

III. S ()

(III) L ()

1. T C ()

(5) R COVID-19 ()

F - , C . I
, C ;
, C .

2. T C

A , C
. A , ()0.5 ()0.366.5 ()0.5 ()0.5 ()0.5

N **F**
 F 2022
 (A RMB Y)
 III. S ()
 (III)

N **F**
F 2022
(A RMB Y)

III. S ()

(III) L ()

2. T C ()

(3) R COVID-19

- F COVID-19 , C .I , C ; C ,
- F COVID-19 , C .I C W , -

NEF
F 2022
(A RMB Y)

III. S ()

(III) L ()

3. S ()

(2) T C

I - , C 2. T
C ; - ,
C , ,
F ,
N III(X)F .

(I) .

T C ,

A C : (1)
; (2)
C ; (3)
C T

() ()

T C ,

1. E
A N III. (XXIV), C
T

NEFIN
F 2022
(A RMB Y)

III. S ()

() () ()

2. *E* A N III. (XVIII), C
T
(N V. (XV))

I EBIT - EBIT
,
C I
EBIT -
C

3. *E*
T C F
() C

4. *M*
I 2022, C
H Y H C., L.
:

| I | E | P |
|---------|---|--------|
| A () | | 180 |
| A (/) | | 570 |
| N | | 10.79% |
| G (/) | | 60 |
| D | | 14.00% |
| P | | 2.50% |

NEFIN
F 2022
(A RMB Y)

III. S ()

(I) C

I 2021, M F N P D I E
A S N .15 I 2022 2023, M F N P
D I E A S N .16 Q&A I
E A S . T C 31
D 2022 -
Q&A. T C

IV. T

(I) M

| V (VAT) | | T VAT | 3%, 6%, 13% |
|-----------|----------------|-------|---------------|
| U | B VAT | | 7% |
| E | B VAT | | 5% |
| E | B | | 15%, 20%, 25% |
| C | | | |
| I | | | |
| W | K H C ., L . | | 15% |
| Z | J H T C ., L . | | 15% |
| Y | K H M C ., L . | | 20% |

NE
F 2022
(A RMB Y)

IV. T ()

(II) P

1. P C O P P P
L VAT P B T (C S [2016] N . 36) M F
S T A , C
A M M I (O S C N . 149)
S C I M A M I
(O M H N . 35) M H

| 附 注 | | 2022 | |
|------|-------|------------|------------|
| (A) | | RMB Y | |
| V. N | (I) C | B | B |
| I | I | I | I |
| Ca | ca | 454,907.26 | 971,773.72 |

附注
F
2022
(A RMB Y)

V. N ()

(III) A

1. A

| A | B | B |
|------|----------------|----------------|
| W 1 | 388,961,193.05 | 303,910,574.15 |
| 1-2 | 4,755,919.87 | 9,812,859.20 |
| 2-3 | 3,941,367.25 | 4,259,870.27 |
| 3 | 5,180,894.08 | 3,140,407.07 |
| S - | 402,839,374.25 | 321,123,710.69 |
| L :P | 20,002,683.36 | 9,365,835.23 |
| T | 382,836,690.89 | 311,757,875.46 |

T C

附注
F
2022
(A 人民币 Y)

V. N ()

(III) A ()

2. A B B P P P P P P P

| C | A | (%) | A | (%) | B | A | (%) | A | (%) | B |
|--------------|----------------|-------|---------------|-------|----------------|----------------|-------|----------------|-------|---------------|
| P | | | | | | | | | | |
| | 18,221,975.88 | 4.52 | 12,514,142.66 | 68.68 | 5,707,833.22 | 7,247,978.61 | 2.26 | 4,590,286.39 | 63.33 | 2,657,692.22 |
| I | | | | | | | | | | |
| M | 18,221,975.88 | 4.52 | 12,514,142.66 | 68.68 | 5,707,833.22 | 7,247,978.61 | 50.00 | 4,590,286.39 | 63.33 | 2,657,692.22 |
| P | | | | | | | | | | |
| 7,488,540.70 | 384,617,398.37 | 95.48 | 95,708,740.70 | 32.00 | 196,286,391.77 | 196,286,391.77 | 50.00 | 151,284,937.09 | 77.06 | 24,155,694.62 |

N **F**
F 2022
(A RMB Y)

V. N ()

(III) A ()

2. A ()

P :

B ()

P ()

P ()

I B (%)

| | | | |
|---|---------------|---------------|-------|
| M | 18,221,975.88 | 12,514,142.66 | 68.68 |
|---|---------------|---------------|-------|

() ()
L ECL

| | | | |
|---|---------------|---------------|---|
| T | 18,221,975.88 | 12,514,142.66 | / |
|---|---------------|---------------|---|

D : N III. (X)

P :

B ()

A ()

P ()

P ()

I (%)

| | | | |
|---|----------------|--------------|------|
| O | 384,617,398.37 | 7,488,540.70 | 1.95 |
|---|----------------|--------------|------|

| | | |
|---|----------------|--------------|
| T | 384,617,398.37 | 7,488,540.70 |
|---|----------------|--------------|

C : N III. (X)

N **F**
F 2022
(A RMB Y)

V. N ()

(III) A ()

| | | | | | | |
|----|---|--|--------------|---------------|--------------|---------------|
| 3. | P | | | | | |
| | | | B | | C | |
| | | | | R | W | B |
| | C | | | | | |
| | P | | | | | |
| | | | 4,590,286.39 | 8,289,230.88 | 365,374.61 | 12,514,142.66 |
| | P | | | | | |
| | | | 4,775,548.84 | 3,379,914.39 | 666,922.53 | 7,488,540.70 |
| | T | | 9,365,835.23 | 11,669,145.27 | 1,032,297.14 | 20,002,683.36 |
| 4. | A | | | | | |
| | I | | | | A | |
| | A | | | | | 365,374.61 |

N **F**
F 2022
(A RMB Y)

V. N ()

(I) A

1. A

| A | B | | B | |
|-----|---------------|--------|---------------|--------|
| | A | P (%) | A | P (%) |
| W 1 | 29,973,748.69 | 93.08 | 11,751,451.87 | 99.11 |
| 1-2 | 2,127,484.58 | 6.61 | 58,511.20 | 0.49 |
| 2-3 | 56,690.70 | 0.18 | 24,163.99 | 0.20 |
| O 3 | 43,300.00 | 0.13 | 24,300.00 | 0.20 |
| T | 32,201,223.97 | 100.00 | 11,858,427.06 | 100.00 |

附注五、非经常性损益

2022年度非经常性损益情况表

| 项目 | 本期发生额 | 上期发生额 |
|--------------------|---------------|---------------|
| 非流动资产处置损益 | | |
| 计入当期损益的政府补助 | | |
| 除上述各项之外的其他营业外收入和支出 | | |
| 其他 | | |
| 合计 | 37,195,219.68 | 29,925,487.99 |
| 合计 | 37,195,219.68 | 29,925,487.99 |

(1) 计入当期损益的政府补助

| 项目 | 本期发生额 | 上期发生额 |
|----------------|---------------|---------------|
| 与资产相关的政府补助 | | |
| 与收益相关的政府补助 | | |
| 合计 | 31,752,956.09 | 20,470,501.76 |
| 1-2 | 12,384,779.19 | 4,096,700.18 |
| 2-3 | 4,035,447.86 | 838,693.49 |
| 3-4 | 1,755,508.40 | 2,814,221.11 |
| 4-5 | 101,363.87 | 1,452,266.68 |
| 其他 | 3,877,306.68 | 2,930,000.00 |
| 合计 | 53,907,362.09 | 32,602,383.22 |
| 其中：计入当期损益的政府补助 | 16,712,142.41 | 2,676,895.23 |
| 合计 | 37,195,219.68 | 29,925,487.99 |

附注五、非经常性损益

2022年度非经常性损益情况表

单位：人民币元

(2) 其他非经常性损益

| 项目 | 2022年度 | | 2021年度 | | 占比 | 2022年度 | | 2021年度 | |
|--------------------|---------------|--------|---------------|-------|---------------|---------------|--------------|--------------|---------------|
| | 金额 | 占比 | 金额 | 占比 | | 金额 | 占比 | 金额 | 占比 |
| 非流动资产处置损益 | 25,337,819.20 | 47.00 | 15,852,030.91 | 62.56 | 9,485,788.29 | 4.40 | 1,435,560.00 | 100.00 | |
| 计入当期损益的政府补助 | | | | | | | | | |
| 除上述各项之外的其他营业外收入和支出 | | | | | | | | | |
| 其他非经常性损益 | | | | | | | 1,435,560.00 | 100.00 | 1,435,560.00 |
| 合计 | 25,337,819.20 | 47.00 | 15,852,030.91 | 62.56 | 9,485,788.29 | | | | |
| 公允价值变动损益 | | | | | | | | | |
| 计入当期损益的政府补助 | 28,569,542.89 | 53.00 | 860,111.50 | 3.01 | 27,709,431.39 | 95.60 | 1,241,335.23 | 3.98 | 29,925,487.99 |
| 除上述各项之外的其他营业外收入和支出 | | | | | | | | | |
| 其他非经常性损益 | | | | | | | | | |
| 合计 | 28,569,542.89 | 53.00 | 860,111.50 | 3.01 | 27,709,431.39 | 95.60 | 1,241,335.23 | 3.98 | 29,925,487.99 |
| 合计 | 53,907,362.09 | 100.00 | 16,712,142.41 | | 37,195,219.68 | 32,602,383.22 | 100.00 | 2,676,895.23 | 29,925,487.99 |

附注五、非经常性损益
 2022 年度非经常性损益情况表
 (A 股人民币元)

五、非经常性损益

(一) 营业外收入

(2) 营业外收入

计入当期损益的政府补助：

| 项目 | 本期发生额 | 上期发生额 | 占利润总额比例 (%) |
|-------------|---------------|---------------|-------------|
| 计入当期损益的政府补助 | 15,852,030.91 | 25,337,819.20 | 62.56 |
| 其他 | | | |
| 合计 | 15,852,030.91 | 25,337,819.20 | 62.56 |

| 项目 | 本期发生额 | 上期发生额 | 占利润总额比例 (%) |
|-------------|---------------|---------------|-------------|
| 计入当期损益的政府补助 | 15,852,030.91 | 25,337,819.20 | 62.56 |
| 其他 | | | |
| 合计 | 15,852,030.91 | 25,337,819.20 | 62.56 |

计入当期损益的政府补助：本期发生额 15,852,030.91 元，上期发生额 25,337,819.20 元。

计入当期损益的政府补助：

| 项目 | 本期发生额 | 上期发生额 | 占利润总额比例 (%) |
|-------------|---------------|---------------|-------------|
| 计入当期损益的政府补助 | 15,852,030.91 | 25,337,819.20 | 62.56 |
| 其他 | | | |
| 合计 | 15,852,030.91 | 25,337,819.20 | 62.56 |

计入当期损益的政府补助：本期发生额 15,852,030.91 元，上期发生额 25,337,819.20 元。

计入当期损益的政府补助：本期发生额 15,852,030.91 元，上期发生额 25,337,819.20 元。

计入当期损益的政府补助：本期发生额 15,852,030.91 元，上期发生额 25,337,819.20 元。

N **F**
 F 2022
 (A RMB Y)
V. N ()
 () O ()
 (3) D

| | 1 | 2 | 3 |
|-----|--------------|---------------|---------------|
| | | L | L |
| | | ECL | L |
| | 12- | (-) | ECL (-) |
| P | ECL | | |
| B | 1,241,335.23 | | 2,676,895.23 |
| B | | | |
| - T | 2 | | |
| - T | 3 | | |
| - R | 2 | | |
| - R | 1 | | |
| P | 141,793.04 | 15,852,030.91 | 15,993,823.95 |
| R | 485,492.80 | 1,435,560.00 | 1,921,052.80 |
| W | 37,523.97 | | 37,523.97 |
| W | | | |
| O | | | |
| B | 860,111.50 | 15,852,030.91 | 16,712,142.41 |

附注五、其他非流动资产
 2022年12月31日
 (A) (人民币千元)

其他非流动资产 (人民币千元)

() 其他非流动资产 (人民币千元)

(3) 其他非流动资产 (人民币千元)

其他非流动资产 (人民币千元) :

| | 2022年12月31日 | 2021年12月31日 | 2020年12月31日 |
|-------------|---------------|---------------|---------------|
| | 其他非流动资产 | 其他非流动资产 | 其他非流动资产 |
| | 12月31日 ECL | 12月31日 ECL | 12月31日 ECL |
| 其他非流动资产 | 31,166,823.22 | 1,435,560.00 | 32,602,383.22 |
| 其他非流动资产 | | | |
| 其他非流动资产 | | | |
| - 其他非流动资产 2 | | | |
| - 其他非流动资产 3 | | | |
| - 其他非流动资产 2 | | | |
| - 其他非流动资产 1 | | | |
| A | 2,428,909.82 | 25,337,819.20 | 27,766,729.02 |
| D | 4,306,570.80 | 1,435,560.00 | 5,742,130.80 |
| O | -719,619.35 | | -719,619.35 |
| 其他非流动资产 | 28,569,542.89 | 25,337,819.20 | 53,907,362.09 |

NEF
F 2022
(A RMB Y)
V. N ()

() O ()

(4) P , ,

| | B | C | R | W | B |
|-----------|--------------|---------------|--------------|-----------|---------------|
| C | | | | | |
| P | 1,435,560.00 | 15,852,030.91 | 1,435,560.00 | | 15,852,030.91 |
| P | 1,241,335.23 | 141,793.04 | 485,492.80 | 37,523.97 | 860,111.50 |
| T | 2,676,895.23 | 15,993,823.95 | 1,921,052.80 | 37,523.97 | 16,712,142.41 |
| O | | | | | |
| N | | | | | |
| H U C | 1,435,560.00 | F | R | M | |
| A T , P C | | | | | |
| T | 1,435,560.00 | | | | |

N 2022
F (A 2022 RMB Y)
V. N ()

() O ()

(5) O

I A

O 37,523.97

(6) O

B B

N

D 20,677,631.31 23,577,997.61

P 816,666.30 4,228,330.66

附注
F
(A 2022 RMB Y)

V. N ()

(I) I

| I | B | B | B | B |
|---|---------------|---------------|---------------|---------------|
| T | 3,697,607.74 | 3,697,607.74 | 2,242,027.51 | 2,242,027.51 |
| C | 54,633,789.63 | 54,633,789.63 | 54,277,273.72 | 54,277,273.72 |
| T | 58,331,397.37 | 58,331,397.37 | 56,519,301.23 | 56,519,301.23 |

(II) O

| I | B | B |
|---|------------|------------|
| I | 196,008.48 | 137,228.50 |
| P | 269,072.88 | 321,191.35 |
| P | 287,243.41 | 348,266.00 |
| T | 752,324.77 | 806,685.85 |

附注七 关联方交易

附注七 关联方交易
2022
(A 币种为人民币)

五、关联交易

(三) 关联担保

| 关联方 | 担保金额 | 担保期限 | 担保类型 | 担保方式 | 担保费用 |
|-----|---------------|------|------|------|------|
| 关联方 | 14,000,000.00 | | | | |
| 关联方 | 14,000,000.00 | | | | |
| 关联方 | 14,000,000.00 | | | | |

(四) 关联租赁

| 关联方 | 承租资产类别 | 年初余额 | 年末余额 | 增减变动 | 其他说明 | | | | |
|-----|--------|----------------|---------------|--------------|---------------|--------------|------------|--------------|----------------|
| 关联方 | 房屋 | 13,156,356.09 | -4,287,457.64 | 5,310,451.69 | 关联方房屋 | | | | |
| 关联方 | 车辆 | 58,100,000.00 | 500,000.00 | | 关联方车辆 | | | | |
| 关联方 | 机器设备 | 22,193,790.14 | -1,090,147.47 | | 关联方机器设备 | | | | |
| 关联方 | 无形资产 | 23,198,356.89 | -1,102,416.10 | | 关联方无形资产 | | | | |
| 关联方 | 其他 | 18,687,211.65 | 74,969.38 | 400,000.00 | 关联方其他 | | | | |
| 关联方 | 房屋 | 11,514,784.92 | -1,309,653.45 | | 关联方房屋 | | | | |
| 关联方 | 房屋 | 5,191,069.69 | | 5,191,069.69 | 关联方房屋 | | | | |
| 关联方 | 房屋 | | | | 关联方房屋 | | | | |
| 合计 | | 129,847,779.24 | 22,193,790.14 | 500,000.00 | -7,714,705.28 | 5,310,451.69 | 400,000.00 | 5,191,069.69 | 143,546,246.10 |

注：2022年10月10日，公司与关联方（以下简称“关联方”）签订《房屋租赁合同》，约定公司向关联方租赁房屋，租赁期限为2022年10月10日至2023年10月9日，租金总额为人民币14,000,000.00元，租金支付方式为按月支付。关联方为履行该租赁合同，于2022年10月10日向公司支付了租金人民币13,922,929.38元。2022年12月31日，公司尚有应付关联方租金人民币8,212,142.17元。关联方为履行该租赁合同，于2022年12月31日向公司支付了租金人民币5,191,069.69元。关联方为履行该租赁合同，于2022年12月31日向公司支付了租金人民币5,191,069.69元。

附注
 2022
 (人民币元)

五、 非流动资产减值准备

(一) 其他非流动资产

| | 本期末余额 | 期初余额 |
|---------|---------------|---------------|
| 其他非流动资产 | 63,116,852.05 | 65,812,274.58 |
| 合计 | 63,116,852.05 | 65,812,274.58 |
| 合计 | 63,116,852.05 | 65,812,274.58 |

V. N
(I F)

(I F)

2. D

F
(A)
2022
RMB Y)

| | B | M | E | F |
|-------|----------------|----------------|--------------|----------------|
| 1. O | 745,833,959.90 | 142,218,120.78 | 6,548,724.87 | 68,038,620.62 |
| (1) B | 811,977.80 | 25,247,491.51 | 6,016,909.41 | 9,508,145.59 |
| (2) I | 811,977.80 | 14,854,645.52 | 2,906,555.91 | 5,748,234.46 |
| -P | | | | |
| -T | | | | |
| -I | | 10,392,845.99 | 3,110,353.50 | 3,759,911.13 |
| -O | | | | |
| (3) D | 70,270,990.67 | 65,654,865.68 | 3,162,440.49 | 25,386,159.55 |
| -D | | 12,438,192.49 | 658,984.47 | 3,310,725.18 |
| -D | | 5,259,711.00 | 565,764.12 | 2,213,845.28 |
| -O | 70,270,990.67 | 47,956,962.19 | 1,937,691.90 | 19,861,589.09 |
| (4) B | 676,374,947.03 | 101,810,746.61 | 9,403,193.79 | 52,160,606.66 |
| | | | | 140,027,233.85 |
| | | | | 140,027,233.85 |
| | | | | 140,027,233.85 |
| | | | | 17,263,110.62 |
| | | | | 140,027,233.85 |
| | | | | 164,474,456.39 |
| | | | | 16,407,902.14 |
| | | | | 140,027,233.85 |
| | | | | 979,776,727.94 |

V. N

(I F) ()

2. D ()

()

F (A

2022 RMB Y

F

| | B | M | M | E | F |
|--|---|---|---|---|---|
|--|---|---|---|---|---|

I

| | | | | | | |
|-------|----------------|---------------|--------------|---------------|---------------|----------------|
| 2. A | | | | | | |
| (1) B | 97,583,529.57 | 93,448,930.55 | 2,620,876.20 | 47,139,318.33 | 66,620,984.90 | 240,792,654.65 |
| (2) I | 21,780,272.36 | 23,765,333.80 | 3,918,211.31 | 9,282,744.01 | 66,620,984.90 | 125,367,546.38 |
| -P | 21,780,272.36 | 21,259,481.17 | 1,035,359.81 | 8,378,127.80 | 576,543.93 | 53,029,785.07 |
| -I | | 2,505,852.63 | 2,882,851.50 | 904,616.21 | | 6,293,320.34 |
| -O | | | | | 66,044,440.97 | 66,044,440.97 |
| (3) D | 12,029,010.56 | 48,647,077.77 | 1,557,788.21 | 19,170,037.34 | | 81,403,913.88 |
| -D | | 6,650,418.76 | 620,766.50 | 1,300,387.75 | | 8,571,573.01 |
| -D | 1,654,288.20 | 3,475,806.87 | 214,904.65 | 1,442,900.18 | | 66,044,440.97 |
| -O | 10,374,722.36 | 38,520,852.14 | 722,117.06 | 16,426,749.41 | | 284,756,287.15 |
| (4) B | 107,334,791.37 | 68,567,186.58 | 4,981,299.30 | 37,252,025.00 | 66,620,984.90 | 66,044,440.97 |
| 3. I | | | | | | |
| (1) B | | | | | | |
| (2) I | | | | | | |
| (3) D | | | | | | |
| (4) B | | | | | | |
| 4. C | | | | | | |
| (1) C | 569,040,155.66 | 33,243,560.03 | 4,421,894.49 | 14,908,581.66 | 73,406,248.95 | 695,020,440.79 |
| (2) C | 648,250,430.33 | 48,769,190.23 | 3,927,848.67 | 20,899,302.29 | | 721,846,771.52 |

附注五、非经常性损益及其金额
 附注六、公允价值变动收益及其金额
 附注七、投资收益及其金额
 附注八、其他业务收入及其金额
 附注九、其他收益及其金额
 附注十、营业外收入及其金额
 附注十一、营业外支出及其金额
 附注十二、所得税费用及其金额
 附注十三、其他综合收益及其金额
 附注十四、其他非流动资产及其金额
 附注十五、其他非流动负债及其金额
 附注十六、其他权益工具及其金额
 附注十七、其他综合收益及其金额
 附注十八、其他非流动资产及其金额
 附注十九、其他非流动负债及其金额
 附注二十、其他权益工具及其金额

V. 非经常性损益及其金额 ()

(II) 其他非流动资产

| 1. 其他非流动资产 | 期末余额 | 期初余额 | 本期增加 | 本期减少 |
|------------|----------------|----------------|---------------|---------------|
| 其他非流动资产 | 152,497,399.68 | 43,795,718.15 | | |
| 合计 | 152,497,399.68 | 43,795,718.15 | | |
| 2. 其他非流动资产 | | | | |
| 其他非流动资产 | | | | |
| 温州康宁医院 | 311,600.00 | 311,600.00 | 782,356.00 | 782,356.00 |
| 温州市中心医院 | | | 1,027,373.54 | 1,027,373.54 |
| 温州市中心医院 | 72,377,326.40 | 72,377,326.40 | 6,213,670.10 | 6,213,670.10 |
| 温州市中心医院 | | | 7,504,860.00 | 7,504,860.00 |
| 温州市中心医院 | | | 27,288,058.64 | 27,288,058.64 |
| 温州市中心医院 | 27,536,449.81 | 27,536,449.81 | 150,609.00 | 150,609.00 |
| 温州市中心医院 | 16,073,697.42 | 16,073,697.42 | | |
| 温州市中心医院 | 35,508,167.99 | 35,508,167.99 | | |
| 温州市中心医院 | 690,158.06 | 690,158.06 | 828,790.87 | 828,790.87 |
| 合计 | 152,497,399.68 | 152,497,399.68 | 43,795,718.15 | 43,795,718.15 |

V. N
F
(A)

(II)C
F

2022
RMB Y

()

()

3. M

| P | B | | D | | B | | I | | A | | I | | C | |
|-------|-----------|--------------|---------------|---------------|-------|---------------|----------------|---------------|----------------|-------|--------------|--------------|-------|--|
| | B | I | D | B | I | A | I | C | (%) | (%) | (%) | (%) | (%) | |
| 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | |
| T | 18,003.00 | 6,213,670.10 | 66,247,515.67 | 72,461,185.77 | 40.25 | 40.00 | 1,883,479.17 | 1,608,608.70 | 4.90 | B | | | | |
| L | Y | H | | | | | | | | | | | | |
| T | P | C | H | | | 24,611,933.00 | 100.00 | 100.00 | 100.00 | | | | 0 | |
| T | O | Y | H | | | 38,310,012.40 | 100.00 | 100.00 | 100.00 | | | | 0 | |
| T | L | C | | | | | | | | | | | | |
| H | | | | | | 16,020.00 | 150,609.00 | 27,385,840.81 | 17.19 | 20.00 | | | 0 | |
| T | H | | | | | | | | | | | | | |
| H | | | | | | 9,848.00 | 16,073,697.42 | 16,073,697.42 | 16.32 | 15.00 | | | 0 | |
| T | J | Y | | | | | | | | | | | | |
| H | | | | | | 6,666.00 | 35,508,167.99 | 35,508,167.99 | 54.15 | 55.00 | | | 0 | |
| T | | | | | | 41,157,197.74 | 173,344,248.65 | 62,921,945.40 | 151,579,500.99 | | 1,883,479.17 | 1,608,608.70 | | |

| N | | F | |
|------|---|----------------|----------------|
| F | | 2022 | |
| (A | Y | RMB Y |) |
| V. N | | () | |
| | | B. 0 | |
| I. | | 0 | |
| 1.O | | | |
| (1)B | | 363,270,419.51 | 363,270,419.51 |
| (2)I | | 37,254,480.17 | 37,254,480.17 |
| -N | | 21,847,297.56 | 21,847,297.56 |
| -I | | 15,407,182.61 | 15,407,182.61 |
| (3)D | | 81,876,743.78 | 81,876,743.78 |
| -D | | 16,772,968.78 | 16,772,968.78 |
| -D | | 65,103,775.00 | 65,103,775.00 |
| (4)B | | 318,648,155.90 | 318,648,155.90 |
| 2.A | | | |
| (1)B | | 105,858,149.38 | 105,858,149.38 |
| (2)I | | 38,189,335.84 | 38,189,335.84 |
| -P | | 38,189,335.84 | 38,189,335.84 |
| (3)D | | 15,803,080.90 | 15,803,080.90 |
| -D | | 4,949,246.94 | 4,949,246.94 |
| -D | | 10,853,833.96 | 10,853,833.96 |
| (4)B | | 128,244,404.32 | 128,244,404.32 |
| 3.I | | | |
| (1)B | | | |
| (2)I | | | |
| (3)D | | | |
| (4)B | | | |
| 4.C | | | |
| (1)C | | 190,403,751.58 | 190,403,751.58 |
| (2)C | | 257,412,270.13 | 257,412,270.13 |

附注
2022
人民币元

五、非流动资产减值准备

(一) 无形资产减值准备

| 项目 | 2022年12月31日 | | 2021年12月31日 | | 2020年12月31日 | | 2019年12月31日 |
|-----------|----------------|--------------|---------------|----------------|---------------|----------------|-------------|
| | 账面余额 | 减值准备 | 账面余额 | 减值准备 | 账面余额 | 减值准备 | 账面余额 |
| 1.0 土地使用权 | | | | | | | |
| (1) 土地使用权 | 102,977,820.17 | 3,061,637.13 | 14,252,889.08 | 129,837,000.00 | 32,400,000.00 | 282,529,346.38 | |
| (2) 无形资产 | 25,616,355.88 | | -3,433,306.28 | 29,000,000.00 | | 51,183,049.60 | |
| -P 无形资产 | 19,841,690.88 | | -4,460,006.28 | | | 15,381,684.60 | |
| -I 无形资产 | 5,774,665.00 | | 1,026,700.00 | 29,000,000.00 | | 35,801,365.00 | |
| (3) 无形资产 | | | 1,141,970.00 | | | 1,141,970.00 | |
| -D 无形资产 | | | 508,000.00 | | | 508,000.00 | |
| -D 无形资产 | | | 633,970.00 | | | 633,970.00 | |
| (4) 土地使用权 | 128,594,176.05 | 3,061,637.13 | 9,677,612.80 | 158,837,000.00 | 32,400,000.00 | 332,570,425.98 | |
| 2.A 无形资产 | | | | | | | |
| (1) 土地使用权 | 9,610,253.66 | 360,120.18 | 9,441,245.79 | 27,772,369.86 | 7,353,571.43 | 54,537,560.92 | |
| (2) 无形资产 | 2,889,207.41 | 330,465.48 | 1,799,113.48 | 17,315,075.42 | 1,500,000.00 | 23,833,861.79 | |
| -P 无形资产 | 2,889,207.41 | 330,465.48 | 1,072,248.57 | 17,315,075.42 | 1,500,000.00 | 23,106,996.88 | |
| -I 无形资产 | | | 726,864.91 | | | 726,864.91 | |
| (3) 无形资产 | | | 485,345.23 | | | 485,345.23 | |
| -D 无形资产 | | | 39,066.67 | | | 39,066.67 | |
| -D 无形资产 | | | 446,278.56 | | | 446,278.56 | |
| (4) 土地使用权 | 12,499,461.07 | 690,585.66 | 10,755,014.04 | 45,087,445.28 | 8,853,571.43 | 77,886,077.48 | |
| 3.I 无形资产 | | | | | | | |
| (1) 土地使用权 | | | | | | | |
| (2) 无形资产 | | | | | | | |
| (3) 无形资产 | | | | | | | |
| (4) 土地使用权 | | | | | | | |
| 4.C 无形资产 | | | | | | | |
| (1) 土地使用权 | 116,094,714.98 | 2,371,051.47 | -1,077,401.24 | 113,749,554.72 | 23,546,428.57 | 254,684,348.50 | |
| (2) 土地使用权 | 93,367,566.51 | 2,701,516.95 | 4,811,643.29 | 102,064,630.14 | 25,046,428.57 | 227,991,785.46 | |

N
F
(A) 2022 RMB Y)

B

D

I

B

Y

()

V. N

() G

I. C

N

NE
 F 2022
 (A RMB Y)
V. N ()
 () G ()

2. I
 A C :
 , :

U : RMB'0,000

| A | 31 D. 2022 |
|------------------|------------------|
| N Y H C.,L . | 927.18 |
| H Y P H C.,L . | 69.03 |
| G Y H C.,L . | 154.90 |
| W N P S H C.,L . | 778.49 |
| B Y H C.,L . | 2,298.73 |
| W Y H T C.,L . | 15.11 |
| H K H C.,L . | 506.9 |
| C K P H C.,L . | 684.33 |
| W C H C.,L . | 1,941.63 |
| P C Y H C.,L . | 5,177.02 |
| H Y N S C.,L . | 127.26 |
| Z F N T C.,L . | 32.60 |
| J S H C.,L . | 506.03 |
| T | 13,219.21 |

I , C) . I
 ,

附注 2022
(A 人民币)

V. N ()
() G ()

3. P ,

| Account Name | Balance | Change | Percentage | Percentage | Percentage |
|-------------------|---------|--------|------------|------------|------------|
| Account Name | (元) | (元) | (%) | (%) | (%) |
| Ne Y H C.,L . | 219 | 337 | 2.50% | 21.33% | 14.00% |
| H Y P H C.,L . | 267 | 289 | 2.50% | 20.60% | 14.00% |
| G Y H C.,L . | | | | | |
| W Ne P S H C.,L . | 323 | 291 | 2.50% | 22.06% | 14.00% |
| B Y H C.,L . | 32 | 1,810 | 2.50% | -2.40% | 14.00% |
| W Y H T C.,L . | | | | | |
| H K H C.,L . | 211 | 196 | 2.50% | 16.94% | 14.00% |
| C K P H C.,L . | 315 | 205 | 2.50% | 17.48% | 14.00% |
| W C H C.,L . | 325 | 546 | 2.50% | 9.59% | 14.00% |
| C K H H C.,L . | 213 | 400 | 2.50% | 19.01% | 14.00% |
| P C Y H C.,L . | 425 | 594 | 2.50% | 6.71% | 14.00% |
| P Y H H C.,L . | 270 | 273 | 2.50% | 15.82% | 14.00% |
| H Y N S C.,L . | 72 | 117 | 2.50% | 21.92% | 14.00% |
| J S H C.,L . | 382 | 284 | 2.50% | 22.65% | 14.00% |

O :

A ; -

附注
F
2022
(A 人民币元)

V. 非流动资产

(一) 长期股权投资

4. 长期股权投资

2022 年，本公司根据《企业会计准则》的规定，对长期股权投资进行减值测试。由于 COVID-19 疫情影响，部分被投资单位经营业绩下滑，导致本公司长期股权投资的可收回金额低于账面价值。因此，本公司计提了长期股权投资减值准备 RMB10,345,460.56 元。

(二) 长期应收款

长期应收款按款项性质分类如下：

| 款项性质 | 2022 年 12 月 31 日 | 2021 年 12 月 31 日 | 2022 年 1 月 1 日 | 2021 年 1 月 1 日 | 2020 年 12 月 31 日 |
|-----------|-----------------------|-----------------------|----------------------|----------------------|-----------------------|
| 应收账款 | 150,328,412.40 | 100,049,601.67 | 46,186,845.31 | 14,777,100.83 | 189,414,067.93 |
| 长期应收款 | 172,625.00 | 94,613.90 | 94,967.96 | | 172,270.94 |
| 合计 | 150,501,037.40 | 100,144,215.57 | 46,281,813.27 | 14,777,100.83 | 189,586,338.87 |

(三) 长期待摊费用

1. 长期待摊费用

| 项目 | 2022 年 12 月 31 日 | 2021 年 12 月 31 日 | 2022 年 1 月 1 日 | 2021 年 1 月 1 日 | 2020 年 12 月 31 日 |
|-----------|-----------------------|----------------------|----------------------|----------------------|------------------|
| 预付账款 | 16,979,155.87 | 3,164,380.59 | 8,026,079.93 | 1,687,621.09 | |
| 使用权资产 | | | | | |
| 长期待摊费用 | 50,169,236.15 | 8,217,114.53 | 18,012,806.84 | 4,503,201.71 | |
| 递延所得税资产 | 4,390,510.38 | 1,097,627.60 | 4,653,187.96 | 1,163,296.99 | |
| 其他 | 54,688,502.33 | 8,203,275.35 | 46,552,302.33 | 6,982,845.35 | |
| 合计 | 126,227,404.73 | 20,682,398.07 | 77,244,377.06 | 14,336,965.14 | |

附注五、非经常性损益
 2022年度非经常性损益情况表
 (A股人民币元)

五、非经常性损益

(二) 非经常性损益

2. 非经常性损益

| 项目 | 本期发生额 | 上期发生额 | 本期发生额 | 上期发生额 |
|--------------------|----------------|---------------|----------------|---------------|
| 非流动资产处置损益 | | | | |
| 公允价值变动损益 | | | | |
| 计入当期损益的政府补助 | 148,564,631.76 | 37,141,157.94 | 144,340,394.12 | 36,085,098.53 |
| 除上述各项之外的其他营业外收入和支出 | 13,116,852.07 | 1,967,527.81 | 15,812,274.60 | 2,371,841.19 |
| 其他 | 6,620,111.12 | 1,439,193.06 | 6,958,909.45 | 1,418,850.23 |
| 合计 | 168,301,594.95 | 40,547,878.81 | 167,111,578.17 | 39,875,789.95 |

(三) 其他非经常性损益

| 项目 | 本期发生额 | 上期发生额 | 本期发生额 | 上期发生额 |
|--------------------|---------------|---------------|---------------|---------------|
| 非流动资产处置损益 | | | | |
| 公允价值变动损益 | | | | |
| 计入当期损益的政府补助 | 6,936,000.00 | 6,936,000.00 | 6,936,000.00 | 6,936,000.00 |
| 除上述各项之外的其他营业外收入和支出 | 6,605,047.21 | 6,605,047.21 | 130,386.60 | 130,386.60 |
| 其他 | | | 14,000,000.00 | 14,000,000.00 |
| 合计 | 13,541,047.21 | 13,541,047.21 | 21,066,386.60 | 21,066,386.60 |

(四) 其他非经常性损益

| 项目 | 本期发生额 | 上期发生额 |
|--------------------|----------------|----------------|
| 非流动资产处置损益 | | |
| 公允价值变动损益 | | |
| 计入当期损益的政府补助 | 195,000,000.00 | 200,000,000.00 |
| 除上述各项之外的其他营业外收入和支出 | 8,000,000.00 | 54,050,000.00 |
| 其他 | | |
| 合计 | 203,000,000.00 | 254,050,000.00 |

附注五、非经常性损益及其他收益和损失
 2022年度非经常性损益及其他收益和损失

单位：人民币元

| 项目 | 本期发生额 | 上期发生额 |
|-------------|---------------|---------------|
| 非流动资产处置损益 | | |
| 计入当期损益的政府补助 | 13,922,929.38 | 13,922,929.38 |
| 其他 | 13,922,929.38 | 13,922,929.38 |
| 合计 | 27,845,858.76 | 27,845,858.76 |

(一) 非流动资产处置损益

| 项目 | 本期发生额 | 上期发生额 |
|-------------|------------|------------|
| 处置固定资产损益 | | |
| 处置无形资产损益 | | |
| 处置长期股权投资损益 | | |
| 处置其他非流动资产损益 | | |
| 合计 | 997,944.00 | 997,944.00 |

(二) 政府补助

| 项目 | 本期发生额 | 上期发生额 |
|----------------|---------------|---------------|
| 与日常经营活动相关的政府补助 | 84,193,738.77 | 55,761,620.69 |
| 与日常经营活动无关的政府补助 | 1,161,389.02 | 2,767,905.77 |
| 与资产相关的政府补助 | 71,968.47 | 168,509.77 |
| 其他 | 345,965.27 | 287,110.78 |
| 合计 | 86,373,061.53 | 58,925,146.91 |

附注五、非经常性损益

2022年度非经常性损益情况表

(A股)

单位：人民币元

(三) 其他非经常性损益

| 项目 | 本期发生额 | 上期发生额 |
|--------------------|---------------|---------------|
| 计入当期损益的政府补助 | 29,436,207.46 | 16,275,602.70 |
| 除上述各项之外的其他营业外收入和支出 | 458,629.04 | |
| 合计 | 29,894,836.50 | 16,275,602.70 |

(四) 其他非经常性损益

| 项目 | 本期发生额 | 上期发生额 |
|-------------|-------|----------|
| 计入当期损益的政府补助 | | 3,240.59 |
| 合计 | | 3,240.59 |

(五) 其他非经常性损益

1. 其他非经常性损益

| 项目 | 本期发生额 | 上期发生额 | 本期发生额 | 上期发生额 |
|--------------------|---------------|----------------|----------------|---------------|
| 计入当期损益的政府补助 | 57,969,287.42 | 498,871,976.49 | 488,702,553.33 | 68,138,710.58 |
| 除上述各项之外的其他营业外收入和支出 | 2,518,896.85 | 30,311,176.43 | 30,410,434.15 | 2,419,639.13 |
| 合计 | 60,488,184.27 | 529,183,152.92 | 519,112,987.48 | 70,558,349.71 |

附注
2022
(人民币元)

五、非流动资产减值准备

(元)

2. 长期股权投资

| 项目 | 账面余额 | 减值准备 | 账面价值 | 减值准备 |
|--|---------------|----------------|----------------|---------------|
| (1) 对被投资单位不具有共同控制或重大影响，且在活跃市场中没有报价、公允价值不能可靠计量的长期股权投资 | 56,230,979.61 | 447,906,594.96 | 437,976,426.00 | 66,161,148.57 |
| (2) 对被投资单位具有共同控制或重大影响的长期股权投资 | 87,835.30 | 10,184,665.65 | 9,965,118.81 | 307,382.14 |
| (3) 对被投资单位不具有共同控制或重大影响，且在活跃市场中没有报价、公允价值不能可靠计量的长期股权投资 | 1,334,394.89 | 19,527,025.66 | 19,397,236.12 | 1,464,184.43 |
| I. 对合营企业投资 | 1,290,685.28 | 18,813,797.48 | 18,678,735.17 | 1,425,747.59 |
| W. 对子公司投资 | 38,841.61 | 641,567.33 | 643,107.24 | 37,301.70 |
| M. 对联营企业投资 | 4,868.00 | 55,652.85 | 60,096.21 | 424.64 |
| O. 其他 | | 16,008.00 | 15,297.50 | 710.50 |
| (4) 其他 | | | | |

| 附注 | | 2022 | |
|------|------|---------------|---------------|
| (A) | | RMB Y | |
| V. N | (I) | B | B |
| I | I | I | I |
| VAT | | 2,399,813.52 | 2,194,179.27 |
| E | | 26,859,279.46 | 22,060,348.34 |
| I | | 1,260,918.02 | 1,102,372.67 |
| C | | 163,205.29 | 39,305.94 |
| P | | 2,292,516.47 | 4,544,055.56 |
| E | | 116,587.33 | 28,135.83 |
| L | | 387,329.69 | 250,083.20 |
| S | | 25,663.04 | 16,848.52 |
| E | | 1,696.00 | |

附注五、非经常性损益

2022年度非经常性损益情况表

单位：人民币元

2. 公允价值变动收益

| | 本期发生额 | 上期发生额 |
|----------|------------|-----------|
| 公允价值变动收益 | 735,000.00 | 86,550.00 |
| 合计 | 735,000.00 | 86,550.00 |

3. 其他收益

| | 本期发生额 | 上期发生额 |
|----------|---------------|---------------|
| 政府补助 | 25,932,146.03 | 8,703,936.40 |
| 利息收入 | 7,000,000.00 | 15,000,000.00 |
| 投资收益 | 3,682,272.62 | 7,166,038.37 |
| 公允价值变动收益 | 1,900,552.80 | 1,094,722.20 |
| 其他收益 | 17,695,375.57 | 7,496,808.30 |
| 其他 | 4,374,261.21 | 4,312,000.00 |
| 合计 | 3,673,024.53 | 6,981,466.40 |
| 合计 | 6,624,054.06 | 4,025,654.97 |
| 合计 | 70,881,686.82 | 54,780,626.64 |

附注五、非经常性损益

非经常性损益明细表

2022年度

(A股)

人民币元

五、非经常性损益

(三) 非经常性损益

| | 本期发生额 | 上年同期发生额 |
|------------------------|----------------|---------------|
| 非流动资产处置损益 | 1,000.00 | 1,000.00 |
| 计入当期损益的政府补助 | 22,470,000.00 | 18,200,000.00 |
| 除金融资产以外的其他权益工具投资公允价值变动 | 99,580,000.00 | |
| 其他 | 25,548,324.39 | 30,040,752.22 |
| 合计 | 147,598,324.39 | 48,240,752.22 |

(一) 计入当期损益的政府补助

| | 本期发生额 | 上年同期发生额 |
|-------------|---------------|---------------|
| 计入当期损益的政府补助 | 22,470,000.00 | 18,200,000.00 |

附注
F
(A 2022 RMB Y)

V. N ()

(I) L

| | B | B |
|-----|---------------|---|
| I | | |
| L - | 42,404,938.54 | |
| S | | |
| T | 42,404,938.54 | |

O : -

| | B | B |
|--------|----------------|---|
| I | | |
| A | 141,984,938.54 | |
| I :U | 9,382,772.07 | |
| L :L - | 99,580,000.00 | |
| T | 42,404,938.54 | |

(II) D

| | B | I | D | B | R |
|---|--------------|---|------------|--------------|---|
| I | | | | | |
| G | 9,341,683.00 | | 303,792.00 | 9,037,891.00 | |

附注五、非经常性损益明细表
 F. 2022
 (A RMB Y)

V. N ()

(II) D ()

P :

A

| | 本期金额 | 上期金额 | 本期金额 | 上期金额 |
|---------|--------------|------------|--------------|-------|
| L | | | | |
| Expense | 9,341,683.00 | 303,792.00 | 9,037,891.00 | A - / |
| T | 9,341,683.00 | 303,792.00 | 9,037,891.00 | - |

(III) ,

| | 本期金额 | I (+)/ (-) | B | B |
|---|---------------|------------|---|---------------|
| I | | | | |
| T | 74,600,300.00 | | | 74,600,300.00 |

(I) C ,

| | 本期金额 | I | D | B |
|-----|----------------|---------------|---|----------------|
| I | | | | |
| S | 783,420,735.87 | | | 783,420,735.87 |
| O | | | | |
| - S | 32,642,955.35 | 12,214,418.85 | | 44,857,374.20 |
| - O | 22,101,704.37 | 4,698,718.86 | | 26,800,423.23 |
| T | 838,165,395.59 | 16,913,137.71 | | 855,078,533.30 |

NE
F 2022
(A RMB Y)

V. N ()

(I)C, ()

O , :

(1) F - N IX.

(2) I 2022, RMB4,698,718.86
R S R S
I P .

()

| | 2022 | 2021 | 2020 |
|---|---------------|---------------|---------------|
| I | 38,399,577.13 | 38,399,577.13 | 38,399,577.13 |
| S | 38,399,577.13 | 38,399,577.13 | 38,399,577.13 |
| T | 38,399,577.13 | 38,399,577.13 | 38,399,577.13 |

O :

I C P ' R C, C 10%
T C
50% T
-

N **F**
F 2022
(A RMB Y)

附注 2022
(A 人民币)
五、

1. 资产负债表

| 项目 | 2022 年 12 月 31 日 | 2021 年 12 月 31 日 | 2022 年 1 月 1 日 | 2021 年 1 月 1 日 |
|-------|------------------|------------------|------------------|----------------|
| 流动资产 | 1,366,816,938.51 | 1,040,114,649.97 | 1,202,774,377.74 | 897,111,635.75 |
| 非流动资产 | 118,086,103.74 | 91,857,292.80 | 94,655,992.09 | 71,320,820.01 |
| 总资产 | 1,484,903,042.25 | 1,131,971,942.77 | 1,297,430,369.83 | 968,432,455.76 |

本集团

| 项目 | 2022 年 12 月 31 日 | 2021 年 12 月 31 日 |
|-------|------------------|------------------|
| 流动资产 | 1,366,816,938.51 | 1,202,774,377.74 |
| 非流动资产 | 118,086,103.74 | 94,655,992.09 |
| 总资产 | 1,484,903,042.25 | 1,297,430,369.83 |

2. 现金流量表

| 项目 | 2022 年 | 2021 年 |
|--------------|------------------|------------------|
| 经营活动产生的现金流量 | 305,118,303.27 | 267,588,282.25 |
| 投资活动产生的现金流量 | 1,061,698,635.24 | 935,186,095.49 |
| 筹资活动产生的现金流量 | 118,086,103.74 | 94,655,992.09 |
| 现金及现金等价物净增加额 | 85,464,736.39 | 51,613,429.22 |
| 期初现金及现金等价物余额 | 3,000,000.00 | 2,970,297.00 |
| 期末现金及现金等价物余额 | 8,067,969.32 | 7,515,329.40 |
| 现金流量净额 | 16,043,547.63 | 16,513,388.84 |
| 现金流量净额 | 21,553,398.03 | 16,513,388.84 |
| 现金流量净额 | 1,484,903,042.25 | 1,297,430,369.83 |

| N | | F | |
|-----------|-----|------|-----|
| 2022 | | 2021 | |
| (A) | (B) | (C) | (D) |
| RMB Y () | | | |
| V. N | | | () |
| (III) | | | |
| I. | | A | |
| | | A | |

附注 2022
(A 人民币)

V. N ()
(L)G

| I | A | A |
|---|----------------|----------------|
| E | 106,839,736.87 | 92,095,322.35 |
| C | 22,821,067.41 | 11,791,502.03 |
| D | 12,364,390.29 | 10,327,372.91 |
| R | 7,928,268.21 | 7,688,976.40 |
| A | 7,169,511.48 | 7,803,052.34 |
| A | 6,366,300.00 | 1,222,900.00 |
| O | 5,452,608.66 | 5,171,123.31 |
| A | 5,226,706.30 | 3,986,627.45 |
| E | 4,539,506.45 | 2,946,383.00 |
| E | 4,412,652.14 | 8,414,462.03 |
| T | 4,358,637.42 | 2,835,174.29 |
| P | 2,798,524.34 | 3,204,882.36 |
| H | 2,653,266.15 | 4,644,062.36 |
| C | 2,527,587.52 | 3,580,020.08 |
| P | 2,521,353.37 | 1,319,556.59 |
| O | 2,099,610.09 | 3,313,286.64 |
| U | 1,889,937.19 | 1,974,023.35 |
| P | | 96,657.59 |
| O | 3,917,508.51 | 3,956,503.74 |
| T | 205,887,172.40 | 176,371,888.82 |

附注五、非经常性损益

2022年度非经常性损益情况表

| 项目 | 2022年度 | 2021年度 |
|------------------------|---------------|---------------|
| 非流动资产处置损益 | 29,575,455.47 | 24,627,424.22 |
| 计入当期损益的政府补助 | 1,164,368.95 | 1,346,035.33 |
| 计入当期损益的债务重组损益 | 550,065.23 | 594,882.24 |
| 计入当期损益的公允价值变动损益 | 400,114.92 | 311,882.70 |
| 计入当期损益的金融资产公允价值变动损益 | 76,467.92 | |
| 计入当期损益的处置金融资产取得的投资收益 | 68,877.00 | 134,907.60 |
| 计入当期损益的自用无形资产处置损益 | 58,690.00 | |
| 计入当期损益的处置无形资产取得的投资收益 | 30,200.00 | |
| 计入当期损益的处置长期股权投资取得的投资收益 | 19,682.96 | 76,999.34 |
| 计入当期损益的处置长期股权投资取得的其他收益 | 11,090.48 | |
| 计入当期损益的处置长期股权投资取得的其他收益 | 3,000.00 | |
| 其他 | 1,069,974.86 | 870,041.96 |
| 合计 | 33,027,987.79 | 27,962,173.39 |

(六) 其他非流动资产

| 项目 | 2022年度 | 2021年度 |
|---------|---------------|---------------|
| 其他非流动资产 | 45,149,998.30 | 36,267,756.91 |
| 其他非流动资产 | 11,935,506.62 | 14,290,203.16 |
| 其他非流动资产 | 2,761,765.05 | 1,691,366.88 |
| 其他非流动资产 | -78,462.87 | 38,704.15 |
| 其他非流动资产 | 1,999,946.76 | 3,043,331.77 |
| 合计 | 44,309,717.14 | 37,658,425.95 |

附注五、营业收入和营业成本 (续)

营业收入 (人民币元)

(续)

| 项目 | 2022年度 | 2021年度 |
|----------|---------------|---------------|
| 营业收入 | 14,907,710.81 | 13,619,635.06 |
| 其中： | | |
| 主营业务收入 | 14,602,195.91 | 13,486,446.80 |
| 其他业务收入 | 37,171.75 | |
| 公允价值变动损益 | 162,213.15 | 133,188.26 |
| 营业外收入 | 106,130.00 | |

| 项目 | 2022年度 | 2021年度 | 变动原因 |
|--------|---------------|---------------|------|
| 主营业务收入 | 14,602,195.91 | 13,486,446.80 | |
| 其中： | | | |
| 药品销售收入 | 859,807.09 | 1,231,900.37 | 减少 |
| 手术收入 | 3,408,933.78 | 3,325,154.99 | 增加 |
| 手术收入 | 1,018,900.00 | 2,270,000.00 | 减少 |
| 医疗服务收入 | 973,813.11 | 244,079.31 | 增加 |
| 其中： | | | |
| DRG收入 | 638,519.98 | | 增加 |
| 手术收入 | 600,000.00 | 50,000.00 | 增加 |
| 手术收入 | 600,000.00 | | 增加 |
| 医疗服务收入 | 440,197.00 | 814,795.52 | 减少 |
| 手术收入 | 311,520.00 | 744,608.99 | 减少 |
| 其他收入 | 303,792.00 | 303,792.00 | 持平 |
| 手术收入 | 300,000.00 | | 增加 |
| 其他收入 | 284,000.00 | 284,000.00 | 持平 |
| 手术收入 | 249,000.00 | | 增加 |
| 手术收入 | 238,400.00 | | 增加 |

NEF
F 2022
(A RMB Y)
V. N ()

(LIII) O ()
G ()

| I | A | A | A - / |
|-----------------|------------|------------|-------|
| H COVID-19 | | | |
| H C P | 197,750.00 | | I - |
| H C C | 174,653.70 | | I - |
| U S B B H R | | | |
| S S | 138,796.96 | | I - |
| O S | 120,835.00 | | I - |
| S | 117,625.00 | | I - |
| W - D H | | | |
| S C | 64,000.00 | | I - |
| H B Y D ,H | 63,971.59 | | I - |
| I D R B P | 55,332.00 | 50,000.00 | I - |
| S I P | 50,000.00 | | I - |
| S | 90,000.00 | 168,696.99 | I - |
| S D P H | 40,000.00 | 40,000.00 | I - |
| T M F S A T | | | |
| | 38,201.19 | | I - |
| E | 36,218.55 | | I - |
| T 2022 | | | |
| E I B Y C | 22,045.69 | | I - |
| S F B N M B P A | 20,000.00 | | I - |
| T - P B | | | |
| W E E B | 20,000.00 | | I - |
| T - | | | |
| H C L D | 20,000.00 | | I - |
| T - C B | | | |
| W E E B | 20,000.00 | | I - |


NEF
F 2022
(A RMB Y)

V. N ()

(LIII) O ()

G ()

| I | A | A | A - / |
|---------------------|-----------|--------------|-------|
| R C | | | |
| D C P | 17,000.00 | | I - |
| S | | | |
| E C J D | 13,610.61 | | I - |
| W L D D R B ' E | | | |
| R I P | 12,000.00 | | I - |
| Y C H B ' S P H S F | 10,200.00 | 13,500.00 | I - |
| W M H C ' F Y M | | | |
| T | 7,000.00 | | I - |
| W M H C ' H R | | | |
| T F | 6,700.00 | | I - |
| S W H P F M C | 4,433.33 | | I - |
| P C H B ' S F | 3,000.00 | 1,904,299.94 | I - |
| L C C D C P ' F M | | | |
| S | 3,000.00 | | I - |
| W H P F M C ' H | | | |
| P F S | 1,833.33 | | I - |
| Y D P D ' F R | | | |
| C R , D B | 1,600.00 | | I - |
| E A S | 1,500.00 | 74,237.34 | I - |
| M S | 1,380.00 | | I - |
| P H S F L D H C | 1,000.00 | | I - |
| P C P F E M - -C | | | |
| T HIV, S, H B | 476.00 | | I - |
| P C P F F P B D | | | |
| P | 450.00 | | I - |
| O D M S A ' S | | | |
| M A D R | 360.00 | | I - |

N  **F**
F 2022
(A  RMB Y )

附注五、非经常性损益及其他收益和损失
 2022年度非经常性损益及其他收益和损失

五、非经常性损益及其他收益和损失

(一) 营业外收入

| | 2022年度 | 2021年度 |
|---------|----------------|--------------|
| 营业外收入 | -2,054,396.53 | 8,407,356.31 |
| 其中：政府补助 | -13,922,929.38 | |
| 其他 | | 1,010,034.42 |
| 合计 | -15,977,325.91 | 9,417,390.73 |

(二) 营业外支出

| | 2022年度 | 2021年度 |
|----------------|---------------|--------------|
| 营业外支出 | 11,260,563.08 | 3,005,695.74 |
| 其中：非流动资产毁损报废损失 | 13,930,978.11 | -865,499.29 |
| 其他 | | |
| 合计 | 25,191,541.19 | 2,140,196.45 |

(三) 其他收益

| | 2022年度 | 2021年度 |
|------|---------------|--------------|
| 其他收益 | 10,345,460.56 | 6,179,290.37 |
| 合计 | 10,345,460.56 | 6,179,290.37 |

附注五、非经常性损益

2022年度非经常性损益情况表

(A股)

单位：人民币元

| 项目 | 2022年度 | 2021年度 | 2020年度 |
|--------------------|------------|-------------|------------|
| 非流动资产处置损益 | - | - | - |
| 计入当期损益的政府补助 | 406,184.95 | -101,512.90 | 406,184.95 |
| 计入当期损益的公允价值变动损益 | 406,184.95 | -101,512.90 | 406,184.95 |
| 除上述各项之外的其他营业外收入和支出 | - | 22,109.35 | - |
| 合计 | 406,184.95 | -79,403.55 | 406,184.95 |

附注六、其他非流动资产

| 项目 | 2022年末 | 2021年末 | 2020年末 |
|---------|--------------|---------------|--------------|
| 其他非流动资产 | 12,737.42 | 154,603.42 | 12,737.42 |
| 其他非流动资产 | 12,737.42 | 154,603.42 | 12,737.42 |
| 其他非流动资产 | 7,435,774.26 | 9,470,530.18 | 7,435,774.26 |
| 其他非流动资产 | 55,075.00 | 265,600.00 | 55,075.00 |
| 其他非流动资产 | 60.10 | - | 60.10 |
| 其他非流动资产 | 35,711.51 | - | 35,711.51 |
| 其他非流动资产 | - | 1,800,000.00 | - |
| 其他非流动资产 | 12,000.00 | - | 12,000.00 |
| 其他非流动资产 | 15,000.00 | - | 15,000.00 |
| 其他非流动资产 | 987,619.57 | 145,198.20 | 987,619.57 |
| 合计 | 8,553,977.86 | 11,835,931.80 | 8,553,977.86 |

附注五、非经常性损益

2022年度非经常性损益情况表

(一) 非经常性损益明细表

| 项目 | 2022年度 | 2021年度 | 2020年度 |
|---|------------|------------|--------|
| 非流动资产处置损益 | - | - | - |
| 计入当期损益的政府补助 | 100,000.00 | - | - |
| 除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、交易性金融负债产生的公允价值变动损益，以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益 | 150,000.00 | - | - |
| 公允价值变动损益 | 5,000.00 | - | - |
| 计入当期损益的金融资产公允价值变动收益 | 75.00 | - | - |
| 计入当期损益的金融负债公允价值变动收益 | 5,000.00 | - | - |
| 计入当期损益的处置长期股权投资产生的损益 | 40,000.00 | - | - |
| 计入当期损益的处置长期债权投资产生的损益 | 5,000.00 | - | - |
| 其他 | 15,600.00 | - | - |
| 合计 | 55,075.00 | 265,600.00 | - |

(二) 非经常性损益对公司经营业绩的影响

| 项目 | 2022年度 | 2021年度 | 2020年度 |
|-----------------|--------------|--------------|--------------|
| 归属于母公司普通股股东的净利润 | 1,587,610.46 | 165,976.73 | 1,587,610.46 |
| 非经常性损益 | 1,587,610.46 | 165,976.73 | 1,587,610.46 |
| 合计 | 3,927,631.03 | 3,333,396.94 | 3,927,631.03 |
| 归属于母公司普通股股东的净利润 | 521,375.57 | - | 521,375.57 |
| 非经常性损益 | 99,809.90 | - | 99,809.90 |
| 合计 | 267,628.43 | - | 267,628.43 |
| 归属于母公司普通股股东的净利润 | 1,754,450.54 | 3,398,511.21 | 1,754,450.54 |
| 非经常性损益 | 1,182,532.80 | 1,738,698.54 | 1,182,532.80 |
| 合计 | 9,341,038.73 | 8,636,583.42 | 9,341,038.73 |

附注五、非经常性损益及其他收益和损失
 2022年度非经常性损益及其他收益和损失

非经常性损益及其他收益和损失合计 ()

(一) 其他收益

1. 政府补助

| 项目 | 2022年度 | 2021年度 |
|------|----------------|---------------|
| 其他收益 | 40,192,565.61 | 26,919,820.08 |
| 合计 | -13,618,853.12 | |

附注五、非经常性损益及其他收益和损失
 2022年度非经常性损益及其他收益和损失

单位：人民币元

(LII) 非经常性损益及其他收益和损失

| 项目 | 2022年度 | 2021年度 |
|-------------------------|----------------|---------------|
| 1. 非流动资产处置损益 | | |
| 处置固定资产、无形资产和其他长期资产产生的损益 | -24,220,782.31 | 44,035,995.21 |
| 处置子公司产生的损益 | 74,600,300.00 | 72,140,300.00 |
| 计入当期损益的政府补助 | -0.32 | 0.61 |
| 其他 | -0.32 | 0.61 |
| 2. 其他收益 | | |
| 计入当期损益的政府补助 | -24,220,782.31 | 44,035,995.21 |
| 其他 | 74,600,300.00 | 74,600,300.00 |
| 3. 公允价值变动损益 | -0.32 | 0.59 |
| 4. 投资收益 | -0.32 | 0.59 |

附注五、非经常性损益明细表
 2022年度
 (A股人民币元)

单位：人民币元

(一) 非经常性损益

1. 计入当期损益的政府补助

| 项目 | 2022年度 金额 | 2021年度 金额 |
|--------------------|----------------|---------------|
| 计入当期损益的政府补助 | 40,253,328.59 | 45,945,728.57 |
| 除上述各项之外的其他营业外收入和支出 | 14,633,117.41 | 13,579,087.19 |
| 公允价值变动损益 | 8,067,969.32 | 7,012,773.24 |
| 债务重组损益 | 10,116,855.54 | 12,851,693.57 |
| 资产处置收益 | 12,751,158.99 | 14,960,534.77 |
| 其他 | 1,035,391.18 | 1,870,927.58 |
| 合计 | 14,000,000.00 | |
| 合计 | 100,857,821.03 | 96,220,744.92 |

2. 计入其他综合收益的政府补助

| 项目 | 2022年度 金额 | 2021年度 金额 |
|--------------------|----------------|---------------|
| 计入其他综合收益的政府补助 | 30,632,892.49 | 23,313,110.97 |
| 除上述各项之外的其他营业外收入和支出 | 82,155,141.49 | 54,235,967.08 |
| 公允价值变动损益 | 6,608,712.31 | 6,714,560.33 |
| 债务重组损益 | 2,927,440.32 | 4,469,403.02 |
| 其他 | 1,082,364.51 | 1,442,594.04 |
| 合计 | 12,498,972.00 | |
| 合计 | 135,905,523.12 | 90,175,635.44 |

3. 计入所有者权益的其他非经常性损益

| 项目 | 2022年度 金额 | 2021年度 金额 |
|------------------|--------------|--------------|
| 计入所有者权益的其他非经常性损益 | 8,770,704.43 | |
| 合计 | 8,770,704.43 | |

| 附注 | | 2022 | |
|--------|-----|----------------|---------------|
| (A) | | RMB Y | |
| V. N | () | | |
| (LI)I | () | | |
| 4. G | | | |
| I | | A | A |
| G | | 150,684,059.10 | |
| G | | 736,190.90 | |
| T | | 151,420,250.00 | |
| 5. G | | | |
| I | | A | A |
| G | | 8,096,992.56 | |
| G | | 43,524,302.81 | 44,807,765.61 |
| F | | 4,500,000.00 | 750,000.00 |
| G | | | 15,118,800.00 |
| T | | 56,121,295.37 | 60,676,565.61 |

附注五、非经常性损益及其他收益和损失
 2022年度非经常性损益及其他收益和损失
 (A股) (人民币元)

(L) 人民币元

1. 公允价值变动收益

| | 2022年度 人民币元 | 2021年度 人民币元 |
|------------------|----------------|----------------|
| 1. 公允价值变动收益 | | |
| 1.1 交易性金融资产 | | |
| 1.1.1 公允价值变动收益 | -10,968,838.36 | 40,860,230.05 |
| 1.1.2 其他 | | |
| 1.2 交易性金融负债 | | |
| 1.2.1 公允价值变动收益 | 25,191,541.19 | 2,140,196.45 |
| 1.2.2 其他 | | |
| 1.3 其他 | | |
| 1.3.1 公允价值变动收益 | 10,345,460.56 | 6,179,290.37 |
| 1.3.2 其他 | | |
| 2. 投资收益 | 53,029,785.07 | 48,274,868.81 |
| 2.1 成本法核算的长期股权投资 | | |
| 2.1.1 公允价值变动收益 | | |
| 2.1.2 其他 | | |
| 2.2 权益法核算的长期股权投资 | 38,189,335.84 | 41,779,572.06 |
| 2.2.1 公允价值变动收益 | | |
| 2.2.2 其他 | 38,189,335.84 | 41,779,572.06 |
| 2.3 其他 | 22,991,163.56 | 14,530,192.10 |
| 2.3.1 公允价值变动收益 | | |
| 2.3.2 其他 | 22,991,163.56 | 14,530,192.10 |
| 3. 其他收益 | 46,397,646.59 | 38,836,785.71 |
| 3.1 公允价值变动收益 | | |
| 3.1.1 公允价值变动收益 | | |
| 3.1.2 其他 | | |
| 3.2 其他 | 46,397,646.59 | 38,836,785.71 |
| 3.2.1 公允价值变动收益 | | |
| 3.2.2 其他 | 46,397,646.59 | 38,836,785.71 |
| 4. 资产处置收益 | | |
| 4.1 公允价值变动收益 | | |
| 4.1.1 公允价值变动收益 | | |
| 4.1.2 其他 | | |
| 4.2 其他 | | |
| 4.2.1 公允价值变动收益 | | |
| 4.2.2 其他 | | |
| 5. 其他 | | |
| 5.1 公允价值变动收益 | | |
| 5.1.1 公允价值变动收益 | | |
| 5.1.2 其他 | | |
| 5.2 其他 | | |
| 5.2.1 公允价值变动收益 | | |
| 5.2.2 其他 | | |
| 6. 其他 | | |
| 6.1 公允价值变动收益 | | |
| 6.1.1 公允价值变动收益 | | |
| 6.1.2 其他 | | |
| 6.2 其他 | | |
| 6.2.1 公允价值变动收益 | | |
| 6.2.2 其他 | | |
| 7. 其他 | | |
| 7.1 公允价值变动收益 | | |
| 7.1.1 公允价值变动收益 | | |
| 7.1.2 其他 | | |
| 7.2 其他 | | |
| 7.2.1 公允价值变动收益 | | |
| 7.2.2 其他 | | |
| 8. 其他 | | |
| 8.1 公允价值变动收益 | | |
| 8.1.1 公允价值变动收益 | | |
| 8.1.2 其他 | | |
| 8.2 其他 | | |
| 8.2.1 公允价值变动收益 | | |
| 8.2.2 其他 | | |
| 9. 其他 | | |
| 9.1 公允价值变动收益 | | |
| 9.1.1 公允价值变动收益 | | |
| 9.1.2 其他 | | |
| 9.2 其他 | | |
| 9.2.1 公允价值变动收益 | | |
| 9.2.2 其他 | | |
| 10. 其他 | | |
| 10.1 公允价值变动收益 | | |
| 10.1.1 公允价值变动收益 | | |
| 10.1.2 其他 | | |
| 10.2 其他 | | |
| 10.2.1 公允价值变动收益 | | |
| 10.2.2 其他 | | |
| 11. 其他 | | |
| 11.1 公允价值变动收益 | | |
| 11.1.1 公允价值变动收益 | | |
| 11.1.2 其他 | | |
| 11.2 其他 | | |
| 11.2.1 公允价值变动收益 | | |
| 11.2.2 其他 | | |
| 12. 其他 | | |
| 12.1 公允价值变动收益 | | |
| 12.1.1 公允价值变动收益 | | |
| 12.1.2 其他 | | |
| 12.2 其他 | | |
| 12.2.1 公允价值变动收益 | | |
| 12.2.2 其他 | | |
| 13. 其他 | | |
| 13.1 公允价值变动收益 | | |
| 13.1.1 公允价值变动收益 | | |
| 13.1.2 其他 | | |
| 13.2 其他 | | |
| 13.2.1 公允价值变动收益 | | |
| 13.2.2 其他 | | |
| 14. 其他 | | |
| 14.1 公允价值变动收益 | | |
| 14.1.1 公允价值变动收益 | | |
| 14.1.2 其他 | | |
| 14.2 其他 | | |
| 14.2.1 公允价值变动收益 | | |
| 14.2.2 其他 | | |
| 15. 其他 | | |
| 15.1 公允价值变动收益 | | |
| 15.1.1 公允价值变动收益 | | |
| 15.1.2 其他 | | |
| 15.2 其他 | | |
| 15.2.1 公允价值变动收益 | | |
| 15.2.2 其他 | | |
| 16. 其他 | | |
| 16.1 公允价值变动收益 | | |
| 16.1.1 公允价值变动收益 | | |
| 16.1.2 其他 | | |
| 16.2 其他 | | |
| 16.2.1 公允价值变动收益 | | |
| 16.2.2 其他 | | |
| 17. 其他 | | |
| 17.1 公允价值变动收益 | | |
| 17.1.1 公允价值变动收益 | | |
| 17.1.2 其他 | | |
| 17.2 其他 | | |
| 17.2.1 公允价值变动收益 | | |
| 17.2.2 其他 | | |
| 18. 其他 | | |
| 18.1 公允价值变动收益 | | |
| 18.1.1 公允价值变动收益 | | |
| 18.1.2 其他 | | |
| 18.2 其他 | | |
| 18.2.1 公允价值变动收益 | | |
| 18.2.2 其他 | | |
| 19. 其他 | | |
| 19.1 公允价值变动收益 | | |
| 19.1.1 公允价值变动收益 | | |
| 19.1.2 其他 | | |
| 19.2 其他 | | |
| 19.2.1 公允价值变动收益 | | |
| 19.2.2 其他 | | |
| 20. 其他 | | |
| 20.1 公允价值变动收益 | | |
| 20.1.1 公允价值变动收益 | | |
| 20.1.2 其他 | | |
| 20.2 其他 | | |
| 20.2.1 公允价值变动收益 | | |
| 20.2.2 其他 | | |
| 21. 其他 | | |
| 21.1 公允价值变动收益 | | |
| 21.1.1 公允价值变动收益 | | |
| 21.1.2 其他 | | |
| 21.2 其他 | | |
| 21.2.1 公允价值变动收益 | | |
| 21.2.2 其他 | | |
| 22. 其他 | | |
| 22.1 公允价值变动收益 | | |
| 22.1.1 公允价值变动收益 | | |
| 22.1.2 其他 | | |
| 22.2 其他 | | |
| 22.2.1 公允价值变动收益 | | |
| 22.2.2 其他 | | |
| 23. 其他 | | |
| 23.1 公允价值变动收益 | | |
| 23.1.1 公允价值变动收益 | | |
| 23.1.2 其他 | | |
| 23.2 其他 | | |
| 23.2.1 公允价值变动收益 | | |
| 23.2.2 其他 | | |
| 24. 其他 | | |
| 24.1 公允价值变动收益 | | |
| 24.1.1 公允价值变动收益 | | |
| 24.1.2 其他 | | |
| 24.2 其他 | | |
| 24.2.1 公允价值变动收益 | | |
| 24.2.2 其他 | | |
| 25. 其他 | | |
| 25.1 公允价值变动收益 | | |
| 25.1.1 公允价值变动收益 | | |
| 25.1.2 其他 | | |
| 25.2 其他 | | |
| 25.2.1 公允价值变动收益 | | |
| 25.2.2 其他 | | |
| 26. 其他 | | |
| 26.1 公允价值变动收益 | | |
| 26.1.1 公允价值变动收益 | | |
| 26.1.2 其他 | | |
| 26.2 其他 | | |
| 26.2.1 公允价值变动收益 | | |
| 26.2.2 其他 | | |
| 27. 其他 | | |
| 27.1 公允价值变动收益 | | |
| 27.1.1 公允价值变动收益 | | |
| 27.1.2 其他 | | |
| 27.2 其他 | | |
| 27.2.1 公允价值变动收益 | | |
| 27.2.2 其他 | | |
| 28. 其他 | | |
| 28.1 公允价值变动收益 | | |
| 28.1.1 公允价值变动收益 | | |
| 28.1.2 其他 | | |
| 28.2 其他 | | |
| 28.2.1 公允价值变动收益 | | |
| 28.2.2 其他 | | |
| 29. 其他 | | |
| 29.1 公允价值变动收益 | | |
| 29.1.1 公允价值变动收益 | | |
| 29.1.2 其他 | | |
| 29.2 其他 | | |
| 29.2.1 公允价值变动收益 | | |
| 29.2.2 其他 | | |
| 30. 其他 | | |
| 30.1 公允价值变动收益 | | |
| 30.1.1 公允价值变动收益 | | |
| 30.1.2 其他 | | |
| 30.2 其他 | | |
| 30.2.1 公允价值变动收益 | | |
| 30.2.2 其他 | | |
| 31. 其他 | | |
| 31.1 公允价值变动收益 | | |
| 31.1.1 公允价值变动收益 | | |
| 31.1.2 其他 | | |
| 31.2 其他 | | |
| 31.2.1 公允价值变动收益 | | |
| 31.2.2 其他 | | |
| 32. 其他 | | |
| 32.1 公允价值变动收益 | | |
| 32.1.1 公允价值变动收益 | | |
| 32.1.2 其他 | | |
| 32.2 其他 | | |
| 32.2.1 公允价值变动收益 | | |
| 32.2.2 其他 | | |
| 33. 其他 | | |
| 33.1 公允价值变动收益 | | |
| 33.1.1 公允价值变动收益 | | |
| 33.1.2 其他 | | |
| 33.2 其他 | | |
| 33.2.1 公允价值变动收益 | | |
| 33.2.2 其他 | | |
| 34. 其他 | | |
| 34.1 公允价值变动收益 | | |
| 34.1.1 公允价值变动收益 | | |
| 34.1.2 其他 | | |
| 34.2 其他 | | |
| 34.2.1 公允价值变动收益 | | |
| 34.2.2 其他 | | |
| 35. 其他 | | |
| 35.1 公允价值变动收益 | | |
| 35.1.1 公允价值变动收益 | | |
| 35.1.2 其他 | | |
| 35.2 其他 | | |
| 35.2.1 公允价值变动收益 | | |
| 35.2.2 其他 | | |
| 36. 其他 | | |
| 36.1 公允价值变动收益 | | |
| 36.1.1 公允价值变动收益 | | |
| 36.1.2 其他 | | |
| 36.2 其他 | | |
| 36.2.1 公允价值变动收益 | | |
| 36.2.2 其他 | | |
| 37. 其他 | | |
| 37.1 公允价值变动收益 | | |
| 37.1.1 公允价值变动收益 | | |
| 37.1.2 其他 | | |
| 37.2 其他 | | |
| 37.2.1 公允价值变动收益 | | |
| 37.2.2 其他 | | |
| 38. 其他 | | |
| 38.1 公允价值变动收益 | | |
| 38.1.1 公允价值变动收益 | | |
| 38.1.2 其他 | | |
| 38.2 其他 | | |
| 38.2.1 公允价值变动收益 | | |
| 38.2.2 其他 | | |
| 39. 其他 | | |
| 39.1 公允价值变动收益 | | |
| 39.1.1 公允价值变动收益 | | |
| 39.1.2 其他 | | |
| 39.2 其他 | | |
| 39.2.1 公允价值变动收益 | | |
| 39.2.2 其他 | | |
| 40. 其他 | | |
| 40.1 公允价值变动收益 | | |
| 40.1.1 公允价值变动收益 | | |
| 40.1.2 其他 | | |
| 40.2 其他 | | |
| 40.2.1 公允价值变动收益 | | |
| 40.2.2 其他 | | |
| 41. 其他 | | |
| 41.1 公允价值变动收益 | | |
| 41.1.1 公允价值变动收益 | | |
| 41.1.2 其他 | | |
| 41.2 其他 | | |
| 41.2.1 公允价值变动收益 | | |
| 41.2.2 其他 | | |
| 42. 其他 | | |
| 42.1 公允价值变动收益 | | |
| 42.1.1 公允价值变动收益 | | |
| 42.1.2 其他 | | |
| 42.2 其他 | | |
| 42.2.1 公允价值变动收益 | | |
| 42.2.2 其他 | | |
| 43. 其他 | | |
| 43.1 公允价值变动收益 | | |
| 43.1.1 公允价值变动收益 | | |
| 43.1.2 其他 | | |
| 43.2 其他 | | |
| 43.2.1 公允价值变动收益 | | |
| 43.2.2 其他 | | |
| 44. 其他 | | |
| 44.1 公允价值变动收益 | | |
| 44.1.1 公允价值变动收益 | | |
| 44.1.2 其他 | | |
| 44.2 其他 | | |
| 44.2.1 公允价值变动收益 | | |
| 44.2.2 其他 | | |
| 45. 其他 | | |
| 45.1 公允价值变动收益 | | |
| 45.1.1 公允价值变动收益 | | |
| 45.1.2 其他 | | |
| 45.2 其他 | | |
| 45.2.1 公允价值变动收益 | | |
| 45.2.2 其他 | | |
| 46. 其他 | | |
| 46.1 公允价值变动收益 | | |
| 46.1.1 公允价值变动收益 | | |
| 46.1.2 其他 | | |
| 46.2 其他 | | |
| 46.2.1 公允价值变动收益 | | |
| 46.2.2 其他 | | |
| 47. 其他 | | |
| 47.1 公允价值变动收益 | | |
| 47.1.1 公允价值变动收益 | | |
| 47.1.2 其他 | | |
| 47.2 其他 | | |
| 47.2.1 公允价值变动收益 | | |
| 47.2.2 其他 | | |
| 48. 其他 | | |
| 48.1 公允价值变动收益 | | |
| 48.1.1 公允价值变动收益 | | |
| 48.1.2 其他 | | |
| 48.2 其他 | | |
| 48.2.1 公允价值变动收益 | | |
| 48.2.2 其他 | | |
| 49. 其他 | | |
| 49.1 公允价值变动收益 | | |
| 49.1.1 公允价值变动收益 | | |
| 49.1.2 其他 | | |
| 49.2 其他 | | |
| 49.2.1 公允价值变动收益 | | |
| 49.2.2 其他 | | |
| 50. 其他 | | |
| 50.1 公允价值变动收益 | | |
| 50.1.1 公允价值变动收益 | | |
| 50.1.2 其他 | | |
| 50.2 其他 | | |
| 50.2.1 公允价值变动收益 | | |
| 50.2.2 其他 | | |
| 51. 其他 | | |
| 51.1 公允价值变动收益 | | |
| 51.1.1 公允价值变动收益 | | |
| 51.1.2 其他 | | |
| 51.2 其他 | | |
| 51.2.1 公允价值变动收益 | | |
| 51.2.2 其他 | | |
| 52. 其他 | | |
| 52.1 公允价值变动收益 | | |
| 52.1.1 公允价值变动收益 | | |
| 52.1.2 其他 | | |
| 52.2 其他 | | |
| 52.2.1 公允价值变动收益 | | |
| 52.2.2 其他 | | |
| 53. 其他 | | |
| 53.1 公允价值变动收益 | | |
| 53.1.1 公允价值变动收益 | | |
| 53.1.2 其他 | | |
| 53.2 其他 | | |
| 53.2.1 公允价值变动收益 | | |
| 53.2.2 其他 | | |
| 54. 其他 | | |
| 54.1 公允价值变动收益 | | |
| 54.1.1 公允价值变动收益 | | |
| 54.1.2 其他 | | |
| 54.2 其他 | | |

N **F**
 F 2022
 (A RMB Y)
V. N ()
 (L) ()

2. N

| | A |
|-------------------|---------------|
| G | 54,309,855.16 |
| I : J S H C.,L . | 21,684,900.00 |
| Y Y TCM- H C.,L . | 32,624,955.16 |
| L : G Y C | 624,153.88 |
| I : J S H C.,L . | 624,153.88 |
| A : G Y | |
| O | 53,685,701.28 |

3. C

| | A | A |
|--------|----------------|----------------|
| I | | |
| I. G | 258,595,990.97 | 188,734,845.77 |
| I : G | 454,907.26 | 971,773.72 |
| D | | |
| G | 257,534,338.59 | 187,484,938.31 |
| O | 606,745.12 | 278,133.74 |
| D | | |
| D | | |
| L | | |
| II. G | | |
| I : B | | |
| III. G | 258,595,990.97 | 188,734,845.77 |
| I : U | | |
| G | | |

附注五、非经常性损益

2022年度非经常性损益情况表

| 项目 | 金额 | 占利润总额比例 |
|--------------------|----------------|---------|
| 非流动资产处置损益 | 498,972.00 | 0.37% |
| 公允价值变动损益 | 12,000,000.00 | 9.00% |
| 计入当期损益的政府补助 | 35,612,151.67 | 27.23% |
| 除上述各项之外的其他营业外收入和支出 | 73,406,248.95 | 56.14% |
| 合计 | 6,107,838.02 | 4.64% |
| 合计 | 133,942,408.61 | 100.00% |

附注六、其他

六、其他非流动资产

六、其他非流动资产

(一) 其他非流动资产

1. 其他非流动资产

其他非流动资产

其他非流动资产

| N | | F | |
|-------|---|-------|---------------|
| F | | 2022 | |
| (A | Y | RMB Y |) |
| VI. C | | | () |
| (I) B | | | () |
| 2. C | | | |
| | | | Y Y J Y S Z F |

附注五十九 2022
(A) RMB Y

VI. C ()

(I) B ()

2. C (C)

(2) I J 2022, Z K H M (G) C L ()
Z K), C C J Y
X , Z F N T C , L . ()
Z F), S ' A Z F
N T C , L , C C RMB3,000,000.00
RMB2,673,987.56 Z
F , RMB326,012.44.

3. I ()

| | Y Y | Y Y | J Y S | Z F | | |
|-----|---------------|---------------|---------------|---------------|--------------|--------------|
| | Fe Va | Ge Va | Fe Va | Ge Va | Fe Va | Ge Va |
| | | | | | | |
| A : | 59,544,389.38 | 46,544,389.38 | 37,912,065.31 | 21,595,600.11 | 3,596,967.56 | 3,596,967.56 |
| C | | | 624,153.88 | 624,153.88 | 3,003,084.38 | 3,003,084.38 |
| R | 3,060,406.64 | 3,060,406.64 | 7,552,399.46 | 7,552,399.46 | | |
| I | | | 505,619.01 | 504,706.60 | 590,783.18 | 590,783.18 |
| O | | | 22,965.97 | 22,965.97 | | |
| F | 4,043,853.80 | 4,043,853.80 | 847,808.30 | 394,720.51 | 3,100.00 | 3,100.00 |
| C | | | 6,651,653.69 | 6,651,653.69 | | |
| I | 13,299,835.09 | 299,835.09 | 15,862,465.00 | | | |
| L | 24,864,697.08 | 24,864,697.08 | | | | |
| O | 14,275,596.77 | 14,275,596.77 | 5,845,000.00 | 5,845,000.00 | | |
| L : | 17,960,741.79 | 17,960,741.79 | 8,244,110.73 | 4,164,994.43 | 422,980.00 | 422,980.00 |
| B | | | | | | |
| P | 14,710,741.79 | 14,710,741.79 | 4,099,565.00 | 4,099,565.00 | 261,041.74 | 261,041.74 |
| E | | | 618,827.28 | 618,827.28 | 159,133.43 | 159,133.43 |
| T | | | -553,397.85 | -553,397.85 | 2,804.83 | 2,804.83 |
| D | 3,250,000.00 | 3,250,000.00 | 4,079,116.30 | | | |
| N | 41,583,647.59 | 28,583,647.59 | 29,667,954.58 | 17,430,605.68 | 3,173,987.56 | 3,173,987.56 |
| L : | | | 15,130,745.84 | 8,889,661.19 | 500,000.00 | 500,000.00 |
| N | 41,583,647.59 | 28,583,647.59 | 14,537,208.74 | 8,540,944.49 | 2,673,987.56 | 2,673,987.56 |

M : T C

N **F**
F 2022
(A RMB Y)

VI. C ()

(III) C

T Z H H RMB7.23 . A
, C 47.48% Z H H

N **F**
F 2022
(A RMB Y)

VII.I

(I) I
1. S G

(%)

(0000') D I M

附 表 2022
(A 股 人民币 元)

VII.I ()

(I) I ()

1. S G ()

| 名称 | 持股比例 | 持股比例 | 持股比例 | 余额 | 比例 | 比例 |
|----------------------------------|------|------|------|----------|--------|----|
| (0000') | D | I | M | (%) | | |
| Z Y H T C.,L . | H | H | T | 2,040.82 | 98.00 | I |
| W Y D C.,L . | W | W | D | 50 | 100.00 | I |
| Y M H E-H (W)C.,L . | W | W | H | 500 | 100.00 | I |
| Z D P C.,L . | W | W | P | 1,000 | 80.00 | I |
| C K P H C.,L . | C | C | M | 2,700 | 64.55 | B |
| C Q L K H C.,L . | H | H | M | 1,000 | 100.00 | I |
| H Y M E R&D C.,L . | H | H | T | 500 | 100.00 | I |
| H Y N C.,L . | H | H | N | 100 | 100.00 | I |
| L C H C.,L . | T | T | M | 5,000 | 100.00 | I |
| S Y H C.,L . | S | S | M | 6,000 | 55.00 | I |
| P Y H H C.,L . (浦江怡寧黃鋒醫院有限公司) | J | J | M | 1,660 | 100.00 | I |
| C K H H C.,L . | H | H | M | 1,000 | 100.00 | I |
| C K H C.,L . | C | C | M | 5,000 | 100.00 | I |
| C Y N C C.,L . | C | C | M | 1,000 | 100.00 | I |
| Y K H C.,L . | Y | Y | M | 100 | 100.00 | I |
| L K H C.,L . | T | T | M | 200 | 80.00 | I |
| O Y E H C.,L . | W | W | M | 1,000 | 100.00 | I |
| Q K H C.,L . | L | L | M | 3,200 | 100.00 | I |
| S Y M I C.,L . | S | S | M | 1,000 | 100.00 | I |

附 表
F
2022
(A 类 人民币 Y 元)

| 名称 | 性质 | 持股比例 (%) | 认缴出资额 (0000' 元) | 实缴出资额 (0000' 元) | 出资方式 | 认缴日期 | 实缴日期 |
|------------|-------|----------|-----------------|-----------------|------|----------|----------|
| 温州康宁医院有限公司 | 全资子公司 | 100.00 | 2,585.98 | 2,585.98 | 货币 | 2018年12月 | 2018年12月 |

W
Y
H
C., L.
B
Y
H
S
H
N

| W Y H C., L. B Y H S H N | 19,028,799.19 | 98,436,498.17 | 117,465,297.36 | 20,546,971.67 | 45,000,000.00 | 65,546,971.67 | 17,869,229.47 | 32,881,657.54 | 50,750,887.01 | 3,824,900.47 | 3,824,900.47 |
|---|---------------|---------------|----------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| W Y H C., L. B Y H S H N | 19,028,799.19 | 98,436,498.17 | 117,465,297.36 | 20,546,971.67 | 45,000,000.00 | 65,546,971.67 | 17,869,229.47 | 32,881,657.54 | 50,750,887.01 | 3,824,900.47 | 3,824,900.47 |
| W Y H C., L. B Y H S H N | 10,169,929.61 | 8,898,422.97 | 19,068,352.58 | 14,398,845.02 | 1,002,833.33 | 15,396,678.35 | 3,758,467.94 | 15,734,695.01 | 19,493,162.95 | 8,024,455.59 | 2,551,303.77 |
| W Y H C., L. B Y H S H N | 14,888,059.45 | 19,086,594.25 | 33,574,653.70 | 34,702,233.46 | 5,720,723.50 | 40,422,976.96 | 11,484,646.25 | 30,441,596.64 | 41,926,242.89 | 29,993,444.43 | 12,842,112.65 |

2022
RMB Y

| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |
|---|---------------|---------------|-----------|---------------|---------------|--------------|---------------|----------------|----------------|---------------|---------------|
| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |
| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |
| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |

2022
RMB Y

| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |
|---|---------------|---------------|-----------|---------------|---------------|--------------|---------------|----------------|----------------|---------------|---------------|
| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |
| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |
| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |

VII.I

(I) I

3. M

2022
RMB Y

| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |
|---|---------------|---------------|-----------|---------------|---------------|--------------|---------------|----------------|----------------|---------------|---------------|
| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |
| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |
| W Y H C., L. B Y H S H N | 17,795,027.95 | 22,869,983.78 | -7,660.85 | -5,248,729.36 | -5,940,009.07 | 6,470,527.75 | 16,068,381.54 | -11,178,282.74 | -14,464,180.35 | -2,808,536.37 | -1,962,864.33 |

N **F**
F 2022
(A RMB Y)

VIII. R

D , C : ,
(,). T
C :

T C ,
C . T C
C . T
, . T C
C
. T C S R M C
. T S R M C
,
C T C A C .

T C
 ,
 .

(I) C. ①

C C

T C , , , .

T C -
 . T C
 .

附注 2022
(A 人民币元)

VIII. R
(II) L

| I | B | | | | | T |
|---|----------------|---|-----|-----|-----|----------------|
| | W | 1 | 1-2 | 2-5 | 0-5 | |
| | 1 | 2 | 3 | 4 | 5 | |
| B | 254,050,000.00 | | | | | 254,050,000.00 |

N **F**
F 2022
(A RMB Y)
VIII. R ()
(III) M ()

N **F**
F 2022
(A RMB Y)

VIII. R ()

(III) M ()

3) O

O
 2022, RMB1,893,506, RMB1,893,506, 3%, 3%.

T C
 . T

O 31 D 2022, RMB1,893,506, RMB1,893,506, 3%, 3%.

IX. D

T

L 1 () C

L 2 L 1

L 3

T

附 表 2022
(A 类 人民币 元)

IX. D ()

(I) C ()

| I | C | | |
|-------|-------|-------|---------------|
| | M L 1 | M L 2 | M L 3 |
| I. C | | | |
| F | | | 10,641,026.00 |
| 1. F | | | 10,641,026.00 |
| (1) | | | |
| (2) I | | | 10,641,026.00 |
| (3) | | | |
| 2. F | | | |
| T | | | 10,641,026.00 |
| | | | 13,922,929.38 |
| 1. | | | 13,922,929.38 |
| (1) | | | |
| (2) | | | |
| (3) | | | 13,922,929.38 |
| 2. F | | | |
| T | | | 13,922,929.38 |

(II) Q ()

1. M ()

2. M ()

C ()

C ()

C ()

N III, (XXXI)

N **F**
F 2022
(A RMB Y)

X. R

() I
T C :G W ,Wa L

(.) I C ,
D C N VII.I

(..) I C ,
F C N VII.I

T
C

N **C**

| | | | |
|---|--------------|---|---|
| C | H K H C ,L . | A | C |
| W | A P C ,L | A | C |
| C | Y H C ,L . | A | C |
| H | Y H C ,L . | A | C |

附注
2022
(人民币元)

X. 其他非流动资产 ()

(一) 其他非流动资产

| 项目 | 2022年12月31日 | 2021年12月31日 |
|---------|--------------|--------------|
| 预付账款 | 1,000,000.00 | 1,000,000.00 |
| 预付款项 | 1,000,000.00 | 1,000,000.00 |
| 其他非流动资产 | 1,000,000.00 | 1,000,000.00 |
| 合计 | 3,000,000.00 | 3,000,000.00 |

(二) 其他非流动资产

| 项目 | 2022年12月31日 | 2021年12月31日 |
|---------|--------------|--------------|
| 1. 预付账款 | 1,000,000.00 | 1,000,000.00 |
| 合计 | 1,000,000.00 | 1,000,000.00 |

N **F**
 F 2022
 (A RMB Y)
X. R ()
 () I ()

3. R
T C :

| N | G | C | E |
|--------------|---------------|------------|--------------|
| Y K H C.,L . | 50,200,000.00 | 2019/8/26 | 2029/8/20 N |
| Q K H C.,L . | 45,000,000.00 | 2019/12/31 | 2024/12/31 N |

T C

| N | G | C | E |
|----------------------|----------------|------------|--------------|
| G W W L | 30,000,000.00 | 2020/6/30 | 2027/6/30 N |
| G W , W H W L | 75,000,000.00 | 2021/11/29 | 2028/11/29 N |
| G W , W H , W L X | 150,000,000.00 | 2020/10/26 | 2026/10/25 N |
| G W , W L W H | 200,000,000.00 | 2020/9/17 | 2023/9/17 N |

4. A

C A
 9

N **F**
 F 2022
 (A RMB Y)
 X. R ()

附注五、营业收入和营业成本
 2022年度营业收入和营业成本
 (A) (人民币元)

X. R ()
 (II)E (C)

I 2021, , :

| | C | | | B O | | | T |
|-----|------------|--------------|-----------|------------|-----------|--|--------------|
| | E | | | | | | |
| E | | | | | | | |
| G W | - | 398,742.00 | 15,795.90 | 78,916.40 | 4,300.00 | | 497,754.30 |
| W L | - | 375,592.00 | - | 46,714.60 | 44,680.00 | | 466,986.60 |
| W H | - | 208,108.00 | - | 42,396.60 | 1,200.00 | | 251,704.60 |
| N | | | | | | | |
| L L | - | - | - | - | - | | - |
| Y Y | - | 28,200.00 | 4,986.80 | 32,385.97 | 8,932.90 | | 74,505.67 |
| I | | | | | | | |
| Z X | 70,000.00 | - | - | - | - | | 70,000.00 |
| Z W | 70,000.00 | - | - | - | - | | 70,000.00 |
| L N | 70,000.00 | - | - | - | - | | 70,000.00 |
| H J | - | - | - | - | - | | - |
| Q C | - | - | - | - | - | | - |
| C J | - | - | - | - | - | | - |
| S F | - | - | - | - | - | | - |
| X T | - | 82,613.40 | 8,885.40 | 54,030.60 | 18,936.60 | | 164,466.00 |
| T | 210,000.00 | 1,093,255.40 | 29,668.10 | 254,444.17 | 78,049.50 | | 1,665,417.17 |

附注 2022
(A 人民币)

X. R ()

(III) F I

I 2022, 2 (2021: 3),

| | A | A |
|---|--------------|--------------|
| I | | |
| W | 3,764,039.10 | 3,424,382.50 |
| S | 4,109,519.26 | 4,411,564.18 |
| T | 7,873,558.36 | 7,835,946.68 |

| | N | N |
|----------------------|---|---|
| 500,000-1,000,000.00 | 1 | 1 |
| 1,000,000.00 | 4 | 4 |
| T | 5 | 5 |

附 表
附 表 2022
(A 附 表 RMB Y 附 表)

XI. S 附 表 - 附 表

(I) 附 表

T 附 表 C 附 表 :

O J 13, 2018, C 附 表 , 2018 附 表 W
 K 附 表 H 附 表 E 附 表 P 附 表 2018, B 附 表 C 附 表
 附 表 . T B 附 表 C 附 表 P 附 表 G 附 表 R
 S 附 表 I 附 表 O 附 表 J 29, 2018 A 附 表 20, 2018, T C 附 表
 附 表 W Z 附 表 K 附 表 I 附 表
 M 附 表 P 附 表 (L 附 表 P 附 表), W J 附 表 K 附 表 I 附 表 M 附 表
 P 附 表 (L 附 表 P 附 表), W E 附 表 K 附 表 I 附 表 M 附 表 P 附 表
 (L 附 表 P 附 表), W J 附 表 K 附 表 I 附 表 M 附 表 P 附 表 (L
 L 附 表 P 附 表) W S 附 表 K 附 表 I 附 表 M 附 表 P 附 表 (L
 L 附 表 P 附 表), 2,460,000 附 表 附 表

附 表 2022
(A 表 RMB Y 元)

XI. S ()

(II) E ()

M :

T C . T C RMB30 .

M :

N **F**
F 2022
(A RMB Y)

XII.C **C**

(I)

1. **C**
.....

NE
 F 2022
 (A RMB Y)

XIV. C

T C :

- C - ;

- ,

T C . T . I , C ,

T C .

A , C :

B B

D /

49.73%

46.16%

附注
F
(A 2022 RMB Y)

XV. O

(I) C

R

A 38 M T S B D E M T
S S C C P R C P
A E ,
2021 :

| C | P | P | A | C |
|---|-----|---|---|---------------|
| I | B R | O | | -9,203,741.45 |
| | | I | | 12,877.91 |
| | | U | | 9,190,863.54 |

(II) I

E C
. D
C

A C W G I J 2021, C

(III) O

1. I

O A 14, 2023, 38 B D W K
H C , L ,

N **F**
F 2022
(A RMB Y)

XV. O ()

(III) O ()

1. I ()

(1) I RMB14.43

B S 2022, I
I A ,
2019 2020 RMB14.43 , RMB5.25
RMB9.18 , T
K H ,
I I C B D ,
(I) 2021, N XV

(2) R S W D C

A C
RMB2,190,700, C
C
T C
C
C

附注 2022
(A 人民币)

XV. 其他非流动资产 ()

(III) 其他非流动资产 ()

1. 其他非流动资产 ()

(3) 其他非流动资产

截至 2022 年 12 月 31 日，其他非流动资产余额为人民币 1,000,000.00 元，较期初增加 100.00%。

其他非流动资产的具体情况如下：
1. 预付账款：I 类 C 类，A 类 C 类。

A 类 C 类：B 类 C 类 T 类 C 类。

N **F**
F 2022
(A RMB Y)

XV. O ()

(III) O ()

2. A ()

(2) I , C
12 2019, 2020 2021
2020 2021
C
2020 2021. T
RMB428,900 2020 RMB335,100 2021, C
C
2020 2021.

(3) O , C
2022

XVI. N

(I) A

1. A

| A | B | B |
|-----|---------------|---------------|
| W 1 | 49,024,983.98 | 40,904,137.67 |
| 1-2 | 709,878.26 | 1,282,268.26 |
| 2-3 | 1,158,221.95 | 2,748,299.92 |
| O 3 | 2,748,299.92 | 1,204,242.08 |
| S | Over 3 years | 1,158,221.95 |

N **F**
 F 2022
 (A RMB Y)
 XVI. N ()

(I) A ()

2. A ()

A :

| | A | B | P | P |
|---|---------------|------------|---|------|
| I | | | | (%) |
| Q | 48,767,668.85 | 487,676.69 | | 1.00 |
| T | 48,767,668.85 | 487,676.69 | | |

3. P ,

B

C

附注六、非经常性损益及其他收益和损失
 2022年度非经常性损益及其他收益和损失情况表
 (A股人民币元)

(II) 其他收益

| 项目 | 本期发生额 | 上期发生额 |
|--------------|----------------|----------------|
| 一、政府补助 | | |
| 1. 与日常活动相关 | | |
| 政府补助 | 53,000,000.00 | 492,034,884.26 |
| 其他 | 547,014,558.58 | 492,034,884.26 |
| 合计 | 600,014,558.58 | 492,034,884.26 |
| 2. 与终止经营相关 | | |
| 政府补助 | 33,000,000.00 | |
| 其他 | 10,000,000.00 | |
| 合计 | 43,000,000.00 | |
| 3. 与企业日常活动无关 | | |
| 政府补助 | 10,000,000.00 | |
| 其他 | 53,000,000.00 | |
| 合计 | 63,000,000.00 | |

N **F**
F 2022
(A RMB Y)

)

(

)

)

)

)

(

)

(II) O

XVI, N

附注六、其他非流动资产

2022 年 12 月 31 日

(A) (人民币元)

XVI. 其他非流动资产

(II) 其他非流动资产

(3) 预付账款

| | 12-31 | 12-31 | 12-31 |
|------|------------|--------------|-------|
| | 2022 | 2021 | 2020 |
| | 期末余额 | 期末余额 | 期末余额 |
| | 账面余额 | 坏账准备 | 账面价值 |
| 预付账款 | 123,061.04 | (123,061.04) | - |
| 预付账款 | 103,420.62 | (103,420.62) | - |
| 预付账款 | 226,481.66 | (226,481.66) | - |
| 合计 | 432,963.32 | (432,963.32) | - |

其他非流动资产减值准备计提情况如下：

| | 12-31 | 12-31 | 12-31 |
|------|----------------|------------------|-------|
| | 2022 | 2021 | 2020 |
| | 期末余额 | 期末余额 | 期末余额 |
| | 账面余额 | 坏账准备 | 账面价值 |
| 预付账款 | 492,157,945.30 | (492,157,945.30) | - |
| 预付账款 | 55,083,094.94 | (55,083,094.94) | - |
| 合计 | 547,241,040.24 | (547,241,040.24) | - |

附注
F
2022
(A RMB Y)

XVI. N ()

(II) O ()

(4) P , C R W B

| C | P | R | W | B |
|---|------------|------------|---|------------|
| P | 123,061.04 | 103,420.62 | - | 226,481.66 |
| T | 123,061.04 | 103,420.62 | - | 226,481.66 |

(5) O B B

| N | B | B |
|---|----------------|----------------|
| A | 507,207,052.64 | 481,560,443.31 |
| P | 33,132,118.55 | 8,954,970.91 |
| D | 5,933,350.00 | 854,300.00 |
| O | 968,519.05 | 788,231.08 |
| T | 547,241,040.24 | 492,157,945.30 |

附注六 资产负债表

2022年12月31日

(A股)

人民币元

XVI. 非流动资产

(III) 长期股权投资

| I 项目 | B 年初余额 | | P 期末余额 | |
|------------|----------------|----------------|----------------|----------------|
| | B 人民币元 | B 美元 | B 人民币元 | B 美元 |
| I 可供出售金融资产 | 649,079,592.72 | 649,079,592.72 | 613,070,215.90 | 613,070,215.90 |
| I 长期股权投资 | 92,882,992.81 | 92,882,992.81 | 71,256,356.09 | 71,256,356.09 |
| | 741,962,585.53 | 741,962,585.53 | 684,326,571.99 | 684,326,571.99 |

1. 可供出售金融资产

| I 项目 | B 年初余额 | | P 期末余额 | |
|-----------------|----------------|---------------|----------------|----------------|
| | B 人民币元 | B 美元 | B 人民币元 | B 美元 |
| S Y M I C.,L. | 10,354,979.06 | | 10,354,979.06 | |
| Z H H M C.,L. | 34,627,432.36 | 34,627,432.36 | | |
| W K J F C | 500,000.00 | | 500,000.00 | |
| Z K H M C.,L. | 203,344,031.86 | 1,322,222.01 | 204,666,253.87 | |
| C K H C.,L. | 51,982,515.15 | 715,222.35 | 52,697,737.50 | |
| Y K H C.,L. | 1,832,112.13 | 301,146.25 | 2,133,258.38 | |
| Y K H C.,L. | 27,447,511.21 | 239,581.90 | 27,687,093.11 | |
| Q K H C.,L. | 32,626,079.15 | 230,565.10 | 32,856,644.25 | |
| L K H C.,L. | 2,110,854.98 | 188,216.41 | 2,299,071.39 | |
| W C H C.,L. | 53,500,000.00 | | 53,500,000.00 | |
| W L Y H C.,L. | 30,000,000.00 | | 30,000,000.00 | |
| W O Y R H C.,L. | 10,000,000.00 | | 10,000,000.00 | |
| P C Y H C.,L. | 154,744,700.00 | | 154,744,700.00 | |
| J S H C.,L. | | 26,684,900.00 | 26,684,900.00 | |
| Y Y T | | | | |
| W M H C.,L. | | 40,954,955.16 | 40,954,955.16 | |
| T | 613,070,215.90 | 70,636,809.18 | 34,627,432.36 | 649,079,592.72 |

附注六、营业收入和营业成本

2022年度营业收入和营业成本按产品类别列示如下：

营业收入和营业成本按地区列示如下：

| 1. 营业收入 | 2022年度 | | 2021年度 | |
|---------|----------------|----------------|----------------|----------------|
| | 人民币元 | 美元 | 人民币元 | 美元 |
| 主营业务收入 | 337,586,514.02 | 264,978,847.50 | 365,462,139.23 | 270,930,179.07 |
| 其他业务收入 | 5,554,936.61 | 45,300.00 | 4,336,166.89 | 559,209.63 |
| 营业收入合计 | 343,141,450.63 | 265,024,147.50 | 369,798,306.12 | 271,489,388.70 |

营业收入按地区列示如下：

| 营业收入 | 2022年度 | | 2021年度 | |
|---------|----------------|----------------|----------------|----------------|
| | 人民币元 | 美元 | 人民币元 | 美元 |
| 中国大陆 | 90,612,303.06 | 93,506,118.66 | 246,974,210.96 | 271,956,020.57 |
| 其他国家和地区 | 246,974,210.96 | 271,956,020.57 | 337,586,514.02 | 365,462,139.23 |
| 营业收入合计 | 337,586,514.02 | 365,462,139.23 | 337,586,514.02 | 365,462,139.23 |

2. 营业成本

2022年度营业成本按产品类别列示如下：

营业成本按地区列示如下：

| 营业收入 | 2022年度 | | 2021年度 | |
|--------|---------------|---------------|---------------|--------------|
| | 人民币元 | 美元 | 人民币元 | 美元 |
| 主营业务收入 | 54,584,000.00 | 1,980,000.00 | - | - |
| 其他业务收入 | -5,377,605.11 | -3,485,811.81 | - | - |
| 营业成本合计 | -18,462.42 | - | - | - |
| 营业成本合计 | 714,348.18 | 6,429,189.35 | 714,348.18 | 6,429,189.35 |
| 营业成本合计 | 49,902,280.65 | 4,923,377.54 | 49,902,280.65 | 4,923,377.54 |

Definitions

| | |
|----------|--|
| CSRC | 中國證券監督管理委員會 |
| D () | () 中國 |
| D S () | 人民幣 () 中國 人民幣 1.00 , RMB 人民幣 S |
| G H | 溫州怡寧老年醫院有限公司 (Wenzhou Yining Old People's Hospital Co., Ltd.), PRC 寧 2, 2015, C |
| G | C |
| G Y H | 冠縣怡寧醫院有限公司 (Guanxian Yining Hospital Co., Ltd.), PRC 寧 1, 2017, C |
| HS () | 香港證券及期貨委員會 () RMB1.00 , M B H K S E |
| H C H | 杭州慈寧醫院有限公司 (Hangzhou Cining Hospital Co., Ltd.), PRC 寧 18, 2017, C |
| H Y H | 杭州怡寧醫院有限公司 (Hangzhou Yining Hospital Co., Ltd.), PRC 寧 A 25, 2016, C . O J 30, 2022, C 28% H Y H T W L L H M C , L . (桐鄉烏鎮蓮芯蓮意健康管理有限公司). U 33% H Y H |
| H Y H | 荷澤怡寧精神病醫院有限公司 (Heze Yining Psychiatric Hospital Co., Ltd.), PRC 寧 A 6, 2017, C |
| HK\$ HKD | 香港 |

Definitions

H K

H K S A R

PRC

H K L R

Definitions

| | |
|----------------------------|---|
| Nanjing Yihuan Hospital | Nanjing Yihuan Hospital Co., Ltd. (南京怡寧醫院有限公司), a PRC company established on July 22, 2018, and is a wholly-owned subsidiary of the Company. |
| Ningbo Kangning Hospital | Ningbo Kangning Hospital Co., Ltd. (寧波康寧醫院有限公司), a PRC company established on May 11, 2015, and is a wholly-owned subsidiary of the Company. |
| Pudong Yihuan Hospital | Pudong Yihuan Hospital Co., Ltd. (浦江怡寧黃鋒醫院有限公司), a PRC company established on September 3, 2018, and is a wholly-owned subsidiary of the Company. |
| PRC Company | People's Republic of China, including Hong Kong, Macao and Taiwan. |
| PRC Company Law | Company Law of the People's Republic of China (中華人民共和國公司法), a PRC law promulgated by the State Council of the PRC on December 28, 2013 and amended on March 1, 2014 (as amended). |
| Pudong Yihuan Hospital | Pudong Yihuan Hospital Co., Ltd. (浦江怡寧黃鋒醫院有限公司), a PRC company established on November 10, 2015, and is a wholly-owned subsidiary of the Company. |
| Qingtian Kangning Hospital | Qingtian Kangning Hospital Co., Ltd. (青田康寧醫院有限公司), a PRC company established on August 1, 2011, and is a wholly-owned subsidiary of the Company. |
| Wenzhou Yihuan Hospital | Wenzhou Yihuan Hospital Co., Ltd. (衢州怡寧醫院有限公司), a PRC company established on November 20, 2015, and is a wholly-owned subsidiary of the Company. |

Definitions

| | |
|--------------|---|
| T R P R P | 截至 2022 年 12 月 31 日 |
| R C | 人民币 |
| RMB | 人民币 (PRC) |
| SFO | 深圳湾口岸 (位于香港), |
| S () | S () C RMB1.00 , D S () HS () |
| S () | () S () |
| S Y H | S Y H (深圳怡宁医院, S Y H C ., L . (深圳市怡宁医院有限公司)), PRC S 22, 2014, C - |
| S R M C | S R M B C O (C 622 H K) |
| () | H K L R |
| S () | S C |
| S C | C S C PRC C |
| T K H | T K H C ., L . (台州康宁医院有限公司), PRC J 30, 2016, C - |

Definitions

W N H W N P S H C ., L . (溫嶺南方精神疾病專科醫院
 有限公司), PRC J 20, 2018,
 C T1 T -05.4175 -30538T (°)T 0.556 -0.

